
<html lang="en"     class="pb-page"  data-request-id="806c447c-76f1-497f-9ada-72e2bea95bf0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2021.64.issue-11;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.1c00578;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Optimization of N-Phenylpropenoyl-l-amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson’s Disease" /></meta><meta name="dc.Creator" content="Xiao-Long  Hu" /></meta><meta name="dc.Creator" content="Xian-Yu  Lv" /></meta><meta name="dc.Creator" content="Rong  Wang" /></meta><meta name="dc.Creator" content="Huan  Long" /></meta><meta name="dc.Creator" content="Jia-Hao  Feng" /></meta><meta name="dc.Creator" content="Bao-Lin  Wang" /></meta><meta name="dc.Creator" content="Wei  Shen" /></meta><meta name="dc.Creator" content="Hao  Liu" /></meta><meta name="dc.Creator" content="Fei  Xiong" /></meta><meta name="dc.Creator" content="Xiao-Qi  Zhang" /></meta><meta name="dc.Creator" content="Wen-Cai  Ye" /></meta><meta name="dc.Creator" content="Hao  Wang" /></meta><meta name="dc.Description" content="N-Phenylpropenoyl-l-amino acids (NPAs) are inducible nitric oxide synthase (iNOS) inhibitors possessing preventive effects for Parkinson’s disease (PD). Here, structural modifications for improving..." /></meta><meta name="Description" content="N-Phenylpropenoyl-l-amino acids (NPAs) are inducible nitric oxide synthase (iNOS) inhibitors possessing preventive effects for Parkinson’s disease (PD). Here, structural modifications for improving..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 21, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00578" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00578" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00578" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00578" /></link>
        
    
    

<title>Optimization of N-Phenylpropenoyl-l-amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson’s Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00578" /></meta><meta property="og:title" content="Optimization of N-Phenylpropenoyl-l-amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson’s Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0015.jpeg" /></meta><meta property="og:description" content="N-Phenylpropenoyl-l-amino acids (NPAs) are inducible nitric oxide synthase (iNOS) inhibitors possessing preventive effects for Parkinson’s disease (PD). Here, structural modifications for improving the iNOS inhibitory activity and blood–brain barrier (BBB) permeability of NPAs were conducted, leading to 20 optimized NPA derivatives (1–20). Compound 18, with the most potent activity (IC50 = 74 nM), high BBB permeability (Pe = 19.1 × 10–6 cm/s), and high selectivity over other NOS isoforms, was selected as the lead compound. Further studies demonstrated that 18 directly binds to iNOS. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced acute PD model, the oral administration of 18 (1 and 2 mg/kg) exerted preventive effects by alleviating the loss of dopaminergic (DAergic) neurons. Notably, in the MPTP-/probenecid-induced chronic PD model, the same dose of 18 also displayed a therapeutic effect by repairing the damaged DAergic neurons. Finally, good pharmacokinetic properties and low toxicity made 18 a promising candidate for the treatment of PD." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00578"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00578">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00578&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00578&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00578&amp;href=/doi/10.1021/acs.jmedchem.1c00578" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 7760-7777</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00551" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00611" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Optimization of <i>N</i>-Phenylpropenoyl-<span class="smallcaps smallerCapital">l</span>-amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson’s Disease</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiao-Long Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiao-Long Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiao-Long++Hu">Xiao-Long Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xian-Yu Lv</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xian-Yu Lv</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xian-Yu++Lv">Xian-Yu Lv</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rong Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rong Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rong++Wang">Rong Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huan Long</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huan Long</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huan++Long">Huan Long</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jia-Hao Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jia-Hao Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jia-Hao++Feng">Jia-Hao Feng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bao-Lin Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bao-Lin Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bao-Lin++Wang">Bao-Lin Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Shen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Shen">Wei Shen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Liu">Hao Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fei Xiong</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fei Xiong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Bioelectronics, Jiangsu Laboratory for Biomaterials and Devices, Southeast University, Nanjing 210009, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#08706167666f6e6d61487b6d7d266d6c7d266b66"><span class="__cf_email__" data-cfemail="f189989e9f96979498b1829484df949584df929f">[email protected]</span></a>. Phone: +86-25-83792496.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fei++Xiong">Fei Xiong</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-3680-4292" title="Orcid link">https://orcid.org/0000-0002-3680-4292</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiao-Qi Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiao-Qi Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou 510632, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiao-Qi++Zhang">Xiao-Qi Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4436-0273" title="Orcid link">https://orcid.org/0000-0002-4436-0273</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wen-Cai Ye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wen-Cai Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou 510632, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wen-Cai++Ye">Wen-Cai Ye</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2810-1001" title="Orcid link">https://orcid.org/0000-0002-2810-1001</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Hao Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#5225333c353a333d123122277c3736277c313c"><span class="__cf_email__" data-cfemail="aaddcbc4cdc2cbc5eac9dadf84cfcedf84c9c4">[email protected]</span></a>. Phone: +86-25-83271328.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Wang">Hao Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3994-9806" title="Orcid link">https://orcid.org/0000-0003-3994-9806</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00578&amp;href=/doi/10.1021%2Facs.jmedchem.1c00578" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 7760–7777</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 21, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 March 2021</li><li><span class="item_label"><b>Published</b> online</span>21 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00578" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00578</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7760%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiao-Long%2BHu%252C%2BXian-Yu%2BLv%252C%2BRong%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D11%26contentID%3Dacs.jmedchem.1c00578%26title%3DOptimization%2Bof%2BN-Phenylpropenoyl-l-amino%2BAcids%2Bas%2BPotent%2Band%2BSelective%2BInducible%2BNitric%2BOxide%2BSynthase%2BInhibitors%2Bfor%2BParkinson%25E2%2580%2599s%2BDisease%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7777%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00578"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">530</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00578" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Optimization of N-Phenylpropenoyl-l-amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson’s Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiao-Long&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Xian-Yu&quot;,&quot;last_name&quot;:&quot;Lv&quot;},{&quot;first_name&quot;:&quot;Rong&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Huan&quot;,&quot;last_name&quot;:&quot;Long&quot;},{&quot;first_name&quot;:&quot;Jia-Hao&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Bao-Lin&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Fei&quot;,&quot;last_name&quot;:&quot;Xiong&quot;},{&quot;first_name&quot;:&quot;Xiao-Qi&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Wen-Cai&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;7760-7777&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00578&quot;},&quot;abstract&quot;:&quot;N-Phenylpropenoyl-l-amino acids (NPAs) are inducible nitric oxide synthase (iNOS) inhibitors possessing preventive effects for Parkinson’s disease (PD). Here, structural modifications for improving the iNOS inhibitory activity and blood–brain barrier (BBB) permeability of NPAs were conducted, leading to 20 optimized NPA derivatives (1–20). Compound 18, with the most potent activity (IC50 = 74 nM), high BBB permeability (Pe = 19.1 × 10–6 cm/s), and high selectivity over other NOS isoforms, was selected as the lead compound. Further studies demonstrated that 18 directly binds to iNOS. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced acute PD model, the oral administration of 18 (1 and 2 mg/kg) exerted preventive effects by alleviating the loss of dopaminergic (DAergic) neurons. Notably, in the MPTP-/probenecid-induced chronic PD model, the same dose of 18 also displayed a therapeutic effect by repairing the damaged DAergic neurons. Finally, good pharmacokinetic properties and low toxicity made&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00578&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00578" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00578&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00578" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00578&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00578" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00578&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00578&amp;href=/doi/10.1021/acs.jmedchem.1c00578" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00578" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00578" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (13 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00578%26sid%3Dliteratum%253Aachs%26pmid%3D34019417%26genre%3Darticle%26aulast%3DHu%26date%3D2021%26atitle%3DOptimization%2Bof%2BN-Phenylpropenoyl-l-amino%2BAcids%2Bas%2BPotent%2Band%2BSelective%2BInducible%2BNitric%2BOxide%2BSynthase%2BInhibitors%2Bfor%2BParkinson%25E2%2580%2599s%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D11%26spage%3D7760%26epage%3D7777%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292504" title="Permeability">Permeability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/jmcmar.2021.64.issue-11/20210610/jmcmar.2021.64.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText"><i>N</i>-Phenylpropenoyl-<span class="smallcaps smallerCapital">l</span>-amino acids (NPAs) are inducible nitric oxide synthase (iNOS) inhibitors possessing preventive effects for Parkinson’s disease (PD). Here, structural modifications for improving the iNOS inhibitory activity and blood–brain barrier (BBB) permeability of NPAs were conducted, leading to 20 optimized NPA derivatives (<b>1–20</b>). Compound <b>18</b>, with the most potent activity (IC<sub>50</sub> = 74 nM), high BBB permeability (<i>P</i><sub>e</sub> = 19.1 × 10<sup>–6</sup> cm/s), and high selectivity over other NOS isoforms, was selected as the lead compound. Further studies demonstrated that <b>18</b> directly binds to iNOS. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced acute PD model, the oral administration of <b>18</b> (1 and 2 mg/kg) exerted preventive effects by alleviating the loss of dopaminergic (DAergic) neurons. Notably, in the MPTP-/probenecid-induced chronic PD model, the same dose of <b>18</b> also displayed a therapeutic effect by repairing the damaged DAergic neurons. Finally, good pharmacokinetic properties and low toxicity made <b>18</b> a promising candidate for the treatment of PD.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Parkinson’s disease (PD) is the second most common age-related neurodegenerative disorder characterized by the loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc), which decreases the interstitial dopamine (DA) level, resulting in bradykinesia, rigidity, and tremor.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Current therapeutics mainly focus on the enhancement of the DA level, such as levodopa (<span class="smallcaps smallerCapital">l</span>-DOPA), catechol-<i>O</i>-methyl-transferase inhibitors, monoamine oxidase type B (MAO-B) inhibitors, and DA receptor agonists.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6">(2−6)</a> These available PD drugs offer valuable symptomatic relief but are often accompanied by serious side effects and cannot slow down the progression of PD.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Neuroinflammation is one of the hallmarks of PD and contributes to DAergic neuron degeneration.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Targeting excessive neuroinflammation could offer new therapeutic opportunities for PD and might slow down the disease progression.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">Inducible nitric oxide synthase (iNOS), the key enzyme for the synthesis process of toxic nitric oxide (NO), plays a critical role in inflammation and neuroinflammation.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> NOS has three isoforms, including endothelial NOS (eNOS), neuronal NOS (nNOS), and iNOS, which are involved in the catalytic production of NO and maintaining normal physiological reactions.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Several studies have demonstrated that iNOS is overexpressed and overactivated in animals and patients with PD, indicating that iNOS is a key target for PD.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> However, much work has been focused on iNOS inhibitors for acute inflammation, severe shock, and diabetes, and only a few are related to PD due to their poor efficiency, blood–brain barrier (BBB) permeability, and isoform selectivity.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Our previous efforts in achieving iNOS inhibitors with excellent potency have led to a class of molecules bearing a scaffold of <i>N</i>-phenylpropenoyl-<span class="smallcaps smallerCapital">l</span>-amino acids (NPAs). Among these NPAs, hit compound <b>4b</b> (IC<sub>50</sub> = 1.09 μM) has shown good efficacy for PD prevention in vitro and in vivo.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> These results reported that NPAs are new potent iNOS inhibitors for PD therapy; therefore, further optimization of <b>4b</b> focusing on activity, isoform selectivity, and BBB permeability was necessary.</div><div class="NLM_p last">In this work, 20 additional optimized NPA derivatives (<b>1–20</b>), which possessed enhanced iNOS inhibitory effects and BBB permeability compared with those of <b>4b</b>, were designed and synthesized. Their structure–activity relationships (SARs) and structure–selectivity relationships were discussed. The preventive effects in the acute PD model and the therapeutic effects in the chronic PD model, the absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) profiles, and the pharmacokinetic profiles of the candidate compound were further investigated. This study led to the identification of highly potent compounds with significant improvement. Among them, compound <b>18</b> proved to be particularly promising.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15102" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15102" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design and Chemistry</h3><div class="NLM_p">Our previous study has demonstrated that NPAs, especially <b>4b</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), are potent iNOS inhibitors with preventive effects in PD.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> This hit compound matched “Lipinski’s rule of five” and it also provided multiple diversification points for robust optimization. With careful analysis, it was supposed that the two phenolic hydroxy groups present in <b>4b</b> might bring some negative effects as follows: (1) the polar of the molecule is strong, which might affect the absorption and BBB permeability and (2) glucuronidation of multi-hydroxyl groups may shorten the action time of the compound within the body. Besides, <b>4b</b> was not potent enough and its activity should be improved in vitro and in vivo. Taken together, structural modifications were conducted to increase the iNOS inhibitory effect and BBB permeability of <b>4b</b>, as well as improve its physicochemical properties. According to the basic principles of drug design, the following strategies were used: (1) the structural skeleton, cinnamic acid moiety, and amino acid moiety (<span class="smallcaps smallerCapital">l</span>-tyrosine) of <b>4b</b> were retained, and minimal modifications were made to the benzene ring of the cinnamic acid moiety to adjust the lipid–water partition coefficients and/or improve its stability/or improve its activity, such as changing the hydroxyl groups and introducing the nitrogen-containing groups, halogen, trifluoromethyl, or aldehyde groups (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and (2) substantial changes were made to the amino acid moiety by replacing the <span class="smallcaps smallerCapital">l</span>-tyrosine with several aliphatic amino acids, aromatic amino acids, and heterocyclic amino acids to enhance the pharmacological effects (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Consequently, 209 compounds were designed belonging to the 19 series (<b>a–s</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf" class="ext-link">Table S1</a>). Then, molecular docking assay was used to predict the inhibitory effects of these 209 compounds on iNOS (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R35">1R35</a>)<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> and ADME properties. The most important factor in identifying drugs for neurological diseases is their ability to penetrate BBB. In the Discovery studio software, only compounds with predicted BBB levels of 0, 1, or 2 were considered to permeate the BBB, while 3 or 4 were not. Usage of levels 0, 1, or 2 as the cutoff for ADMET_BBB_LEVEL ensured that only the compounds that could pass the BBB would be retained. In addition, the higher the absolute values of -CDOCKER energy are, the more stable the binding is. Notably, although some compounds, such as compounds <b>i-I</b>, <b>i-II</b>, and <b>i-III</b> and <b>j-I</b> and <b>s-I</b> (in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf" class="ext-link">Table S2</a>), showed higher -CDOCKER energy than <b>4b</b>, their BBB levels were predicted to be level 3 or level 4 and therefore, they were not considered. As a result, 20 of these compounds (red font in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf" class="ext-link">Table S2</a>) with the higher absolute values of -CDOCKER energy than <b>4b</b> (24.3 kcal/mol) and higher BBB permeability (level 1 or level 2) than <b>4b</b> (level 4) were screened out. Here, in this work, these 20 NPAs (<b>1–20</b>) were efficiently synthesized under mild and water-compatible conditions (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Notably, compounds <b>1</b>–<b>20</b> can be easily obtained in a 10 g scale without the use of column chromatography techniques.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Strategies for further structural optimization of <b>4b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>1</b>–<b>20</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Inhibitory Effects of <b>1</b>–<b>20</b> on NO Production and iNOS Activity</h3><div class="NLM_p">All the synthesized NPAs were tested for their anti-neuroinflammatory effects using a lipopolysaccharide (LPS)-induced BV-2 cell activation model. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <b>1–20</b> exhibited stronger NO inhibitory effects than <b>4b</b>, especially <b>13–20</b> (1 μM, inhibition rate > 50%). The inhibitory effects of these compounds and <b>4b</b> on iNOS were further tested using the iNOS enzyme activity assay. Results showed that <b>13–20</b> also showed promising iNOS inhibitory effects with half maximal inhibitory concentration (IC<sub>50</sub>) values ranging from 74 to 434 nM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), consistent with the tendency of NO inhibition. This result suggests that these compounds exerted anti-neuroinflammatory effects by targeting iNOS.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of compounds <b>1</b>–<b>20</b> and <b>4b</b> on NO release in BV-2 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effects of <b>1</b>–<b>20</b> on NOS Activity and BBB Permeability</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">IC<sub>50</sub> (nM)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">selectivity<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp.</th><th class="colsep0 rowsep0" align="center" char="±">iNOS</th><th class="colsep0 rowsep0" align="center" char="±">nNOS</th><th class="colsep0 rowsep0" align="center" char="±">eNOS</th><th class="colsep0 rowsep0" align="center" char=".">hnNOS/hiNOS</th><th class="colsep0 rowsep0" align="center" char=".">heNOS/hiNOS</th><th class="colsep0 rowsep0" align="center">Pe (10<sup>–6</sup> cm s<sup>–1</sup>) PAMPA-BBB</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">630 ± 38</td><td class="colsep0 rowsep0" align="char" char="±">64314 ± 5320</td><td class="colsep0 rowsep0" align="char" char="±">66194 ± 5480</td><td class="colsep0 rowsep0" align="char" char=".">102</td><td class="colsep0 rowsep0" align="char" char=".">105</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">820 ± 53</td><td class="colsep0 rowsep0" align="char" char="±">125618 ± 7860</td><td class="colsep0 rowsep0" align="char" char="±">147301 ± 9870</td><td class="colsep0 rowsep0" align="char" char=".">153</td><td class="colsep0 rowsep0" align="char" char=".">180</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char="±">594 ± 41</td><td class="colsep0 rowsep0" align="char" char="±">20679 ± 1980</td><td class="colsep0 rowsep0" align="char" char="±">30605 ± 2400</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char="±">645 ± 33</td><td class="colsep0 rowsep0" align="char" char="±">25814 ± 2100</td><td class="colsep0 rowsep0" align="char" char="±">33142 ± 3100</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char="±">731 ± 67</td><td class="colsep0 rowsep0" align="char" char="±">102382 ± 9810</td><td class="colsep0 rowsep0" align="char" char="±">106370 ± 8920</td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">146</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char="±">945 ± 84</td><td class="colsep0 rowsep0" align="char" char="±">156987 ± 10920</td><td class="colsep0 rowsep0" align="char" char="±">188770 ± 10020</td><td class="colsep0 rowsep0" align="char" char=".">166</td><td class="colsep0 rowsep0" align="char" char=".">199</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char="±">782 ± 56</td><td class="colsep0 rowsep0" align="char" char="±">39784 ± 3100</td><td class="colsep0 rowsep0" align="char" char="±">48850 ± 3950</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char="±">916 ± 88</td><td class="colsep0 rowsep0" align="char" char="±">56719 ± 4900</td><td class="colsep0 rowsep0" align="char" char="±">46610 ± 3980</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char="±">766 ± 65</td><td class="colsep0 rowsep0" align="char" char="±">110555 ± 9870</td><td class="colsep0 rowsep0" align="char" char="±">110680 ± 9810</td><td class="colsep0 rowsep0" align="char" char=".">151</td><td class="colsep0 rowsep0" align="char" char=".">144</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char="±">993 ± 67</td><td class="colsep0 rowsep0" align="char" char="±">148510 ± 9860</td><td class="colsep0 rowsep0" align="char" char="±">163860 ± 10210</td><td class="colsep0 rowsep0" align="char" char=".">149</td><td class="colsep0 rowsep0" align="char" char=".">165</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char="±">765 ± 74</td><td class="colsep0 rowsep0" align="char" char="±">29640 ± 2800</td><td class="colsep0 rowsep0" align="char" char="±">29745 ± 1800</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char="±">640 ± 34</td><td class="colsep0 rowsep0" align="char" char="±">25613 ± 2120</td><td class="colsep0 rowsep0" align="char" char="±">30560 ± 2000</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="char" char="±">291 ± 25</td><td class="colsep0 rowsep0" align="char" char="±">31905 ± 2540</td><td class="colsep0 rowsep0" align="char" char="±">37620 ± 2980</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="char" char=".">129</td><td class="colsep0 rowsep0" align="left">4.61 ± 0.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char="±">188 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">34210 ± 2800</td><td class="colsep0 rowsep0" align="char" char="±">38000 ± 2700</td><td class="colsep0 rowsep0" align="char" char=".">182</td><td class="colsep0 rowsep0" align="char" char=".">202</td><td class="colsep0 rowsep0" align="left">4.32 ± 1.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char="±">434 ± 29</td><td class="colsep0 rowsep0" align="char" char="±">18480 ± 1550</td><td class="colsep0 rowsep0" align="char" char="±">17100 ± 1250</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="left">4.88 ± 0.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char="±">421 ± 41</td><td class="colsep0 rowsep0" align="char" char="±">20250 ± 1400</td><td class="colsep0 rowsep0" align="char" char="±">21050 ± 1590</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="left">4.97 ± 0.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char="±">110 ± 7</td><td class="colsep0 rowsep0" align="char" char="±">11994 ± 980</td><td class="colsep0 rowsep0" align="char" char="±">15530 ± 1200</td><td class="colsep0 rowsep0" align="char" char=".">109</td><td class="colsep0 rowsep0" align="char" char=".">141</td><td class="colsep0 rowsep0" align="left">10.42 ± 0.97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char="±">74 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">16650 ± 1010</td><td class="colsep0 rowsep0" align="char" char="±">18500 ± 1580</td><td class="colsep0 rowsep0" align="char" char=".">225</td><td class="colsep0 rowsep0" align="char" char=".">250</td><td class="colsep0 rowsep0" align="left">19.02 ± 1.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char="±">195 ± 12</td><td class="colsep0 rowsep0" align="char" char="±">6120 ± 540</td><td class="colsep0 rowsep0" align="char" char="±">5600 ± 380</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="left">8.05 ± 1.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char="±">178 ± 14</td><td class="colsep0 rowsep0" align="char" char="±">8360 ± 700</td><td class="colsep0 rowsep0" align="char" char="±">9600 ± 740</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="left">9.01 ± 0.89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4b</b></td><td class="colsep0 rowsep0" align="char" char="±">892 ± 45</td><td class="colsep0 rowsep0" align="char" char="±">40330 ± 2900</td><td class="colsep0 rowsep0" align="char" char="±">46590 ± 3800</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="left">1.23 ± 0.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1400W</b><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">1980 ± 140</td><td class="colsep0 rowsep0" align="char" char="±">51200 ± 4520</td><td class="colsep0 rowsep0" align="char" char=".">236</td><td class="colsep0 rowsep0" align="char" char=".">6095</td><td class="colsep0 rowsep0" align="left">3.18 ± 0.95</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Selectivity = IC<sub>50(human nNOS)</sub>/IC<sub>50(human iNOS)</sub>; IC<sub>50(human eNOS)</sub>/IC<sub>50(human iNOS).</sub></p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">1400W is a selective iNOS inhibitor, used as the reference control.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> SAR Analysis and Three-Dimensional Quantitative Structure–Activity Relationship Model</h3><div class="NLM_p">SARs were discussed by structural moieties. For the cinnamic acid moiety, the C-4 position of the NPAs functionalized with one trifluoromethyl electron-withdrawing group (<b>17–20</b>, IC<sub>50</sub> = 74–195 nM) can substantially increase iNOS inhibitory effects compared with that of the NPAs substituted by methyl (<b>13–16</b>, IC<sub>50</sub> = 188–434 nM) and chlorine (<b>5–8</b>, IC<sub>50</sub> = 731–945 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), indicating that introducing an electronegative group to the C-4 position might increase the inhibitory effects of NPAs on iNOS. For the amino acid moiety, NPAs containing an aromatic amino acid moiety were found to exert stronger iNOS inhibitory effects than those with aliphatic amino acid moiety, such as the IC<sub>50</sub> values of <b>13</b> (291 nM) and <b>14</b> (188 nM) < <b>15</b> (434 nM) and <b>16</b> (421 nM), respectively, as well as <b>17</b> (110 nM) and <b>18</b> (74 nM) < <b>19</b> (195 nM) and <b>20</b> (178 nM), respectively (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition, a three-dimensional quantitative SAR (3D-QSAR) model was built by Discovery Studio 3.0 (DS 3.0) software to evaluate the factors in correlation with in the bioassay results, and the structural features contributing to the corresponding activities. The results showed that the QSAR model was acceptable because the correlation coefficient (<i>R</i><sup>2</sup>) between the observed and predicted activities of training was 0.664, whereas that of the test set was 0.917 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf" class="ext-link">Figure S1</a>). The molecules aligned with the iso-surfaces of the 3D-QSAR model coefficients on van der Waals grids (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) and electrostatic potential grids (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) were also listed. Red contours in the electrostatic map indicate the regions where a high-electron density (negative charge) is expected to increase activity, and the blue contours represent regions where a low-electron density (partial positive charge) is expected to increase activity. Likewise, the steric map indicates the regions where steric bulk is predicted to increase (green) or decrease (yellow) activity. According to the maps, these compounds possessing a highly negative charge at the C-4 position and big bulk group would show higher iNOS inhibitory effects. These results provided a strategy for the design and optimization of NPA derivatives as potent iNOS inhibitors.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. 3D-QSAR model. (A) 3D-QSAR model coefficients on electrostatic potential grids. Blue represents positive coefficients and red represents negative coefficients. (B) 3D-QSAR model coefficients on van der Waals grids. Green represents positive coefficients and yellow represents negative coefficients.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Isoform Selectivity</h3><div class="NLM_p last">The current iNOS inhibitors have not been converted into clinically available drugs for PD due to their poor isoform selectivity for iNOS over eNOS and nNOS.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> These two isoforms share very similar structural features in the active site as that of iNOS. The overinhibition of these two NOS isoforms should be avoided because they take part in the maintenance of normal physiological function.<a onclick="showRef(event, 'ref16 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref19">(16,19)</a> First, eight compounds (<b>13–20</b>), with potent iNOS inhibitory effects, were selected for the evaluation of their NOS isoform selectivity. <b>13</b>, <b>14</b>, <b>17</b>, and <b>18</b> exhibited human eNOS/human iNOS selectivity, and human nNOS/human iNOS selectivity in the 100–250 range, especially <b>14</b> and <b>18</b> (in the range of 180–250). However, <b>15</b>, <b>16</b>, <b>19</b>, and <b>20</b> showed poor (<60-fold) isoform selectivity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The results indicated that the NPAs containing an aromatic amino acid moiety might have better iNOS selectivity than those with an aliphatic amino acid moiety. The NOS isoform selectivity of <b>1–12</b> was detected as corroborative evidence to further verify the inference. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> shows that the NPAs with aromatic amino acid moieties (<b>1</b>, <b>2</b>, <b>5</b>, <b>6</b>, <b>9</b>, and <b>10</b>), respectively, show better iNOS selectivity than the NPAs with aliphatic amino acid moieties (<b>3</b>, <b>4</b>, <b>7</b>, <b>8</b>, <b>11</b>, and <b>12</b>). These results demonstrated that the aromatic amino acid moiety of NPAs contributed greatly to iNOS selectivity.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Effects of <b>13</b>–<b>20</b> on Artificial Membrane Permeability</h3><div class="NLM_p last">The poor BBB permeability of reported iNOS inhibitors greatly limits the delivery of these compounds into the brain.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Therefore, <b>13–20</b> with potent inhibitory effects and selectivity were selected to evaluate their effects on cell membrane permeability through parallel artificial membrane permeability for the BBB (PAMPA-BBB) assay. In the PAMPA-BBB assay, a compound with good BBB penetration is classified as a central neural system (CNS) (+) molecule, if its effective permeability (<i>P</i><sub>e</sub>) is greater than 4.0 × 10<sup>–6</sup> cm/s.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Results showed that <b>13–20</b> exhibited CNS (+) characteristics, and <b>17–20</b> (<i>P</i><sub>e</sub> = 8.05 × 10<sup>–6</sup> to 19.02 × 10<sup>–6</sup> cm/s) displayed higher permeability than <b>13–16</b> (<i>P</i><sub>e</sub> = 4.32 × 10<sup>–6</sup> to 4.97 × 10<sup>–6</sup> cm/s; <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The results suggest that introducing trifluoromethyl functionality could improve the BBB permeability of NPAs (<b>17–20</b>) considerably. Replacing methyl (<b>13</b>) with the trifluoromethyl group (<b>17</b>) resulted in an approximately 2.5-fold increase in permeability and introducing fluorine on the aromatic ring of amino acids (<b>18</b>) resulted in an approximately 4.5-fold increase in permeability (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Therefore, introducing fluorine atoms into NPAs can increase the activity, selectivity, and BBB permeability of NPAs. Compound <b>18</b>, which had the most potent iNOS inhibitory effects, high isoform selectivity, and desirable BBB permeability, was selected as the lead compound for further exploration.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Docking and Molecular Dynamics Simulation of <b>18</b> Bound to iNOS</h3><div class="NLM_p">We used docking and atomistic force field-based molecular dynamic (MD) simulations to model <b>18</b> bound to iNOS. First, the crystal structure of iNOS (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R35">1R35</a>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> was used for the docking studies. As seen in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,B, the protein aids ligand’s anchoring within the pocket by the H bond between <b>18</b> and GLU371 (2.1 Å), TRP366 (2.8 Å), GLN257 (2.8 Å), and ARG260 (2.7 Å). The binding of a small molecule in the binding pocket of a protein can led to large conformational changes. Root-mean square deviation (RMSD) is one of the most important fundamental properties used to evaluate the structural stability of a protein.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Results showed that the average RMSD values of the iNOS and iNOS-<b>18</b> complexes were 0.31 and 0.21 nm, respectively (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). The binding of <b>18</b> led to lower RMSD values at several parts and showed equilibration throughout the 100 ns MD simulations (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). In addition, the average fluctuations of all residues and the root-mean square fluctuations (RMSFs) of iNOS upon ligand binding were plotted during the simulation as a function of the residue number to further assess local structural flexibility (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). The RMSF plot reveals the residual fluctuations in iNOS at several regions of the protein structure. These residual fluctuations were minimized upon the binding of <b>18</b> throughout the simulations in a region spanning from the N-terminal to the C-terminal. These results suggested the strong binding between iNOS and <b>18</b>. Therefore, <b>18</b> might directly target iNOS.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Molecular docking and MD simulation. (A) Predicted 3D binding mode of <b>18</b> with the iNOS crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R35">1R35</a>). Hydrogen bonds between inhibitors and amino acid residues are indicated by green dashed lines. (B) Predicted two-dimensional binding mode of <b>18</b> toward iNOS. (C) RMSD plot of native iNOS and complexed with EuC in black and red colors, respectively. (D) <i>R</i><sub>g</sub> plot of native iNOS and complexed with <b>18</b> in black and red colors, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> <b>18</b> Directly Binds to iNOS</h3><div class="NLM_p">Thermodynamic and kinetic experiments were carried out to evaluate the binding character between <b>18</b> and iNOS. The cellular thermal shift assay (CETSA) was used in the thermodynamic test to study the thermal stabilization of the proteins upon ligand binding.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> This assay has been used extensively on purified proteins to detect the interactions between donors and ligands. Results showed that the apparent aggregation temperatures were obtained with either <b>18</b> or dimethyl sulfoxide (DMSO), which could be compared, and substantial shifts demonstrated the binding of <b>18</b> and target proteins. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A shows that the thermal stabilization of iNOS increased compared with that of the control group (DMSO) after <b>18</b> was bound to iNOS. This thermal stabilization between <b>18</b> and iNOS was dose dependent according to the isothermal dose–response fingerprint (ITDRF) in CETSA (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Surface plasmon resonance, which is the most recognized method for studying the dynamic properties between ligands and donors,<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> was used in the kinetic test to further confirm the binding between <b>18</b> and iNOS. Results showed a strong binding between <b>18</b> and iNOS (<i>K</i><sub>D</sub> = 18 nM, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). These results fully demonstrated that <b>18</b> directly binds to iNOS. In addition, <b>18</b> contained a Michael-acceptor moiety (propenamide), which is a common warhead of a number of drugs that irreversibly inactivate their targets. Therefore, a time-dependent inhibition study of treatment with iNOS was carried out to distinguish <b>18</b> between inhibitors and inactivators. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D shows that <b>18</b> had no time-dependent effects, suggesting <b>18</b> is an iNOS inhibitor rather than an inactivator.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Thermodynamic and kinetic experiments of <b>18</b> toward iNOS. (A,B) CETSA and ITDRF<sub>cesta</sub> were used to evaluate the binding between <b>18</b> and iNOS at the thermodynamic level. (C) SPR was used to assess the binding between <b>18</b> and iNOS at the kinetic level. (D) Effects of <b>18</b> on iNOS activity at different time points (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <b>18</b>-Protected SH-SY5Y Cells from Neurotoxicity Induced by Microglial Activation</h3><div class="NLM_p">Microglia, a brain-resident immune cell, plays a central role in the process of PD by neuroinflammation. Activated microglia promote the production and activation of iNOS to generate overload NO, which make DAergic neurons more vulnerable to degeneration or toxicity.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In this study, the cell medium (CM) of BV-2 microglia treated with LPS was collected to stimulate DAergic neurons (SH-SY5Y cells), which were used to evaluate the in vitro anti-PD effects of <b>18</b>. Results showed that the cell viability of SH-SY5Y was decreased by 40% after 24 h of incubation with CM. However, CM derived from BV-2 cells with <b>18</b> (0.1, 1, and 10 μM) treatment for 6 h prior to LPS administration reduced SH-SY5Y cell injury in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B). Microscopic observation (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C), Hoechst 33258 staining (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D), and annexin V/FITC–propidium iodide (PI) double staining (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>E,F) showed that <b>18</b> can reduce cell apoptosis in a dose-dependent manner. These results demonstrated that <b>18</b> can alleviate the injury of DAergic neurons induced by neuroinflammatory toxicity.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>18</b> protected DAergic neurons from neurotoxicity induced by microglial activation. SH-SY5Y cells were incubated for 24 h with conditioned medium derived from cultures of BV-2 cells. Before collecting culture media, BV-2 cells were pre-treated with <b>18</b> (0.1, 1, or 10 μM) for 2 h and incubated with LPS (0 or 500 ng/mL). (A) Cell viability measured with the MTT assay (<i>n</i> = 6). (B) LDH leakage assay (<i>n</i> = 6). (C) Morphological observation. (D) Cell nuclei stained with Hoechst 33258 (blue). (E) Apoptosis of SH-SY5Y cells evaluated by FCM detection of annexin V–PI double staining [distribution of viable (lower left), necrotic (upper left), late apoptotic (upper right), and early apoptotic (lower right) cells]. (F) Statistical analysis of three independent experiments of annexin V–PI double staining. All data are presented as means ± SD or SEM. **<i>p</i> < 0.01 or ***<i>p</i> < 0.001, compared with the control group; #<i>p</i> < 0.05, ##<i>p</i> < 0.01, or ###<i>p</i> < 0.001, compared with the LPS group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Pre-treatment of <b>18</b> Alleviated the PD-like Behavior of the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Acute PD Model</h3><div class="NLM_p">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a <span class="smallcaps smallerCapital">l</span>-DOPA-responsive Parkinsonian syndrome, which is characterized by all the cardinal symptoms of PD and represents the best PD-like clinical picture obtainable in experimental animals.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In this study, traction test, rotarod test, and open-field test were used to evaluate the in vivo anti-PD effects of <b>18</b> in the MPTP-induced acute PD model (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). The traction test showed that MPTP treatment decreased strength as the hind limb grip score of the MPTP model was lower than that of the control group. However, oral pre-treatment with <b>18</b> (1 or 2 mg/kg) can considerably increase the traction score. Therefore, prophylactic treatment with <b>18</b> could alleviate the reduction in the strength and equilibrium of muscles caused by MPTP (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). The rotarod test showed that the time taken by MPTP-treated mice in the rotarod apparatus was remarkably reduced compared with the control. MPTP-treated mice that were given <b>18</b> stayed on the apparatus significantly longer than MPTP mice (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C). The open-field test showed that the total distances (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D,F) and average speed (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E) of the control and of the MPTP model group were substantially decreased and shortened, respectively, and the difference was statistically significant compared with those of the control group. The total distance and average speed of the MPTP + <b>18</b> group were significantly higher and longer compared with those of the model group. Although the positive drug, <span class="smallcaps smallerCapital">l</span>-DOPA, showed similar effects, its dose–effect relationship was far less than that of <b>18</b>. These behavioral results suggested that <b>18</b> could effectively alleviate movement disorders related to acute PD and had a preventive effect on PD at low dosages.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Prevention of <b>18</b> on MPTP-induced acute PD motor deficits. The behavioral measurements were carried out in the 4th, 24th, 48th, and 72nd h after the last injection of MPTP. (A) Experimental procedure and drug administration scheme. (B) Traction test. (C) Rotarod test. (D) Motion trail of the first three mice in each group in the open-field test (<i>n</i> = 8 mice/group). (E) Total distance of mice in the open-field test (<i>n</i> = 8 mice). (F) Mean velocity of mice in the open-field test (<i>n</i> = 8 mice). All data are presented as means ± SD. **<i>p</i> < 0.01 or ***<i>p</i> < 0.001, compared with the control group; #<i>p</i> < 0.05, ##<i>p</i> < 0.01, or ###<i>p</i> < 0.001, compared with the MPTP treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Pre-treatment with <b>18</b> Decreased the Level of NO and Increased the Levels of DA and Tyrosine Hydroxylase in the MPTP-Induced Acute PD Model</h3><div class="NLM_p">MPTP remarkably induces DAergic neuron loss by activating the iNOS/NO/pathway in microglia cells, which results in the reduction of DA levels.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Results showed that MPTP remarkably increased the NO level and decreased the DA level in the SNpc and striatum (STR) compared with the control group. However, pre-treatment with <b>18</b> remarkably decreased the NO level and increased the DA level in the SNpc and STR compared with the MPTP group (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A,B). Tyrosine hydroxylase (TH), the rate-limiting step in the biosynthesis of DA, is commonly regarded as a marker of DAergic neurons to evaluate the degrees of PD. Results from the immunohistochemistry and immunoblotting of the TH protein showed that the number of TH positive cells (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C,D) and the expression of TH (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>E) in the SNpc and STR of the MPTP-treated mice were decreased markedly compared with the control mice but were increased remarkably in the <b>18</b> pre-treated mice. These results indicated that <b>18</b> elicited neuroprotective effects against DAergic neuronal cell death in PD.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Prevention of <b>18</b> on MPTP-induced nigrostriatal DAergic injury. (A) Level of NO in SNpc and STR. (B) Level of DA in SNpc and STR. (C) Immunohistochemical staining showing TH positive cells in the SNpc and STR (scale bar: 200 μm). (D) Stereological counting of TH positive cells (<i>n</i> = 6). (E) Western blot analysis of the changes in the protein level of TH in both SNpc and STR. All data are presented as means ± SEM. **<i>p</i> < 0.01 or ***<i>p</i> < 0.001, compared with the control group; #<i>p</i> < 0.05, ##<i>p</i> < 0.01, or ###<i>p</i> < 0.001, compared with MPTP treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pre-treatment of <b>18</b> Inhibited the Mitochondrial Apoptotic Pathway of SNpc and STR in the MPTP-Induced Acute PD Model</h3><div class="NLM_p">The apoptosis of DAergic neurons in the SNpc was the main reason for DA loss.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The mitochondria of DAergic neurons are a preferential target of the NO induced by MPTP; thus, myriads of studies explored mitochondrial function in PD in the subsequent decades, and MPTP induction provides a formidable animal model of PD. Our results showed that the Bcl-2/Bax ratios in the SNpc and STR were remarkably decreased and the activities of caspase-3/9 in the SNpc and STR were increased in the MPTP-treated group compared with the control group. However, the pre-treatment with <b>18</b> can increase the Bcl-2/Bax ratio (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) and decrease the activities of caspase-3 (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) and caspase-9 (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) in the SNpc (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C) and the STR (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>D–F) in a dose-dependent manner. <span class="smallcaps smallerCapital">l</span>-DOPA almost showed no inhibitory effects on mitochondrial apoptosis-related proteins. These results demonstrated that <b>18</b> can decrease the DAergic neuron loss by inhibiting the mitochondrial apoptotic pathway.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <b>18</b> alleviated the apoptosis of the SNpc neuron in the MPTP-induced acute PD model. (A,D) Original bands of Bax and Bcl-2 in SNpc and STR, β-actin served as control. (B,E) Quantitative analysis of blots. (C,F) Caspase-3 and caspase-9 activities in SNpc and STR. All data are presented as means ± SEM. ***<i>p</i> < 0.001, compared with the control group; ##<i>p</i> < 0.01 or ###<i>p</i> < 0.001, compared with the MPTP treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <b>18</b> Showed a Therapeutic Effect in the MPTP/Probenecid-Induced Behavior Disorder of the Chronic PD Model</h3><div class="NLM_p">Most reported anti-PD agents were pre-treated to mice; hence, the agents possess preventive effects on PD but not therapeutic effects and have limitations in clinical application. Indeed, the DAergic nigrostriatal deficits obtained with the acute administration of MPTP (four injections over 1 day) tend to be reversible. The addition of probenecid potentiates the effects of MPTP, which allows the gradual loss of SNpc neurons and is associated with a substantial loss of striatal DA and DA uptakes.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> This effect lasts for at least 6 months after withdrawal from treatment. Therefore, in this section, the chronic MPTP/probenecid-induced mice model of PD (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A), which closely mimics the chronic and progressive neurodegeneration and behavioral deficits observed in human PD, was used to further investigate the therapeutic effect of <b>18</b> on PD.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Results showed that the mice began to have motor disorders in several behavior tests, namely, traction test (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B), pole test (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C), and open-field test (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>D–G), after 30 days of MPTP/probenecid injection. However, oral treatment with <b>18</b> (1 or 2 mg/kg) considerably reversed these disorders, whereas <span class="smallcaps smallerCapital">l</span>-DOPA did not. These behavior tests indicated that <b>18</b> had therapeutic effects on PD.</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Therapeutic effects of <b>18</b> on MPTP/probenecid-induced chronic PD motor deficits. (A) Experimental procedure and drug administration scheme. (B) Traction test. (C) Rotarod test. (D) Motion trail of the first three mice in each group (no. 1, 2, and 3) in the open-field test (<i>n</i> = 8 mice/group). (E) Total distance of mice in the open-field test (<i>n</i> = 8 mice). (F) Mean velocity of mice in the open-field test (<i>n</i> = 8). (F) Mean speed of mice in the open-field test (<i>n</i> = 8). All data are presented as means ± SEM. ***<i>p</i> < 0.001, compared with the control group; ##<i>p</i> < 0.01 or ###<i>p</i> < 0.001, compared with the MPTP treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <b>18</b> Can Increase the DAergic Neuron Loss Induced by MPTP/Probenecid</h3><div class="NLM_p">Behavior tests demonstrated that <b>18</b> can prevent and treat PD in very low dosages. The therapeutic effects suggest that <b>18</b> might have a function in the repairing of DAergic neuron injury in PD. Immunohistochemistry with TH and DOPA decarboxylase, the two key neural markers of DAergic neurons, was conducted to evaluate the repairing effect of <b>18</b> on DAergic neuron injury and verify the assumption. Results showed that the number of cells positive for TH and DOPA decarboxylase was remarkably decreased compared with the control group after 30 days of MPTP/probenecid injection. This result indicates that many DAergic neurons in the SNpc were lost. However, the number of TH- and DOPA decarboxylase positive cells increased after 20 consecutive days of treatment with <b>18</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A–C). Western blot analysis showed that <b>18</b> can greatly increase the expression of TH and DOPA decarboxylase compared with the MPTP/probenecid group (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>D,E). These results indicated that <b>18</b> can repair damaged DAergic neurons in PD.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effects of <b>18</b> on the repair of DAergic neurons. (A) Immunohistochemical staining showing TH and DOPA decarboxylase-positive cells in the SN (scale bar: 200 μm). (B,C) Stereological counting of TH and DOPA decarboxylase-positive cells (<i>n</i> = 3). (D) Western blot analysis of the changes in the protein level of TH in SNpc. (E) Western blot analysis of the changes in the protein level of DOPA in SNpc. (F,G) Immunofluorescence staining showing GDNF in microglia of mice. All data are presented as means ± SEM. ***<i>p</i> < 0.001, compared with the control group; ##<i>p</i> < 0.01 or ###<i>p</i> < 0.001, compared with the MPTP treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Glial cell line-derived neurotrophic factor (GDNF), which is secreted by microglia, can promote the regeneration of DAergic neurons in the SNpc.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> Therefore, the effect of <b>18</b> on GDNF secretion in glial cells was detected by immunofluorescence histochemistry and enzyme-linked immunosorbent assay. Results showed that <b>18</b> can substantially increase the level of GDNF in glial cells compared with the control and MPTP/probenecid groups (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>F). Furthermore, the level of GDNF in the SNpc was also remarkably increased by <b>18</b> in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>G). These data suggested that the therapeutic effect of <b>18</b> would most likely promote the secretion of GDNF in glial cells to repair damaged DAergic neurons in the SNpc.</div></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> In Vitro ADME/Tox and In Vivo Pharmacokinetic Properties of <b>18</b></h3><div class="NLM_p">The drug-like properties of <b>18</b> were examined through CYP inhibition and microsomal stability tests. The inhibitory effects of <b>18</b> on CYP enzymes (subtypes 2C19, 2D6, 2C9, 1A2, and 3A4) were tested for the possibility of drug–drug interactions. The results are expressed as the percentage of CYP activity that remained after treatment with <b>18</b> at 10 μM (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The stability of <b>18</b> was determined from the percentage of the parent compound remaining after 30 min of incubation with human liver microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The plasma stability of <b>18</b> in mice was also excellent, with 94.2% of the parent compound remaining after 30 min of incubation. In addition, the physicochemical properties of <b>18</b> were confirmed to be compatible with beneficial drug-like properties (predicted p<i>K</i><sub>a</sub> = 6.95; <i>c</i> log <i>P</i> = 2.75). A summary of data related to compound <b>18</b> are shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. In the pharmacokinetic study, we observed that <b>18</b> dosed as an oral solution was rapidly absorbed, and its blood and brain concentrations reached the ideal range (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) and were higher than those of <b>4b</b>. The results suggested that our structure optimization was successful, and the optimization method can increase the activity and improve the efficacy of <b>18</b> in vivo.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Summary of Properties of <b>18</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0014.gif" alt="" id="GRAPHIC-d7e2188-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>a</sub>, log <i>P</i> (<i>c</i> log <i>P</i>)</td><td class="colsep0 rowsep0" align="left">4.03 (4.27)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">inhibition of iNOS response (IC<sub>50</sub>, nM)</td><td class="colsep0 rowsep0" align="left">74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP inhibition (% of control activity, 10 μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">77.4 (2C19), 99.7 (2D6), 96.7 (2C9), 87.2 (1A2), 97.4 (3A4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human microsomal stability (1 μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">86.3 (30 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma stability (% of untreated control)</td><td class="colsep0 rowsep0" align="left">90.2 (60 min)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAMPA-BBB (<i>P</i><sub>e</sub>, cms<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">19.02 ± 1.32 (CNS<sup>+</sup>)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Cytochrome P450 (CYP) inhibition assay was performed using a P450-Glo assay system (Promega).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">In vitro microsomal stability of the synthesized compound; % remaining was determined after 30 min of incubation with human microsomes. The % of parent compound remaining is calculated by comparing peak areas.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetic Properties of <b>18</b> and <b>4b</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">blood</th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">brain</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp.</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0–∞</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0–∞</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4b</b></td><td class="colsep0 rowsep0" align="char" char="±">3453.5 ± 441.9</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">1004.3 ± 107.2</td><td class="colsep0 rowsep0" align="char" char="±">567.3 ± 43.1</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">40.2 ± 5.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char="±">18977.3 ± 1209.2</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">4936.3 ± 267.2</td><td class="colsep0 rowsep0" align="char" char="±">2100.4 ± 100.9</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">578.2 ± 43.1</td></tr></tbody></table></div></div></div><div id="sec2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Safety Profiles of <b>18</b></h3><div class="NLM_p last">In the in vivo toxicity study, <b>18</b> showed satisfactory maximum tolerated doses with a median lethal dose of 3.45 g/kg after being orally administered to mice. The hematoxylin and eosin (HE) staining of the main viscera (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf" class="ext-link">Figure S2</a>) showed that <b>18</b> had no detectable adverse effects in the heart, liver, spleen, lung, and kidney at 1000 mg/kg in the 14-day toxicity study. Organ coefficients (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf" class="ext-link">Table S3</a>), blood biochemistry analysis (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf" class="ext-link">Table S4</a>), body weight (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf" class="ext-link">Figure S3</a>), and blood routine analysis (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf" class="ext-link">Figure S2</a>) also indicated that <b>18</b> can be considered for long-term administration as PD medication.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21885" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21885" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Our previous efforts in achieving iNOS inhibitors with excellent potency have led to a class of molecules bearing a scaffold of NPAs. However, their iNOS inhibitory effects and BBB levels still have much room for improvement. This study describes the design, synthesis, and biological activities of a series of NPA derivatives that act as potent selective iNOS inhibitors. First, 209 NPA derivatives were designed, and among these compounds, 20 NPA derivatives (<b>1–20</b>) with both predicted potent activities, and higher BBB permeability, were finally confirmed to be synthesized through a concise, efficient, and gram-scale method. Some generalities about the SARs of these compounds can be made as the following: (1) the introduction of trifluoromethyl group into the cinnamic acid moiety remarkably increased the activity; (2) NPAs containing aromatic amino acid exhibited better iNOS selectivity than those with aliphatic amino acid. The structure–permeability relationship of these compounds showed that the introduction of the aromatic amino acid and trifluoromethyl group make great contributions to BBB permeability. Notably, the oral administration of <b>18</b> at low dosages (1 and 2 mg/kg) demonstrated preventive and therapeutic effects in the MPTP-induced acute PD model and MPTP/probenecid-induced chronic PD model through iNOS inhibition and DAergic neuronal repair pathways. Our study provided evidence supporting <b>18</b> as a potential candidate for PD treatment because of its potency in vitro and in vivo, impressive penetration of the BBB, and low toxicity.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12676" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12676" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Chemistry</h3><div class="NLM_p last">Reagents and solvents were purchased from common commercial suppliers and were used without further purification. Reaction progress was monitored using analytical thin-layer chromatography on precoated silica gel GF<sub>254</sub> (Qingdao Haiyang Chemical Plant, Qingdao, China) plates. The melting point was determined on a XT4MP apparatus (Taike Corp, Beijing, China). <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained by a BRUKER AVANCE AV-500 (<sup>1</sup>H NMR, 500 MHz; <sup>13</sup>C NMR, 125 MHz) or by BRUKER AVANCE AV-300 (<sup>1</sup>H NMR, 300 MHz; <sup>13</sup>C NMR, 75 MHz) with DMSO-<i>d</i><sub>6</sub> as the solvents and TMS as the internal standard. High-resolution electron impact mass spectra (HRMS) are recorded under an Agilent 6520 Q-TOF mass spectrometer (Agilent Technologies, USA). Optical rotations were measured on a Rudolph Autopol IV polarimeter at 20 °C. The purities of all compounds were confirmed to be higher than 95% by the high-performance liquid chromatography (HPLC) method performed with an Agilent 1260 HPLC System.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure for Synthesis of <b>1</b>–<b>20</b></h3><div class="NLM_p">Under a nitrogen atmosphere, SOCl<sub>2</sub> (1 mL, 13.75 mmol) was added in portions to a solution of <span class="smallcaps smallerCapital">l</span>-amino acid (6 mmol) in methanol (25 mL) at −10 °C within 30 min, and the mixture was warmed to room temperature and stirred for 12 h. After the solvent was removed in vacuum, 80% aqueous ethanol (50 mL) was added to dissolve amino acid methyl ester hydrochloride, and 5.0 mmol corresponding to the substituted cinnamic acid (6 mmol), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl morpholinium chloride (1.65 g, 5.5 mol), NaHCO<sub>3</sub> (500 mg, 6 mmol) was added. The solution was stirred at room temperature for 6 h. The mixture was concentrated and the residue was extracted with EtOAc/H<sub>2</sub>O (50 mL × 3). The combined organic layer was washed with a saturated NaHCO<sub>3</sub> solution and saturated brine solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuum. After recrystallization in PE/EtOAc (5:1–3:1), a series of intermediates, the methyl ester of the target product, were obtained as colorless crystals. The mentioned intermediate was dissolved in 80% aqueous methanol (50 mL), K<sub>2</sub>CO<sub>3</sub> (2.075 g, 15 mmol) was added in portions and the solution was stirred at room temperature for 2 h. The mixture was concentrated, and KHSO<sub>4</sub> (50 mL, 1 M) aqueous solution was added. The residue was extracted with EtOAc (30 mL × 5), and the combined organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuum to afford the final product as a white powder.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-Chloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-phenylalanine Acid (<b>1</b>)</h4><div class="NLM_p last">White powder in 46% yield, mp 126–127 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −14.7 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.80 (s, 1H), 8.53 (1H, d, <i>J</i> = 7.8 Hz), 7.72 (1H, m), 7.70 (1H, d, <i>J</i> = 15.8 Hz), 7.55 (1H, m), 7.44 (2H, m), 7.33–7.22 (5H, m), 6.80 (1H, d, <i>J</i> = 15.8 Hz), 4.61 (1H, m), 3.16 (1H, dd, <i>J</i> = 6.9, 2.9 Hz), 2.98 (1H, dd, <i>J</i> = 6.9, 5.6 Hz); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.32, 164.88, 138.02, 134.97, 133.77, 133.08, 133.06, 131.46, 129.55 (2C), 128.71 (2C), 128.26, 128.05, 126.95, 125.21, 54.19, 37.31. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>ClNO<sub>3</sub>, 330.0819; found, 330.0889.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Chloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-4-F-phenylalanine Acid (<b>2</b>)</h4><div class="NLM_p last">White powder in 55% yield, mp 139–140 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −15.2 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.83 (1H, s), 8.52 (1H, d, <i>J</i> = 9.0 Hz), 7.73–7.67 (1H, m), 7.69 (1H, d, <i>J</i> = 15.7 Hz), 7.51 (1H, dd, <i>J</i> = 5.8, 3.5 Hz), 7.40 (2H, m), 7.29 (2H, m), 6.76 (1H, d, <i>J</i> = 15.7 Hz), 4.60 (1H, m), 3.14 (1H, dd, <i>J</i> = 13.8, 4.9 Hz), 2.94 (1H, dd, <i>J</i> = 13.8, 9.3 Hz); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 172.67, 164.35, 162.63, 159.43, 134.49, 133.61, 133.57, 133.28, 132.52, 130.93, 130.82, 129.92, 127.70, 127.51, 124.61, 115.00, 114.73, 53.64, 35.92. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>15</sub>ClFNO<sub>3</sub>, 348.0724; found, 348.0796.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-Chloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-leucine Acid (<b>3</b>)</h4><div class="NLM_p last">White powder in 42% yield, mp 85–87 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −16.1 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.59 (1H, s), 8.45 (1H, d, <i>J</i> = 8.0 Hz), 7.74 (1H, d, <i>J</i> = 15.8 Hz), 7.71 (1H, m), 7.53 (1H, m), 7.42 (2H, m), 6.78 (1H, d, <i>J</i> = 15.8 Hz), 4.37 (1H, dd, <i>J</i> = 15.1, <i>J</i> = 8.7 Hz), 1.67–1.58 (3H, m), 0.90 (6H, q, <i>J</i> = 6.3Hz); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 177.00, 167.45, 137.51, 136.36, 135.72, 134.00, 133.04, 130.84, 130.62, 127.89, 53.57, 27.46, 25.87, 24.39. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>ClNO<sub>3</sub>, 296.0975; found, 296.1046.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Chloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-isoleucine Acid (<b>4</b>)</h4><div class="NLM_p last">White powder in 53% yield, mp 66–67 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −15.5 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.61 (1H, s), 8.34 (1H, d, <i>J</i> = 8.0 Hz), 7.77(1H, d, <i>J</i> = 15.8 Hz), 7.76 (1H, m), 7.55 (1H, br s), 7.45 (2H, m), 6.95 (1H, d, <i>J</i> = 15.7 Hz), 4.37 (1H, t, <i>J</i> = 4.3 Hz), 1.86 (1H, m), 1.48 (1H, m), 1.26 (1H, m), 0.92 (7H, m); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.34, 165.16, 134.88, 133.80, 133.23, 131.40, 130.48, 128.26, 127.99, 125.50, 56.98, 37.01, 25.25, 16.12, 11.77. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>ClNO<sub>3</sub>, 296.0975; found, 296.1046.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-Chloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-phenylalanine Acid (<b>5</b>)</h4><div class="NLM_p last">White powder in 64% yield, mp 221–224 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −16.9 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.77 (1H, s), 8.42 (1H, d, <i>J</i> = 7.8 Hz), 7.60 (1H, d, <i>J</i> = 8.0 Hz), 7.49 (1H, d, <i>J</i> = 8.0 Hz), 7.42 (1H, d, <i>J</i> = 15.8 Hz), 7.31–7.23 (6H, m), 6.75 (1H, d, <i>J</i> = 15.8 Hz), 4.62 (1H, dd, <i>J</i> = 7.6, <i>J</i> = 4.9 Hz), 3.17 (1H, dd, <i>J</i> = 8.3, 2.7 Hz), 2.96 (1H, dd, <i>J</i> = 8.3, 5.7 Hz); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.41, 165.16, 138.35, 138.06, 134.45, 134.26, 129.73 (2C), 129.55 (2C), 129.44 (2C), 128.69 (2C), 126.93, 123.02, 54.13, 37.35. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>ClNO<sub>3</sub>, 330.0819; found, 330.1046.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-Chloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-4-F-phenylalanine Acid (<b>6</b>)</h4><div class="NLM_p last">White powder in 64% yield, mp 234–235 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −17.7 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.76 (1H, s), 8.42 (1H, d, <i>J</i> = 8.2 Hz), 7.60 (2H, d, <i>J</i> = 8.3 Hz), 7.49 (2H, d, <i>J</i> = 8.3 Hz), 7.41 (1H, d, <i>J</i> = 15.8 Hz), 7.30 (1H, dd, <i>J</i> = 5.3, 3.5 Hz), 7.12 (2H, t, <i>J</i> = 5.3 Hz), 6.73 (1H, d, <i>J</i> = 15.8 Hz), 4.59 (1H, m), 3.14 (1H, dd, <i>J</i> = 8.3, 2.9 Hz), 2.96 (1H, dd, <i>J</i> = 8.3, 5.6 Hz); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.28, 165.15, 162.52, 160.59, 138.38, 134.46, 134.24, 134.19, 131.43, 129.75 (2C), 129.45 (2C), 122.95, 115.47, 115.30, 54.10, 36.47. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>15</sub>ClFNO<sub>3</sub>, 348.0724; found, 348.0797.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-Chloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-leucine Acid (<b>7</b>)</h4><div class="NLM_p last">White powder in 67% yield, mp 158–159 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −18.5 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.58 (1H, s), 8.35 (1H, d, <i>J</i> = 8.0 Hz), 7.59 (2H, d, <i>J</i> = 8.2 Hz), 7.47 (2H, d, <i>J</i> = 8.2 Hz), 7.43 (1H, d, <i>J</i> = 15.8 Hz), 6.74 (1H, d, <i>J</i> = 15.8 Hz), 4.37 (1H, dd, <i>J</i> = 9.0, 6.0 Hz), 1.68–1.55 (3H, m), 0.89 (6H, q, <i>J</i> = 6.2 Hz); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 177.07, 167.76, 140.84, 136.98, 136.89, 132.62 (2C), 132.26 (2C), 125,66, 53.47, 27.45, 25.87, 24.37. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>ClNO<sub>3</sub>, 296.0972; found, 296.1044.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-Chloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-isoleucine Acid (<b>8</b>)</h4><div class="NLM_p last">White powder in 63% yield, mp 137–138 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −19.3 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.58 (1H, s), 8.23 (1H, d, <i>J</i> = 6.8 Hz), 7.61 (2H, br), 7.51 (2H, br), 7.45 (1H, d, <i>J</i> = 15.8 Hz), 6.89 (1H, d, <i>J</i> = 15.8 Hz), 4.37 (1H, t, <i>J</i> = 5.0 Hz), 1.86 (1H, m), 1.48 (1H, m), 1.27 (1H, m), 0.90 (7H, m); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.42, 165.29, 138.20, 134.42, 134.37, 129.67 (2C), 129.46 (2C), 123.30, 56.90, 37.01, 25.23, 16.11, 11.76. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>ClNO<sub>3</sub>, 296.0973; found, 296.1064.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3,4-Dichloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-phenylalanine Acid (<b>9</b>)</h4><div class="NLM_p last">White powder in 59% yield, mp 137–138 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −14.7 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.79 (1H, s), 8.40 (1H, d, <i>J</i> = 7.8 Hz), 7.86 (1H, s), 7.70 (1H, d, <i>J</i> = 8.3 Hz), 7.58 (1H, d, <i>J</i> = 8.3 Hz), 7.39 (1H, d, <i>J</i> = 15.8 Hz), 7.23 (1H, m), 6.80 (1H, d, <i>J</i> = 15.8 Hz), 4.62 (1H, m), 3.17 (1H, dd, <i>J</i> = 8.3, 3.1 Hz), 2.97 (1H, dd, <i>J</i> = 8.2, 5.6 Hz); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.31, 164.87, 137.98, 137.11, 136.24, 132.17, 131.54, 129.93 (2C), 129.55 (2C), 128.70, 127.81, 126.95, 124.48, 54.11, 37.31. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>ClNO<sub>3</sub>, 364.0429; found, 364.0505.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 3,4-Dichloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-4-F-phenylalanine Acid (<b>10</b>)</h4><div class="NLM_p last">White powder in 80% yield, mp 153–154 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −15.6 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.83 (1H, s), 8.40 (1H, d, <i>J</i> = 8.3 Hz), 7.86 (1H, s), 7.70 (1H, d, <i>J</i> = 5.0 Hz), 7.58 (1H, d, <i>J</i> = 5.0 Hz), 7.40 (1H, d, <i>J</i> = 15.8 Hz), 7.31 (1H, m), 7.13 (1H, m), 6.80 (1H, d, <i>J</i> = 15.8 Hz), 4.60 (1H, m), 3.12 (1H, dd, <i>J</i> = 8.3, 2.8 Hz), 2.93 (1H, dd, <i>J</i> = 8.3, 5.5 Hz); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 175.77, 167.44, 167.44, 165.73, 139.72, 138.79, 136.70, 136.66, 134.75, 134.10, 134.03, 133.92, 132.50, 130.38, 126.99, 118.10, 117.82, 56.68, 39.04. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>14</sub>Cl<sub>2</sub>FNO<sub>3</sub>, 382.0335; found, 382.0409.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3,4-Dichloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-leucine Acid (<b>11</b>)</h4><div class="NLM_p last">White powder in 42% yield, mp 107–109 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −16.1 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.60 (1H, s), 8.35 (1H, d, <i>J</i> = 8.0 Hz), 7.85 (1H, br s), 7.68 (1H, d, <i>J</i> = 8.4 Hz), 7.57 (1H, dd, <i>J</i> = 8.4, 1.7 Hz), 7.42 (1H, d, <i>J</i> = 15.8 Hz), 6.78 (1H, d, <i>J</i> = 15.8 Hz), 4.37 (1H, dd, <i>J</i> = 14.6, 8.1 Hz), 1.70–1.55 (3H, m), 0.89 (6H, q, <i>J</i> = 6.3 Hz); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 176.99, 167.47, 139.59, 138.89, 134.14, 132.51, 130.31, 127.17, 53.51, 27.45, 25.88, 24.38. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>17</sub>Cl<sub>2</sub>NO<sub>3</sub>, 330.0583; found, 330.0656.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 3,4-Dichloro-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-isoleucine Acid (<b>12</b>)</h4><div class="NLM_p last">White powder in 54% yield, mp 98–101 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −17.7 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.61 (1H, s), 8.22 (1H, d, <i>J</i> = 8.5 Hz), 7.87 (1H, d, <i>J</i> = 2.6 Hz), 7.70 (1H, d, <i>J</i> = 8.5 Hz), 7.58 (1H, dd, <i>J</i> = 8.5, 2.6 Hz), 7.44 (1H, d, <i>J</i> = 15.8 Hz), 6.96 (1H, d, <i>J</i> = 15.8 Hz), 4.35 (1H, dd, <i>J</i> = 5.0, 3.5 Hz), 1.87 (1H, m), 1.49 (1H, m), 1.25 (1H, m), 0.90 (7H, m); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.37, 164.96, 136.86, 136.43, 132.17, 132.08, 131.56, 129.83, 127.75, 124.88, 57.03, 37.09, 25.22, 16.11, 11.79. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>17</sub>Cl<sub>2</sub>NO<sub>3</sub>, 330.0585; found, 330.0655.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-Methyl-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-phenylalanine Acid (<b>13</b>)</h4><div class="NLM_p last">White powder in 48% yield, mp 135–137 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −19.4 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.76 (1H, s), 8.36 (1H, d, <i>J</i> = 8.0 Hz), 7.44 (2H, d, <i>J</i> = 7.4 Hz), 7.36 (1H, d, <i>J</i> = 15.8 Hz), 7.28–7.20 (7H, m), 6.65 (1H, d, <i>J</i> = 15.8 Hz), 4.59 (1H, m), 3.13 (1H, dd, <i>J</i> = 13.8, 4.8 Hz), 2.95 (1H, dd, <i>J</i> = 11.6, 9.5 Hz), 2.31 (3H, s); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 176.07, 168.08, 142.23, 142.20, 140.68, 135.10, 132.57 (2C), 132.11 (2C), 131.25 (2C), 130.57 (2C), 129.47, 123.72, 56.67, 39.93, 23.97. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>19</sub>NO<sub>3</sub>, 310.1365; found, 310.1437.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-Methyl-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-4-F-phenylalanine Acid (<b>14</b>)</h4><div class="NLM_p last">White powder in 52% yield, mp 143–144 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −19.7 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.75 (1H, s), 8.37 (1H, d, <i>J</i> = 7.8 Hz), 7.47 (1H, d, <i>J</i> = 8.4 Hz), 7.38 (1H, d, <i>J</i> = 15.8 Hz), 6.97 (1H, d, <i>J</i> = 15.8 Hz), 4.60 (1H, m), 3.14 (1H, dd, <i>J</i> = 8.2, 2.6 Hz), 2.96 (1H, dd, <i>J</i> = 8.2, 5.6 Hz), 2.35 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.40, 165.52, 160.59, 139.79, 139.68, 134.26, 134.24, 132.24, 131.43, 131.36, 130.00, 128.02, 121.12, 115.46, 115.29, 54.10, 36.51, 21.39. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>18</sub>FNO<sub>3</sub>, 328.1271; found, 328.1342.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-Methyl-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-leucine Acid (<b>15</b>)</h4><div class="NLM_p last">White powder in 42% yield, mp 94–96 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −20.7 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.55 (1H, s), 8.29 (1H, d, <i>J</i> = 7.8 Hz), 7.48 (2H, d, <i>J</i> = 7.8 Hz), 7.43 (1H, d, <i>J</i> = 15.8 Hz), 7.25 (2H, d, <i>J</i> = 7.8 Hz), 6.70 (1H, d, <i>J</i> = 15.8 Hz), 4.40 (1H, dd, <i>J</i> = 8.5, 4.6 Hz), 2.35 (3H, s), 1.72–1.58 (3H, m), 0.92 (6H, q, <i>J</i> = 3.8Hz); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 174.61, 165.55, 139.72, 139.56, 132.62, 130.02 (2C), 127.97 (2C), 121.28, 50.87, 24.89, 23.31, 21.81, 21.40. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>NO<sub>3</sub>, 276.1521; found, 276.1593.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-Methyl-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-isoleucine Acid (<b>16</b>)</h4><div class="NLM_p last">White powder in 62% yield, mp 75–78 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −19.9 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 8.10 (1H, d, <i>J</i> = 7.2 Hz), 7.48 (2H, d, <i>J</i> = 7.8 Hz), 7.40 (1H, d, <i>J</i> = 15.8 Hz), 7.24 (2H, d, <i>J</i> = 7.8 Hz), 6.86 (1H, d, <i>J</i> = 15.8 Hz), 4.32 (1H, dd, <i>J</i> = 4.3, 3.5 Hz), 1.86 (1H, m), 1.49 (1H, m), 1.25 (1H, m), 0.90 (7H, m); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.87, 165.37, 139.52, 139.08, 132.81, 129.97 (2C), 127.94 (2C), 121.96, 57.72, 37.40, 25.27, 21.38, 16.23, 11.90. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>NO<sub>3</sub>, 276.1521; found, 276.1592.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-Trifluoromethyl-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-phenylalanine Acid (<b>17</b>)</h4><div class="NLM_p last">White powder in 73% yield, mp 222–224 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −20.7 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.85 (1H, s), 8.49 (1H, d, <i>J</i> = 8.0 Hz), 7.79 (4H, s), 7.48 (1H, d, <i>J</i> = 15.8 Hz), 7.32–7.23 (6H, m), 6.86 (1H, d, <i>J</i> = 15.8 Hz), 4.60 (1H, m) 3.14 (1H, dd, <i>J</i> = 8.3, 2.9 Hz), 2.94 (1H, dd, <i>J</i> = 8.3, 5.6 Hz); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.36, 164.85, 139.09, 138.07, 137.98, 129.56 (2C), 128.68 (2C), 126.92 (2C), 126.28 (2C), 125.05, 54.22, 37.35. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>3</sub>, 364.1082; found, 364.1154.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-Trifluoromethyl-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-4-F-phenylalanine Acid (<b>18</b>)</h4><div class="NLM_p last">White powder in 61% yield, mp 236–238 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −19.8 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.79 (1H, s), 8.51 (1H, d, <i>J</i> = 8.1 Hz), 7.77 (4H, s), 7.47 (1H, d, <i>J</i> = 15.9 Hz), 7.28 (2H, m), 6.84 (1H, d, <i>J</i> = 15.9 Hz), 4.58 (1H, m), 3.14 (1H, dd, <i>J</i> = 13.9, 4.9 Hz), 2.94 (1H, dd, <i>J</i> = 13.9, 9.3 Hz); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 175.78, 167.45, 165.72, 162.52, 141.92, 140.63, 136.69, 134.03, 133.92, 132.55, 131.25 (2C), 128.86 (2C), 127.50 (2C), 118.10, 117.82, 56.72, 39.05. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>15</sub>F<sub>4</sub>NO<sub>3</sub>, 382.0988; found, 382.1059.</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-Trifluoromethyl-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-leucine Acid (<b>19</b>)</h4><div class="NLM_p last">White powder in 46% yield, mp 236–238 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −15.7 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.60 (1H, s), 8.44 (1H, d, <i>J</i> = 7.9 Hz), 7.78 (4H, s), 7.51 (1H, d, <i>J</i> = 15.8 Hz), 6.85 (1H, d, <i>J</i> = 15.8 Hz), 4.37 (1H, m), 1.70–1.56 (3H, m), 0.90 (6H, q, <i>J</i> = 6.3 Hz); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 177.00, 167.49, 140.52, 131.21 (2C), 128.33 (2C), 127.66, 53.53, 27.46, 25.88, 24.38. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>, 330.1239; found, 330.1311.</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-Trifluoromethyl-(<i>E</i>)-cinnamoyl]-<span class="smallcaps smallerCapital">l</span>-isoleucine Acid (<b>20</b>)</h4><div class="NLM_p last">White powder in 51% yield, mp 123–125 °C, [α]<sub class="stack">D</sub><sup class="stack">20</sup> −16.4 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 12.63 (1H, s), 8.33 (1H, d, <i>J</i> = 7.8 Hz), 7.80 (4H, s), 7.53 (1H, d, <i>J</i> = 15.8 Hz), 7.02 (1H, d, <i>J</i> = 15.8 Hz), 4.37 (1H, m), 1.88 (1H, m), 1.48 (1H, m), 1.25 (1H, m), 0.92 (7H, m); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 173.35, 165.03, 139.53, 137.90, 129.84, 129.59, 128.61, 126.31, 126.28, 125.28, 56.95, 37.02, 25.23, 16.11, 11.76. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>, 330.1238; found, 330.1311.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Molecular Simulation Study</h3><div class="NLM_p last">A docking study was conducted as per our previous study.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The iNOS crystal structure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R35">1R35</a>) carries an active site where the standard molecule I58 was pre-boned as a co-crystal in IR35.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The filtered 209 designed compounds were subjected to docking in that active site by the CDOCKER protocol on Discovery Studio 3.0 (DS 3.0) software. The protein preparation protocol had been followed for preparing the protein, and the filtered molecules were docked into the active sites on the prepared protein. During the analysis, -CDOCKER energy for every single conformational pose were chosen as a selection criterion. MD simulations for 100 ns were performed on iNOS without and with EuC at 300 K at the molecular mechanic level using the GROMOS96 43a1 force field in GROMACS. The iNOS-<b>18</b> complex was solvated in a cube box of 0.9% NaCl, and the distance between solute and the box was 5 Å. Both the systems were minimized using 1500 steps of the steepest descent for energy minimization. The resulting trajectories were analyzed using <i>rms</i> and <i>rmsf</i> utilities of GROMACS. The GROMACS 5.1.2 program was used for MD, and all graphs were prepared using GraphPad Prism 8.0 software.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Cellular Thermal Shift Assay and Isothermal Dose–Response Fingerprint</h3><div class="NLM_p last">For cellular thermal shift assay (CETSA) and isothermal dose–-response fingerprint (ITDRF) experiments were conducted similar to the previous report.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Briefly, for CESTA experiments, spleen cells were seeded in 10 cm culture dishes and then, the cells were incubated with <b>18</b> (1 μM) in fresh growth medium) for 3 h at 37 °C with an atmosphere of 95% air and 5% CO<sub>2</sub>. The same volume of DMSO was used for a negative control in another 10 cm dish. Subsequently, the medium was removed, and the cells were washed with phosphate-buffered saline (PBS) and distributed into five different microtubes with 80 μL of cell suspension in each tube for both <b>18</b> and DMSO-treated cells. The microtubes were heated at the designated temperature (37 to 73 °C) for 4 min on a heating block. After heating, the microtubes were removed and balanced at 25 °C for another 3 min. Then, the cells were lysed to extract the proteins, separated by sodium dodecyl-sulfate polyacrylamide gel electrophoresis, followed by transfer to a poly(vinylidene difluoride) membrane for western blot analysis. For ITDRF<sub>CETSA</sub> experiments, all procedures are the same as CETSA, and just the cells were incubated with <b>18</b> in different concentrations at designated temperatures.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Surface Plasmon Resonance Assay</h3><div class="NLM_p last">Surface plasmon resonance (SPR) experiments were performed to investigate the binding affinity between <b>18</b> and human recombinant protein iNOS. The procedures were conducted as previously reported with some modifications.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Briefly, purified human recombinant protein iNOS (final concentration: 15 μg/mL) was loaded into the chip at 0.5 μL/s in NaAc buffer (pH 5.5) for 20 min at 4 °C. Then, different concentrations of <b>18</b> (10 mM stock solution in DMSO) in PBS flowed through the surface of the chip at 0.5 μL/s in PBST (pH 7.4) for 600 s at 4 °C. Finally, the proteins were dissociated from the chip at 2 μL/s in glycine–HCl (pH 2.0) for 360 s at 4 °C. The binding signals (RU) were detected by SPR using a Biacore T200 (GE Healthcare, USA). The RU responses of test compounds with purified recombinant protein iNOS were recorded and ranked, and the binding curve and affinity data were calculated by the system according to the Langmuir binding model.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Cell Culture</h3><div class="NLM_p last">The immortalized murine microglial cell line BV-2 cells and human neuroblastoma SH-SY5Y cells were routinely maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin at 37 °C in a humidified atmosphere of 95% air and 5% CO<sub>2</sub>. All reagents for cell culture were purchased from Invitrogen (CA, USA).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Animals</h3><div class="NLM_p last">Male C57BL/6 mice (6–8 weeks old, weighing 20–22 g) were purchased from Comparative Medicine Center (Yangzhou University, China). Mice were acclimatized for 7 days before use. All animals were maintained under a standard housing environment at a temperature of 22–25 °C and kept on a 12 h light–dark cycle and were allowed free access to food and water. All experimental procedures were approved by the Ethical Committee of the China Pharmaceutical University (no. SYXK2016-0011).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> NO Production Assay</h3><div class="NLM_p last">For the compound screening experiments, the cells were plated in 96-well plates at a density of 5 × 10<sup>3</sup> cells/well and 24 h later were treated with compounds <b>1</b>–<b>20</b> or <b>4b</b> at 1 μM. Then, 6 h later the cells were treated with LPS (500 ng/mL) and incubated for another 24 h, and the culture media were collected for the detection of the NO inhibition using a commercial NO detection kit (Beyotime, China) at 540 nm (microplate reader, TECAN, Infinite M200, Austria).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> NOS Enzyme Inhibition Assay</h3><div class="NLM_p last">The inhibitory effect of compounds <b>1</b>–<b>20</b> on NOS isoforms were evaluated mainly according to previous studies.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Compounds <b>1</b>–<b>20</b> were evaluated for their abilities to inhibit human iNOS, eNOS, and nNOS (which were purchased from Abcam) mediated the conversion of [<sup>3</sup>H]arginine to [<sup>3</sup>H]citrulline. Various concentrations of compounds (0.01–10 μM) were incubated with 10 nM [<sup>3</sup>H]arginine and [<sup>14</sup>C]citrulline (80–120 nM) as an internal standard, cofactors (1.4 mM β-NADP<sup>+</sup>, 3.0 mM glucose-6-phosphate (G6P), 3.4 mM MgCl<sub>2</sub>, 0.4 U/mL G6P dehydrogenase, 5.0 μM FAD, 5.0 μM FMN, 5.0 μM BH<sub>4</sub>), and enzyme in 100 μL of 50 mM HEPES buffer for 1 h at 37 °C. For eNOS and nNOS assays, additional cofactors 25 nM calmodulin, 0.5 mM CaCl<sub>2</sub>, and 3.5 mM glutathione were included in the reactions. The reactions were stopped by the addition of 25 μL of 1 M MES and filtered through a AG-50W-X8 (200–400 mesh, Na form) cation exchange resin that had been loaded onto 96-well filter plates using a 100 μL column loader (Millipore). Then, the filtrate was rinsed with 75 and 25 μL ddH<sub>2</sub>O, respectively, and the filtrate was collected and the radioactivity in the filtrate was counted. Background activity was determined in the presence of 10 μM AMT. Dose–response curves were drawn according to eight test concentrations (0.01–10 μM), and IC<sub>50</sub> values were calculated by GraphPad Prism 8.0 (for macOS) and were from a single experiment that was repeated three times with similar results. The calculated standard deviations from dose–response curves of the assays were less than 10% with all NOSs.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> D-QSAR Study</h3><div class="NLM_p last">Among all the 20 compounds, 80% (i.e., 16) were utilized as a training set for QSAR modeling and the remaining 20% (i.e., 4) were chosen as an external test subset for validating the reliability of the QSAR model by the diverse molecules protocol in DS 3.0 software. The inhibitory activity of the compounds [IC<sub>50</sub> (μM)] was initially changed into the minus logarithmic scale [IC<sub>50</sub> (μM)] and then used for subsequent QSAR analysis as the response variable. QSAR models were built by using the create 3D QSAR model protocol in DS 3.0.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> PAMPA-BBB Assay</h3><div class="NLM_p last">The PAMPA-BBB assay was performed as per previous study.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Briefly, the assay was conducted in 10 mM PBS buffer (PH 7.4), and compounds were tested at a concentration of 200 μM. The donor plate was first coated with 4 μL of the porcine brain lipid (20 mg/mL in dodecane), followed by an addition of 250 μL of a test compound. The acceptor plate was filled with 250 μL of PBS, and the donor plate was carefully placed on top of the acceptor plate to make a “sandwich”. The plate was incubated at 25 °C for 17 h in a saturated humidity atmosphere with an orbital agitation at 100 rpm. After that, 150 μL of the test solution was collected from each well from both sides (donor and acceptor) and transferred to the UV plate for measurement. The effective permeability (<i>P</i><sub>e</sub>) was calculated by the equation: <span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_m001.gif" alt="" id="_i56" /></img></span>, where <i>P</i><sub>e</sub> is the effective permeability (cm s<sup>–1</sup>); <i>V</i><sub>A</sub> and <i>V</i><sub>D</sub> are the volumes of the acceptor and donor wells (0.25 cm<sup>3</sup>), respectively; <i>C</i><sub>A(<i>t</i>)</sub> is the concentration of the acceptor well at time <i>t</i>; <i>C</i><sub>D(0)</sub> and <i>C</i><sub>D(<i>t</i>)</sub> are the concentrations of the donor well at <i>t</i><sub>0</sub> and <i>t</i>, respectively; <i>A</i> is the filter well area (0.21 cm<sup>2</sup>); <i>t</i> is the incubation time (s); τ<sub>ss</sub> is the time to reach a steady state (usually very short compared with the incubation time); and <i>R</i> is the retention membrane factor and was calculated using the following equation: <span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_m002.gif" alt="" id="_i57" /></img></span>. <i>P</i><sub>e</sub> was reported as an average of a triplicate with a standard deviation.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Cell Medium Collection</h3><div class="NLM_p last">BV-2 cells (1 × 10<sup>4</sup> cells/well in a 24-well plate) were pre-treated with <b>18</b> (0.1, 1, and 10 μM) for 2 h and then stimulated with LPS (500 ng/mL) for 24 h. The culture media were collected as CM after centrifugation at 2000 rpm for 5 min.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Cell Viability and LDH Release Assays</h3><div class="NLM_p last">SH-SY5Y cells (1 × 10<sup>4</sup> cells/well in a 96-well plate) were seeded 24 h before the CM test. The CM from LPS-stimulated cells was added to SH-SY5Y cells, which were further incubated at 37 °C for 24 h, and then the supernatant was collected to detect the LDH release using the LDH cytotoxicity assay kit (Beyotime, China), and cell viability was measured using the CCK8 assay according to the kit specifications (Dojindo Laboratories, Japan).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Hoechst 33258 Staining and Annexin V–PI Double Staining</h3><div class="NLM_p last">SH-SY5Y cells (2 × 10<sup>5</sup> cells/well in a 6-well plate) were seeded 24 h before the CM test. The CM from LPS-stimulated cells was added to SH-SY5Y cells, which were further incubated at 37 °C for 24 h. For Hoechst 33258 staining (Beyotime, China), the cells were washed with cold PBS three times, and then added Hoechst 33258 (final concentration of 5 μg/mL) for 30 min. After that, cells were washed with cold PBS three times. Finally, images were obtained using a fluorescence microscope (Ts-100, Nikon, Japan). For annexin V–PI double staining, the cells were washed with cold PBS three times and were adjusted to the density of 1 × 10<sup>6</sup> cells/mL with binding buffer. Then, the staining assay was conducted according to the kit (BD Pharmingen, USA). Finally, all samples were detected by a flow cytometer (Becton Dickin-son, NJ, USA).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Establishment of the MPTP-Induced Acute PD Model and Drug Treatment</h3><div class="NLM_p last">40 C57BL/6 mice were randomly divided into five groups (<i>n</i> = 8 mice/group), including the control group, MPTP-treated group, MPTP + <span class="smallcaps smallerCapital">l</span>-DOPA (15 mg/kg, i.g.) group, MPTP + <b>18</b> (1 mg/kg, i.g.) group, and MPTP + <b>18</b> (2 mg/kg, i.g.) group and allowed 3 days to acclimate before any treatments. DI water containing 0.5% CMC-Na and 1% Tween 80 was used to dissolve <b>18</b> and <span class="smallcaps smallerCapital">l</span>-DOPA. From day 1 to day 3, for all mice behavior training was conducted. Then, <b>18</b> and <span class="smallcaps smallerCapital">l</span>-DOPA were pre-administered daily for 10 days (day 4 to day 13). The control group and model group were administered equal volumes of the blank solvent. At day 14, four intraperitoneally (i.p.) injections of MPTP hydrochloride (20 mg/kg) were administered to mice at 2 h intervals a day. After the last MPTP injection, the mice were subjected to the rotarod test, traction test, and open-field test at different time points. 10 days later after MPTP injection, SNpc and STR were collected to perform western blot, immunohistochemistry, and the other biochemical criterion detection.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Establishment of the MPTP/Probenecid-Induced Chronic PD Model and Drug Treatment</h3><div class="NLM_p last">32 C57BL/6 mice were randomly divided into four groups (<i>n</i> = 8 mice/group), including control group, MPTP/probenecid-treated group, MPTP/probenecid + <b>18</b> (1 mg/kg, i.g.) group, and MPTP/probenecid + <b>18</b> (2 mg/kg, i.g.) group and allowed 3 days to acclimate before any treatments. DI water containing 0.5% CMC-Na and 1% Tween 80 was used to dissolve <b>18</b>. From day 1 to day 32, the mice were administered MPTP hydrochloride (25 mg/kg in saline) in combination with probenecid (250 mg/kg in DMSO, ip) every three-and-a-half days. After the last MPTP/prob injection, the mice were continually treated daily with <b>18</b> (1 or 2 mg/kg) for the next 20 days. Then, the traction test, rotarod test, and open-field test were conducted from day 52 to day 54 to evaluate the therapeutic effects of <b>18</b> on PD. At day 55, all mice were sacrificed to perform further biochemical detections.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Traction Test<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></h3><div class="NLM_p last">Traction test was performed as a previous study to assess the limb impairment. Mice were hung from a horizontal wire by its forepaws. The mouse was scored 3 points if it grasped the wire with both hind paws, and 2 points if it grasped the wire with one hind paw, and 1 point if it did not grasp the wire with either hind paws. The average time of three tests was calculated for statistical analyses.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Rotarod Test<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></h3><div class="NLM_p last">The rotarod test was performed as our previous study using a rotary rod apparatus. All mice were pre-trained for 3 days prior to drug administration. The training consisted of three consecutive runs with a gradual increase in rpm up to a maximum 25 rpm until the mice were able to keep themselves without falling from the rotary rod for up to 180 s. The average time of three tests was calculated for statistical analyses.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Open-Field Test<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h3><div class="NLM_p last">Spontaneous locomotor activity was assessed using the open-field test with an automatic recording open-field working station (ZhongShi, Beijing, China). Mice were placed individually in an acrylic apparatus (30 cm × 30 cm × 15 cm) with a floor divided into 6 × 6 cm equal squares in order to explore the arena. The arena was cleaned with 75% ethanol solution and let dry after testing each mouse to avoid the presence of olfactory cues. Total distance and mean velocity were analyzed over a period of 5 min.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Detection of the NO Level, DA Level, and GDNF Level</h3><div class="NLM_p last">Brains were removed to strip the SNpc and STR. Samples were homogenized and centrifuged at 2000<i>g</i> for 15 min at 4 °C to separate the supernatant. The concentrations of GDNF and DA were measured by the enzyme-linked immunosorbent assay kits (CUSABIO, Wuhan, China) and the NO level was measured by Griess Reagent (Beyotime, China); the procedures followed the instructions.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Histochemical Analysis</h3><div class="NLM_p last">The TH and DOPA decarboxylase immunohistochemical analyses were performed as previously described. Briefly, brains were removed and cut into 30 μm sections using a freezing microtome (Microm, Walldorf, Germany), and the coronal sections through the substantia nigra (SNpc) and STR were processed. The sections were incubated with primary antibodies against TH or DOPA decarboxylase (Abcam, MA, USA) and the labeled proteins were visualized using 0.06% hydrogen peroxidase and 0.05% 3,3′-diaminobenzidine. After DAB staining, the sections were observed using a light microscope (Nikon, Ts-100, Japan), and the number of positively stained cells in each group was recorded.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Fluorescence Immunohistochemistry</h3><div class="NLM_p last">The sections were incubated with the following primary antibody GDNF: a polyclonal rabbit anti-GDNF (Abcam, MA, USA) with a dilution of 1:100 dilution. After incubation, the sections were then incubated with the following secondary antibodies: Alexa Fluor 488 rabbit anti-mouse (1:1000 dilution; Abcam, MA, USA). The sections were counterstained with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; KeyGen, China). Each section was analyzed microscopically (Nikon, Ts-100, Japan).</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Western Blot Analysis</h3><div class="NLM_p last">The western blot analysis was conducted as per our previous study.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Briefly, at the end of the last day, brains were removed to strip the SNpc and STR. Then, the SNpc and STR were adequately lysed in RIPA (100 mg tissue/mL PBS). Then, the BCA assay (Beyotime, China) was used to adjust the concentration of each sample protein to 3 mg/mL. Equal amounts of protein extracts (30 μg) were subject to immunoblot analysis using primary antibodies (all in 1:1000 dilution) followed by secondary antibodies (1:5000 dilution). All the antibodies were purchased from Abcam (MA, USA). The exposure was conducted by a chemiluminescence apparatus (Tanon 5200, China).</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> CYP Inhibition Assay</h3><div class="NLM_p last">CYP inhibition was conducted using a P450-Glo screening system (Promega, Corp.) according to the instructions (Promega Technical Bulletin, P540-Glo). Briefly, the CYP enzyme and the substrate were mixed in KH<sub>2</sub>PO<sub>4</sub> buffer (100 mM, pH 7.4) with or without <b>18</b> (10 μM), and the reaction was initiated by the addition of the NADPH regeneration system (containing NADP<sup>+</sup>, MgCl<sub>2</sub>, G6P, and G6P dehydrogenase). After incubation for 10–30 min at 37 °C (different incubation times depending on the CYP isotype), the reconstituted luciferin detection reagent was added to stop the reaction and generate the luminescent signal. After incubation for 20 min to stabilize the luminescence, signals were detected using a microplate reader (TECAN, Infinite M200, Austria); the inhibition of each CYP isotype by <b>18</b> was expressed as the percentage of activity versus control.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Human Microsomal Stability</h3><div class="NLM_p last">Human liver microsomes (0.5 mg/mL) were preincubated with <b>18</b> at 1 μM in 0.1 M phosphate buffer (pH 7.4) at 37 °C for 5 min before adding the NADPH regeneration buffer (ditto). The incubation was started by treating the NADPH regeneration buffer and terminating with chlorpropamide in acetonitrile after 30 min at 37 °C. Precipitated proteins were removed by centrifugation for 5 min at 14,000<i>g</i> at 4 °C. The supernatant was injected into a liquid chromatography/mass spectrometry (LC–MS) system and analyzed using a Shimadzu Nexera XR system (Shimadzu Corporation, Kyoto, Japan). The HPLC column was a Luna C<sub>18</sub> column (2.0 × 5 mm, 4.6 μm), and the mobile phase was distilled water (A) containing 0.1% formic acid and acetonitrile (B) containing 0.1% formic acid. Data analysis was performed using Xcalibur 1.6 software. The percentage of remaining <b>18</b> was calculated by comparing the peak area.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Plasma Stability</h3><div class="NLM_p last">In vitro stability of <b>18</b> was carried out with an initial concentration of 1000 ng/mL in the rat plasma at 37 °C. A 100 μL of plasma was aliquoted from the incubation solution at 0.5 h, followed by solid-phase extraction. 10 μL of supernatant of each sample was injected into a LC–MS system and analyzed using a Shimadzu Nexera XR system (Shimadzu Corporation, Kyoto, Japan). The HPLC column was a Luna C<sub>18</sub> column (2.0 × 5 mm, 4.6 μm), and the mobile phase was distilled water (A) containing 0.1% formic acid and acetonitrile (B) containing 0.1% formic acid. Data analysis was performed using Xcalibur 1.6 software. The percentage of remaining <b>18</b> was calculated by comparing the peak area.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Pharmacokinetic Analysis</h3><div class="NLM_p last">Male BALB/c mice were randomly divided into two groups, including the control group and the drug treatment group. After 16 h of fasting, mice in the drug treatment group were intragastrically administered <b>18</b> at a single dose of 30 mg/kg, while the control group were given the same volume of the blank solvent. Then, blood samples and brain samples were collected at 5, 10, 15, and 30 min and 1, 2, 6, 8, 12, and 24 h after dosing, following the decapitation of the animal. The plasma was prepared by centrifuging the blood at 5000 rpm for 10 min and the brains were homogenized with saline, centrifuged at 10,000<i>g</i> for 10 min, and then the supernatant was collected. After that, 300 μL of methyl alcohol was added to 300 μL of plasma or brain supernatant, and vortexed 3 min, centrifuged at 10,000<i>g</i> for 10 min, and then the supernatant was collected. Then, a 5 μL aliquot of the plasma or brain extract was injected into the LC–MS system on a Shimadzu LCMS-2020 single quadrupole system (Shimadzu Scientific Instruments Inc., Japan). For the detection of <b>18</b> and <b>4b</b>, an isocratic chromatographic procedure was used with a mobile phase of 40% acetonitrile (0.1% formic acid) and 65% acetonitrile (0.1% formic acid), respectively, at a flow rate of 0.5 mL/min. The chromatographic procedure was performed using the Agilent SB-C18 column (2.1 × 50 mm, 1.8 μm, Agilent Technologies, USA) at 30 °C.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> In Vivo Toxicity Assessment</h3><div class="NLM_p last">Male BALB/c mice were administered (i.g.) with <b>18</b> at 500, 1000, 2000, and 3000 mg/kg for 14 consecutive days. During the 14 days, the mortality of each group (<i>n</i> = 12 mice/group) was counted. At the 15th day, the mice (1000 mg/kg group) were killed, and the blood was collected to conduct blood biochemical analysis (Siemens, ADVIA 2120I, Germany), and the main viscera, including the heart, liver, spleen, lung, and kidney, were removed to perform HE staining.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> HE Staining</h3><div class="NLM_p last">HE staining was conducted as per a previous study. Briefly, the heart, liver, spleen, lung, and kidney were collected to be cut into 30 μm sections using a freezing microtome (Microm, Walldorf, Germany). Then, the HE staining was performed on the sections according to the kit’s specification (KeyGEN BioTECH, China).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Statistical Analysis</h3><div class="NLM_p last">The data were expressed as mean ± SD or SEM and analyzed using a one-way analysis of variance (ANOVA), followed by Dunnett’s post hoc test. <i>p</i> < 0.05 was considered statistically significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00578" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85454" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85454" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00578?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00578</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Structure characterization of compounds <b>1</b>–<b>20</b> by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and ESI/HRMS spectroscopy; HPLC analysis of compounds <b>1</b>–<b>20</b>; chemical structures of 209 designed compounds; docking scores (-kcal/mol) and BBB level prediction of 209 compounds; organ coefficients and blood biochemistry analysis; correlation coefficient R2; H–E staining of main viscera; and effects of <b>18</b> on the body weight and hemocyte number (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular string files for compounds <b>1</b>–<b>20</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Compound <b>18</b> with 1R35 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf">jm1c00578_si_001.pdf (2.55 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_002.csv">jm1c00578_si_002.csv (1.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_003.pdb">jm1c00578_si_003.pdb (534.68 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00578" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fei Xiong</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Bioelectronics, Jiangsu Laboratory for Biomaterials
and Devices, Southeast University, Nanjing 210009, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-3680-4292" title="Orcid link">https://orcid.org/0000-0002-3680-4292</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#90e8f9fffef7f6f5f9d0e3f5e5bef5f4e5bef3fe"><span class="__cf_email__" data-cfemail="dba3b2b4b5bcbdbeb29ba8beaef5bebfaef5b8b5">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, School of Traditional Chinese
Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3994-9806" title="Orcid link">https://orcid.org/0000-0003-3994-9806</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9aedfbf4fdf2fbf5daf9eaefb4fffeefb4f9f4"><span class="__cf_email__" data-cfemail="d4a3b5bab3bcb5bb94b7a4a1fab1b0a1fab7ba">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao-Long Hu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, School of Traditional Chinese
Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xian-Yu Lv</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, School of Traditional Chinese
Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rong Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, School of Traditional Chinese
Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huan Long</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, School of Traditional Chinese
Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia-Hao Feng</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, School of Traditional Chinese
Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bao-Lin Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, School of Traditional Chinese
Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Shen</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, School of Traditional Chinese
Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, School of Traditional Chinese
Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao-Qi Zhang</span> - <span class="hlFld-Affiliation affiliation">Institute
of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou 510632, People’s Republic
of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4436-0273" title="Orcid link">https://orcid.org/0000-0002-4436-0273</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen-Cai Ye</span> - <span class="hlFld-Affiliation affiliation">Institute
of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou 510632, People’s Republic
of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2810-1001" title="Orcid link">https://orcid.org/0000-0002-2810-1001</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Financial support from the China Postdoctoral Science Foundation (nos. 2019M662006, 2019TQ0357), the National Natural Science Foundation of China (nos. 81973206 and 82073804), the Major National Science and Technology Projects of the Chinese 13th five-year plan (no. 2017ZX09309024), the Jiangsu Province Graduate Student Training Innovation Project (no. KYLX16_1208), and the Pharmaceutical Top-Notch Innovative Talent Training Program of China Pharmaceutical University is acknowledged.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ANOVA</td><td class="NLM_def"><p class="first last">analysis of variance</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">CETSA</td><td class="NLM_def"><p class="first last">cellular thermal shift assay</p></td></tr><tr><td class="NLM_term">CM</td><td class="NLM_def"><p class="first last">culture medium</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">COMT</td><td class="NLM_def"><p class="first last">catechol-<i>O</i>-methyl-transferase</p></td></tr><tr><td class="NLM_term">DA</td><td class="NLM_def"><p class="first last">dopamine</p></td></tr><tr><td class="NLM_term">DS</td><td class="NLM_def"><p class="first last">Discovery Studio</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium</p></td></tr><tr><td class="NLM_term">DAPI</td><td class="NLM_def"><p class="first last">4′,6-diamidino-2-phenylindole dihydrochloride</p></td></tr><tr><td class="NLM_term">DMTMM</td><td class="NLM_def"><p class="first last">4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride</p></td></tr><tr><td class="NLM_term">eNOS</td><td class="NLM_def"><p class="first last">endothelial nitric oxide synthase</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">GDNF</td><td class="NLM_def"><p class="first last">glial cell line-derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">HE</td><td class="NLM_def"><p class="first last">hematoxylin–eosin</p></td></tr><tr><td class="NLM_term">iNOS</td><td class="NLM_def"><p class="first last">inducible nitric oxide synthase</p></td></tr><tr><td class="NLM_term">MPTP</td><td class="NLM_def"><p class="first last">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</p></td></tr><tr><td class="NLM_term">MAO-B</td><td class="NLM_def"><p class="first last">monoamine oxidase type B</p></td></tr><tr><td class="NLM_term">NPAs</td><td class="NLM_def"><p class="first last"><i>N</i>-phenylpropenoyl-<span class="smallcaps smallerCapital">l</span>-amino acids</p></td></tr><tr><td class="NLM_term">NOS</td><td class="NLM_def"><p class="first last">nitric oxide synthase</p></td></tr><tr><td class="NLM_term">nNOS</td><td class="NLM_def"><p class="first last">neuronal nitric oxide synthase</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">QSAR</td><td class="NLM_def"><p class="first last">quantitative structure–activity relationship</p></td></tr><tr><td class="NLM_term">RMSF</td><td class="NLM_def"><p class="first last">root-mean-square fluctuations</p></td></tr><tr><td class="NLM_term">RMSD</td><td class="NLM_def"><p class="first last">root-mean-square deviation</p></td></tr><tr><td class="NLM_term">STR</td><td class="NLM_def"><p class="first last">striatum</p></td></tr><tr><td class="NLM_term">SNpc</td><td class="NLM_def"><p class="first last">substantia nigra pars compacta</p></td></tr><tr><td class="NLM_term">SARs</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">TH</td><td class="NLM_def"><p class="first last">tyrosine hydroxylase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10520" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10520" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dostrovsky, J. O.</span></span> <span> </span><span class="NLM_article-title">New developments in understanding the etiology of Parkinson’s disease and in its treatment</span>. <i>Curr. Opin. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1016/s0959-4388(98)80122-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2FS0959-4388%2898%2980122-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=9914234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADyaK1MXhs12rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=783-790&author=A.+M.+Lozanoauthor=A.+E.+Langauthor=W.+D.+Hutchisonauthor=J.+O.+Dostrovsky&title=New+developments+in+understanding+the+etiology+of+Parkinson%E2%80%99s+disease+and+in+its+treatment&doi=10.1016%2Fs0959-4388%2898%2980122-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">New developments in understanding the etiology of Parkinson's disease and in its treatment</span></div><div class="casAuthors">Lozano, Andres M.; Lang, Anthony E.; Hutchison, William D.; Dostrovsky, Jonathon O.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurobiology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">783-790</span>CODEN:
                <span class="NLM_cas:coden">COPUEN</span>;
        ISSN:<span class="NLM_cas:issn">0959-4388</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">A review, with 68 refs.  Important recent advances have been made in understanding the etiol. and pathogenesis of Parkinson's disease, as well as in developing novel treatments.  Two newly identified genes, α-synuclein and parkin, have been linked to parkinsonism.  In addn., disturbances to the normal basal ganglia circuits in Parkinson's patients are being described at both anatomical and physiol. levels.  These developments provide a strong scientific basis for novel medical and surgical strategies to treat the profound motor disturbances in patients with Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodlpVrZ3PxRbVg90H21EOLACvtfcHk0lhGXFQWq9c1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhs12rtw%253D%253D&md5=92603a33810b19c8c3b1eb2b23e470ae</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0959-4388%2898%2980122-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-4388%252898%252980122-0%26sid%3Dliteratum%253Aachs%26aulast%3DLozano%26aufirst%3DA.%2BM.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DHutchison%26aufirst%3DW.%2BD.%26aulast%3DDostrovsky%26aufirst%3DJ.%2BO.%26atitle%3DNew%2520developments%2520in%2520understanding%2520the%2520etiology%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520in%2520its%2520treatment%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D1998%26volume%3D8%26spage%3D783%26epage%3D790%26doi%3D10.1016%2Fs0959-4388%2898%2980122-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcão, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease</span>. <i>Eur. J. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">815</span>, <span class="refDoi"> DOI: 10.1111/ene.12666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1111%2Fene.12666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=25649051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A280%3ADC%252BC2MritlCqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=815&author=J.+J.+Ferreiraauthor=J.-F.+Rochaauthor=A.+Falc%C3%A3oauthor=A.+Santosauthor=R.+Pintoauthor=T.+Nunesauthor=P.+Soares-da-Silva&title=Effect+of+opicapone+on+levodopa+pharmacokinetics%2C+catechol-O-methyltransferase+activity+and+motor+fluctuations+in+patients+with+Parkinson%E2%80%99s+disease&doi=10.1111%2Fene.12666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease</span></div><div class="casAuthors">Ferreira J J; Rocha J-F; Falcao A; Santos A; Pinto R; Nunes T; Soares-da-Silva P</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">815-25, e56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Opicapone (OPC) is a novel third generation catechol-O-methyltransferase (COMT) inhibitor that enhances levodopa availability.  This study investigated the effects of OPC in comparison with placebo on levodopa pharmacokinetics, tolerability and safety, COMT activity and motor response to levodopa in Parkinson's disease (PD) patients with motor fluctuations.  METHODS:  This was a randomized, multicentre, double-blind and placebo-controlled study in four parallel groups of PD patients treated with standard-release 100/25 mg levodopa/carbidopa or levodopa/benserazide and with motor fluctuations (wearing-OFF phenomenon).  Subjects were sequentially assigned to be administered, once-daily, up to 28 days (maintenance phase), placebo (n = 10) or 5 (n = 10), 15 (n = 10) and 30 mg (n = 10) OPC.  Two levodopa tests were performed, one at baseline and another following the maintenance phase.  Subjects kept a diary to record motor fluctuations (ON/OFF periods) throughout the study.  RESULTS:  In relation to placebo, levodopa exposure (AUC0-6) increased 24.7%, 53.9% and 65.6% following 5, 15 and 30 mg OPC, respectively.  Maximum COMT inhibition (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg OPC).  The study was not designed to detect any significant differences in motor performance, but the exploratory analysis performed shows improvement in various motor outcomes, including a dose-dependent change in absolute OFF time corresponding to a percentage decrease of 4.16% (P > 0.05), 29.55% (P > 0.05) and 32.71% (P < 0.05) with 5, 15 and 30 mg OPC, respectively.  Treatments were generally well tolerated and safe.  CONCLUSIONS:  OPC is a promising new COMT inhibitor that significantly decreased COMT activity, increased systemic exposure to levodopa and improved motor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEuvMtwfdhHOQ4Pl9hzjQhfW6udTcc2ea2vf8cFvzWeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MritlCqsA%253D%253D&md5=7b33ae752bc6ace3867a38b8f9e6e9c8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fene.12666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fene.12666%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DJ.%2BJ.%26aulast%3DRocha%26aufirst%3DJ.-F.%26aulast%3DFalc%25C3%25A3o%26aufirst%3DA.%26aulast%3DSantos%26aufirst%3DA.%26aulast%3DPinto%26aufirst%3DR.%26aulast%3DNunes%26aufirst%3DT.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26atitle%3DEffect%2520of%2520opicapone%2520on%2520levodopa%2520pharmacokinetics%252C%2520catechol-O-methyltransferase%2520activity%2520and%2520motor%2520fluctuations%2520in%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Neurol.%26date%3D2015%26volume%3D22%26spage%3D815%26doi%3D10.1111%2Fene.12666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, A. H. V.</span></span> <span> </span><span class="NLM_article-title">Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1071</span>, <span class="refDoi"> DOI: 10.2165/11596310-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.2165%2F11596310-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=22133327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1061-1071&author=A.+H.+V.+Schapira&title=Monoamine+oxidase+B+inhibitors+for+the+treatment+of+Parkinson%E2%80%99s+disease%3A+a+review+of+symptomatic+and+potential+disease-modifying+effects&doi=10.2165%2F11596310-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects</span></div><div class="casAuthors">Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1061-1071</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease is a disorder characterized pathol. by progressive neurodegeneration of the dopaminergic cells of the nigrostriatal pathway.  Although the resulting dopamine deficiency is the cause of the typical motor features of Parkinson's disease (bradykinesia, rigidity, tremor), addnl. non-motor symptoms appear at various timepoints and are the result of non-dopamine nerve degeneration.  Monoamine oxidase B (MAO-B) inhibitors are used in the symptomatic treatment of Parkinson's disease as they increase synaptic dopamine by blocking its degrdn.  Two MAO-B inhibitors, selegiline and rasagiline, are currently licensed in Europe and North America for the symptomatic improvement of early Parkinson's disease and to reduce off-time in patients with more advanced Parkinson's disease and motor fluctuations related to levodopa.  A third MAO-B inhibitor (safinamide), which also combines addnl. non-dopaminergic properties of potential benefit to Parkinson's disease, is currently under development in phase III clin. trials as adjuvant therapy to either a dopamine agonist or levodopa.  MAO-B inhibitors have also been studied extensively for possible neuroprotective or disease-modifying actions.  There is considerable lab. evidence that MAO-B inhibitors do exert some neuroprotective properties, at least in the Parkinson's disease models currently available.  However, these models have significant limitations and caution is required in assuming that such results may easily be extrapolated to clin. trials.  Rasagiline 1 mg/day has been shown to provide improved motor control in terms of Unified Parkinson's Disease Rating Scale (UPDRS) score at 18 mo in those patients with early disease who began the drag 9 mo before a second group.  There are a no. of possible explanations for this effect that may include a disease-modifying action; however, the US FDA recently declined an application for the licence of rasagiline to be extended to cover disease modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2AHDUDO6Ch7Vg90H21EOLACvtfcHk0lhR76X8pFZKPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D&md5=a6c6a9380eaa9056a877fa0df9e39446</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2165%2F11596310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26atitle%3DMonoamine%2520oxidase%2520B%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520review%2520of%2520symptomatic%2520and%2520potential%2520disease-modifying%2520effects%26jtitle%3DCNS%2520Drugs%26date%3D2011%26volume%3D25%26spage%3D1061%26epage%3D1071%26doi%3D10.2165%2F11596310-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koprich, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piggott, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotchie, J. M.</span></span> <span> </span><span class="NLM_article-title">UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2014.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.neuropharm.2014.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=24447715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFynt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=76-87&author=P.+Huotauthor=T.+H.+Johnstonauthor=K.+D.+Lewisauthor=J.+B.+Koprichauthor=M.+G.+Reyesauthor=S.+H.+Foxauthor=M.+J.+Piggottauthor=J.+M.+Brotchie&title=UWA-121%2C+a+mixed+dopamine+and+serotonin+re-uptake+inhibitor%2C+enhances+L-DOPA+anti-parkinsonian+action+without+worsening+dyskinesia+or+psychosis-like+behaviours+in+the+MPTP-lesioned+common+marmoset&doi=10.1016%2Fj.neuropharm.2014.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset</span></div><div class="casAuthors">Huot, Philippe; Johnston, Tom H.; Lewis, Katie D.; Koprich, James B.; Reyes, M. Gabriela; Fox, Susan H.; Piggott, Matthew J.; Brotchie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-87</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease (PD), but its long-term administration is complicated by wearing-off and dyskinesia.  UWA-101, a dual, equipotent inhibitor of dopamine (DAT) and serotonin (SERT) transporters, has previously been shown to successfully extend duration of anti-parkinsonian benefit of L-DOPA (ON-time), without exacerbating dyskinesia, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset.  However, UWA-101 is racemic and it is unclear whether one or both enantiomers contribute to its actions, and whether a better therapeutic effect might be attained by using a single antipode.  In the current study, we synthesized the two enantiomers of UWA-101, R-101 (UWA-121) and S-101 (UWA-122), characterized their pharmacol. profiles and administered them to MPTP-lesioned marmosets.  Parkinsonism, dyskinesia, psychosis-like behaviors and duration of ON-time were evaluated.  UWA-121 is a dual DAT > SERT inhibitor, with an approx. 10:1 DAT:SERT affinity ratio (inhibitory consts. (Ki) of 307 and 3830 nM, resp.).  In combination with L-DOPA, UWA-121 extended duration of ON-time when compared to L-DOPA/vehicle treatment (by 40%, P < 0.01).  UWA-121 also extended duration of ON-time without dyskinesia (by 215%, P < 0.05) and ON-time without psychosis-like behaviors when compared to L-DOPA/vehicle treatment (by 345%, P < 0.01).  UWA-121 did not worsen the severity of dyskinesia or psychosis-like behaviors (P > 0.05).  UWA-122 is a selective SERT inhibitor (Ki 120 nM, Ki at DAT > 50 μM) and, in combination with L-DOPA, had no effect on ON-time, dyskinesia or psychosis-like behaviors (P > 0.05).  These data indicate that dual DAT and SERT inhibitors effectively enhance L-DOPA anti-parkinsonian action without worsening dyskinesia and that compds. with such a pharmacol. profile represent promising agents against wearing-off in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbiBB5fc-TBrVg90H21EOLACvtfcHk0lhR76X8pFZKPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFynt7o%253D&md5=2c88b90b665cabea18d5116c44878d9b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DHuot%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DT.%2BH.%26aulast%3DLewis%26aufirst%3DK.%2BD.%26aulast%3DKoprich%26aufirst%3DJ.%2BB.%26aulast%3DReyes%26aufirst%3DM.%2BG.%26aulast%3DFox%26aufirst%3DS.%2BH.%26aulast%3DPiggott%26aufirst%3DM.%2BJ.%26aulast%3DBrotchie%26aufirst%3DJ.%2BM.%26atitle%3DUWA-121%252C%2520a%2520mixed%2520dopamine%2520and%2520serotonin%2520re-uptake%2520inhibitor%252C%2520enhances%2520L-DOPA%2520anti-parkinsonian%2520action%2520without%2520worsening%2520dyskinesia%2520or%2520psychosis-like%2520behaviours%2520in%2520the%2520MPTP-lesioned%2520common%2520marmoset%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D82%26spage%3D76%26epage%3D87%26doi%3D10.1016%2Fj.neuropharm.2014.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chunfeng, L.</span></span> <span> </span><span class="NLM_article-title">Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">S168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=S168&author=J.+Chenauthor=J.+Hongauthor=L.+Chunfeng&title=Effect+of+dopamine+agonists+versus+levodopa+as+initial+treatment+in+Parkinson%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DChunfeng%26aufirst%3DL.%26atitle%3DEffect%2520of%2520dopamine%2520agonists%2520versus%2520levodopa%2520as%2520initial%2520treatment%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DMov.%2520Disord.%26date%3D2018%26volume%3D33%26spage%3DS168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A. E.</span></span> <span> </span><span class="NLM_article-title">Pharmacological treatment of Parkinson disease: a review</span>. <i>J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1683</span>, <span class="refDoi"> DOI: 10.1001/jama.2014.3654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1001%2Fjama.2014.3654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=24756517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFems7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2014&pages=1670-1683&author=B.+S.+Connollyauthor=A.+E.+Lang&title=Pharmacological+treatment+of+Parkinson+disease%3A+a+review&doi=10.1001%2Fjama.2014.3654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment of Parkinson disease: a review</span></div><div class="casAuthors">Connolly, Barbara S.; Lang, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1670-1683, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">A review.  Importance: Parkinson disease is the second most common neurodegenerative disease worldwide.  Although no available therapies alter the underlying neurodegenerative process, symptomatic therapies can improve patient quality of life.  Objective: To provide an evidence-based review of the initial pharmacol. management of the classic motor symptoms of Parkinson disease; describe management of medication-related motor complications (such as motor fluctuations and dyskinesia), and other medication adverse effects (nausea, psychosis, and impulse control disorders and related behaviors); and discuss the management of selected nonmotor symptoms of Parkinson disease, including rapid eye movement sleep behavior disorder, cognitive impairment, depression, orthostatic hypotension, and sialorrhea.  Evidence Review: Refs. were identified using searches of PubMed between Jan. 1985 and Feb. 2014 for English-language human studies and the full database of the Cochrane Library.  The classification of studies by quality (classes I-IV) was assessed using the levels of evidence guidelines from the American Academy of Neurol. and the highest-quality data for each topic.  Results: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.  Motor fluctuations may be managed by modifying the levodopa dosing regimen or by adding several other medications, such as MAOBIs, catechol-O-methyltransferase inhibitors, or dopamine agonists.  Impulse control disorders are typically managed by reducing or withdrawing dopaminergic medication, particularly dopamine agonists.  Evidence-based management of some nonmotor symptoms is limited by a paucity of high-quality pos. studies.  Conclusions and Relevance: Strong evidence supports using levodopa and dopamine agonists for motor symptoms at all stages of Parkinson disease.  Dopamine agonists and drugs that block dopamine metab. are effective for motor fluctuations and clozapine is effective for hallucinations.  Cholinesterase inhibitors may improve symptoms of dementia and antidepressants and pramipexole may improve depression.  Evidence supporting other therapies for motor and nonmotor features is less well established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq4bHOyyI7XrVg90H21EOLACvtfcHk0lhR76X8pFZKPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFems7rP&md5=a3faf879f5febdfc11a8992db89f2e67</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.3654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.3654%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DB.%2BS.%26aulast%3DLang%26aufirst%3DA.%2BE.%26atitle%3DPharmacological%2520treatment%2520of%2520Parkinson%2520disease%253A%2520a%2520review%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2014%26volume%3D311%26spage%3D1670%26epage%3D1683%26doi%3D10.1001%2Fjama.2014.3654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beitz, J. M.</span></span> <span> </span><span class="NLM_article-title">Parkinson’s disease: a review</span>. <i>Front. Biosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>S6</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.2741/s415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.2741%2FS415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2rsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=S6&publication_year=2014&pages=65-74&author=J.+M.+Beitz&title=Parkinson%E2%80%99s+disease%3A+a+review&doi=10.2741%2Fs415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's disease: a review</span></div><div class="casAuthors">Beitz, Janice M.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience, Scholar Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">S6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-74, 10</span>CODEN:
                <span class="NLM_cas:coden">FBSEAU</span>;
        ISSN:<span class="NLM_cas:issn">1945-0524</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Parkinson's Disease is the second most common progressive neurodegenerative disorder affecting older American adults and is predicted to increase in prevalence as the United States population ages.  Resulting from a pathophysiol. loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain and the development of neuronal Lewy Bodies, idiopathic Parkinson's Disease is assocd. with risk factors including aging, family history, pesticide exposure and environmental chems. (e.g., synthetic heroin use).  Its ultimate cause(s) is (are) unknown.  Characterized by both motor and non-motor symptoms, PD patients classically display rest tremor, rigidity, bradykinesia, and stooping posture.  PD can also be assocd. with neurobehavioral disorders (depression, anxiety), cognitive impairment (dementia), and autonomic dysfunction (e.g., orthostasis and hyperhidrosis).  Recent decades have witnessed a proliferation of medical pharmacol. therapies and innovative surgical interventions like deep brain stimulation (DBS).  However, definitive disease-modifying therapy is still lacking.  Exptl. therapies are being developed and tested with limited results.  Knowledge of strategies to promote optimal quality of life for PD patients is of paramount importance for caregivers, health providers and patients themselves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB281kduGUebVg90H21EOLACvtfcHk0liLIxmKK-o26g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2rsL3P&md5=b9b2b61a02391bbc113185f2b4f99e53</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2741%2FS415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252FS415%26sid%3Dliteratum%253Aachs%26aulast%3DBeitz%26aufirst%3DJ.%2BM.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%253A%2520a%2520review%26jtitle%3DFront.%2520Biosci.%26date%3D2014%26volume%3DS6%26spage%3D65%26epage%3D74%26doi%3D10.2741%2Fs415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagotti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targa, A.D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noseda, A. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilkiwa, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuproski, A. P.</span></span> <span> </span><span class="NLM_article-title">Potential new therapies against a toxic relationship: neuroinflammation and Parkinson’s disease</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1097/fbp.0000000000000512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1097%2FFBP.0000000000000512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=31703030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlygtb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=676-688&author=L.+S.+Rodriguesauthor=J.+Fagottiauthor=A.D.+S.+Targaauthor=A.+C.+D.+Nosedaauthor=J.+L.+Ilkiwaauthor=A.+P.+Chuproski&title=Potential+new+therapies+against+a+toxic+relationship%3A+neuroinflammation+and+Parkinson%E2%80%99s+disease&doi=10.1097%2Ffbp.0000000000000512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Potential new therapies against a toxic relationship: neuroinflammation and Parkinson's disease</span></div><div class="casAuthors">Rodrigues, Lais S.; Fagotti, Juliane; D. S. Targa, Adriano; D. Noseda, Ana Carolina; L. Ilkiwa, Jessica; Chuproski, Ana Paula; W. C. Dorieux, Flavia; D. dos Santos, Patricia; M. S. Lima, Marcelo</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">676-688</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Parkinsons disease (PD) is a neurodegenerative disorder classically assocd. with motor symptoms, but several nonmotor disturbances appear decades before the clin. diagnosis of the disease.  A variety of hypotheses exist to explain the onset of PD, and neuroinflammation is one of the most investigated processes.  In fact, strong evidence suggests that PD begins with an inflammatory process; currently, however, no anti-inflammatory therapy is clin. employed to alleviate the typical motor and the prodromal disturbances such as olfactory loss, cognitive impairments, depression and anxiety, sleep disturbances, and autonomic disorders.  In fact, the classical dopaminergic therapies are not effective in alleviating these symptoms and there is no other specific therapy for these outcomes.  Therefore, in this review, we will discuss novel potential pharmacol. therapeutic strategies focusing on cannabinoids, caffeine, melatonin, and dietary compds., which could act as adjuvants to regular PD therapy.  These described chems. have been extensively investigated as anti-inflammatory agents possibly promoting beneficial effects on nonmotor symptoms of PD.  The investigation of the inflammatory process at different stages of PD progression should give us a better view of the therapeutic scenario and could improve our understanding of the mechanisms of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Qvtpyqa707Vg90H21EOLACvtfcHk0liLIxmKK-o26g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlygtb7K&md5=55684104a98ce4c4b229ef6a0a4e6a32</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1097%2FFBP.0000000000000512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0000000000000512%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DL.%2BS.%26aulast%3DFagotti%26aufirst%3DJ.%26aulast%3DTarga%26aufirst%3DA.D.%2BS.%26aulast%3DNoseda%26aufirst%3DA.%2BC.%2BD.%26aulast%3DIlkiwa%26aufirst%3DJ.%2BL.%26aulast%3DChuproski%26aufirst%3DA.%2BP.%26atitle%3DPotential%2520new%2520therapies%2520against%2520a%2520toxic%2520relationship%253A%2520neuroinflammation%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2019%26volume%3D30%26spage%3D676%26epage%3D688%26doi%3D10.1097%2Ffbp.0000000000000512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miscusi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germanò, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuzzocrea, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasello, F.</span></span> <span> </span><span class="NLM_article-title">Nitric oxide in the injured spinal cord: synthases cross-talk, oxidative stress and inflammation</span>. <i>Brain Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.brainresrev.2007.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.brainresrev.2007.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=17500094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Kqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2007&pages=205-218&author=A.+Contiauthor=M.+Miscusiauthor=S.+Cardaliauthor=A.+German%C3%B2author=H.+Suzukiauthor=S.+Cuzzocreaauthor=F.+Tomasello&title=Nitric+oxide+in+the+injured+spinal+cord%3A+synthases+cross-talk%2C+oxidative+stress+and+inflammation&doi=10.1016%2Fj.brainresrev.2007.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide in the injured spinal cord: Synthases cross-talk, oxidative stress and inflammation</span></div><div class="casAuthors">Conti, Alfredo; Miscusi, Massimo; Cardali, Salvatore; Germano, Antonino; Suzuki, Hisanori; Cuzzocrea, Salvatore; Tomasello, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">205-218</span>CODEN:
                <span class="NLM_cas:coden">BRERD2</span>;
        ISSN:<span class="NLM_cas:issn">0165-0173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) is a unique informational mol. involved in a variety of physiol. processes in the central nervous system (CNS).  It has been demonstrated that it can exert both protective and detrimental effects in several disease states of the CNS, including spinal cord injury (SCI).  The effects of NO on the spinal cord depend on several factors such as: concn. of produced NO, activity of different synthase isoforms, cellular source of prodn. and time of release.  Basically, it has been shown that low NO concns. may play a role in physiol. processes, whereas large amts. of NO may be detrimental by increasing oxidative stress.  However, this does not explain all the discrepancies evidenced studying the effects of NO in SCI models.  The anal. of the different synthase isoforms, of their temporal profile of activation and cellular source has shed light on this topic.  Two post-injury time intervals can be defined with ref. to the NO prodn.: immediately after injury and several hours-to-days later.  The initial immediate peak of NO prodn. after injury is due to the up-regulation of the neuronal NO synthase (nNOS) in resident spinal cord cells.  The late peak is due primarily to the activity of inducible NOS (iNOS) produced by inflammatory infiltrating cells.  High NO levels produced by up-regulated nNOS and iNOS are neurotoxic; the down-regulation of nNOS corresponds temporally to the expression of iNOS.  On the bases of those evidence, therapeutic approaches should be aimed: (1) to reduce the NO-elicited damage by inhibition of specific synthases according to the temporal profile of activation; (2) by maintaining physiol. amt. of NO to keep the induction of iNOS expression suppressed and avoiding ischemia/reperfusion injuries; (3) by using scavengers of oxygen and nitrogen reactive species or using inhibitors of the specific kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAtVKal9OJ1LVg90H21EOLACvtfcHk0liLIxmKK-o26g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Kqtrw%253D&md5=8edc09dcea5634e9ba2015d3791e34c3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2007.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2007.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DConti%26aufirst%3DA.%26aulast%3DMiscusi%26aufirst%3DM.%26aulast%3DCardali%26aufirst%3DS.%26aulast%3DGerman%25C3%25B2%26aufirst%3DA.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DCuzzocrea%26aufirst%3DS.%26aulast%3DTomasello%26aufirst%3DF.%26atitle%3DNitric%2520oxide%2520in%2520the%2520injured%2520spinal%2520cord%253A%2520synthases%2520cross-talk%252C%2520oxidative%2520stress%2520and%2520inflammation%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2007%26volume%3D54%26spage%3D205%26epage%3D218%26doi%3D10.1016%2Fj.brainresrev.2007.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hague, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peuralinna, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eerola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tienari, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, A. B.</span></span> <span> </span><span class="NLM_article-title">Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1212/01.wnl.0000110191.38152.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1212%2F01.WNL.0000110191.38152.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=14981185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FptFOguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2004&pages=635-636&author=S.+Hagueauthor=T.+Peuralinnaauthor=J.+Eerolaauthor=O.+Hellstromauthor=P.+J.+Tienariauthor=A.+B.+Singleton&title=Confirmation+of+the+protective+effect+of+iNOS+in+an+independent+cohort+of+Parkinson+disease&doi=10.1212%2F01.wnl.0000110191.38152.29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease</span></div><div class="casAuthors">Hague S; Peuralinna T; Eerola J; Hellstrom O; Tienari P J; Singleton A B</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">635-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nitric oxide is a biologic messenger molecule involved in a diverse range of physiologic processes.  An exon 22 inducible nitric oxide synthase genotype has recently been reported to be protective against Parkinson disease in a European cohort.  The authors confirm the protective effect of this genotype (OR = 0.5, 95% CI 0.27 to 0.93) in an independent Finnish case-control series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHx6fXWaFfSFf1XRtfYM0dfW6udTcc2eZ935YMTH7GH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FptFOguw%253D%253D&md5=228e7ceebcd75e9282bd66b2de32558e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1212%2F01.WNL.0000110191.38152.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252F01.WNL.0000110191.38152.29%26sid%3Dliteratum%253Aachs%26aulast%3DHague%26aufirst%3DS.%26aulast%3DPeuralinna%26aufirst%3DT.%26aulast%3DEerola%26aufirst%3DJ.%26aulast%3DHellstrom%26aufirst%3DO.%26aulast%3DTienari%26aufirst%3DP.%2BJ.%26aulast%3DSingleton%26aufirst%3DA.%2BB.%26atitle%3DConfirmation%2520of%2520the%2520protective%2520effect%2520of%2520iNOS%2520in%2520an%2520independent%2520cohort%2520of%2520Parkinson%2520disease%26jtitle%3DNeurology%26date%3D2004%26volume%3D62%26spage%3D635%26epage%3D636%26doi%3D10.1212%2F01.wnl.0000110191.38152.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boissière, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucheux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouatt-Prigent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agid, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E. C.</span></span> <span> </span><span class="NLM_article-title">Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/0306-4522(95)00578-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2F0306-4522%2895%2900578-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=8737406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADyaK28XisFCksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1996&pages=355-363&author=S.+Hunotauthor=F.+Boissi%C3%A8reauthor=B.+Faucheuxauthor=B.+Bruggauthor=A.+Mouatt-Prigentauthor=Y.+Agidauthor=E.+C.+Hirsch&title=Nitric+oxide+synthase+and+neuronal+vulnerability+in+Parkinson%E2%80%99s+disease&doi=10.1016%2F0306-4522%2895%2900578-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide synthase and neuronal vulnerability in Parkinson's disease</span></div><div class="casAuthors">Hunot, S.; Boissiere, F.; Faucheux, B.; Brugg, B.; Mouatt-Prigent, A.; Agid, Y.; Hirsch, E. C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">355-63</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Parkinson's disease is characterized by a loss of dopaminergic neurons in the mesencephalon.  Although the mechanism of this neuronal loss is still unknown, oxidative stress is very likely involved in the cascade of events leading to nerve cell death.  Since nitric oxide could be involved in the prodn. of free radicals, we analyzed, using immunohistochem. and histochem., the prodn. systems of nitric oxide in the mesencephalon of four patients with idiopathic Parkinson's disease and three matched control subjects.  Using specific antibodies directed against the inducible isoform of nitric oxide synthase (the enzyme involved in the synthesis of nitric oxide), we found evidence to suggest that this isoform was present solely in glial cells displaying the morphol. characteristics of activated macrophages.  Immunohistochem. anal. performed with antibodies against the neuronal isoform of nitric oxide synthase, however, revealed perikarya and processes of neurons but o glial cell staining.  The no. of nitric oxide synthase-contg. cells was investigated by histoenzymol., using the NADPH-diaphorase activity of nitric oxide synthase.  Histochem. revealed (i) a significant increase in NADPH-diaphorase-pos. glial cell d. in the dopaminergic cell groups characterized by neuronal loss in Parkinson's disease and (ii) a neuronal loss in Parkinson's disease that was two-fold greater for pigmented NADPH-diaphorase-neg. neurons than for pigmented NADPH-diaphorase-pos. neurons.  These data suggest a potentially deleterious role of glial cells producing excessive levels of nitric oxide in Parkinson's disease, which may be neurotoxic for a subpopulation of dopaminergic neurons, esp. those not expressing NADPH-diaphorase activity.  However, it cannot be excluded that the presence of glial cells expressing nitric oxide synthase in the substantia nigra of patients with Parkinson's disease represents a consequence of dopaminergic neuronal loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4SORDlRL1TrVg90H21EOLACvtfcHk0lgr8iHO1hDc3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XisFCksro%253D&md5=2096cb70025e015e0d53dc14503b8aa8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2F0306-4522%2895%2900578-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0306-4522%252895%252900578-1%26sid%3Dliteratum%253Aachs%26aulast%3DHunot%26aufirst%3DS.%26aulast%3DBoissi%25C3%25A8re%26aufirst%3DF.%26aulast%3DFaucheux%26aufirst%3DB.%26aulast%3DBrugg%26aufirst%3DB.%26aulast%3DMouatt-Prigent%26aufirst%3DA.%26aulast%3DAgid%26aufirst%3DY.%26aulast%3DHirsch%26aufirst%3DE.%2BC.%26atitle%3DNitric%2520oxide%2520synthase%2520and%2520neuronal%2520vulnerability%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeuroscience%26date%3D1996%26volume%3D72%26spage%3D355%26epage%3D363%26doi%3D10.1016%2F0306-4522%2895%2900578-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broom, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinova-Mutafchieva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medhurst, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dexter, D. T.</span></span> <span> </span><span class="NLM_article-title">Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">633</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2010.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.freeradbiomed.2010.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=21185368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlejtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=633-640&author=L.+Broomauthor=L.+Marinova-Mutafchievaauthor=M.+Sadeghianauthor=J.+B.+Davisauthor=A.+D.+Medhurstauthor=D.+T.+Dexter&title=Neuroprotection+by+the+selective+iNOS+inhibitor+GW274150+in+a+model+of+Parkinson+disease&doi=10.1016%2Fj.freeradbiomed.2010.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease</span></div><div class="casAuthors">Broom, Lauren; Marinova-Mutafchieva, Lilia; Sadeghian, Mona; Davis, John B.; Medhurst, Andrew D.; Dexter, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">633-640</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neuroinflammation and the activation of inducible nitric oxide synthase (iNOS) have been proposed to play a role in the pathogenesis of Parkinson disease (PD).  In this study we investigated the effects of the selective iNOS inhibitor GW274150 in the 6-OHDA model of PD.  6-OHDA administration was assocd. with increased nos. of cells expressing iNOS.  Administration of the iNOS inhibitor twice daily for 7 days, beginning 2 days after the 6-OHDA lesioning, led to a significant neuroprotection as shown by assessment of the integrity of the nigrostriatal system by tyrosine hydroxylase immunocytochem. and HPLC assessment of striatal dopamine content.  However, GW274150 displayed a bell-shaped neuroprotective profile, being ineffective at high doses.  6-OHDA lesioning was assocd. with an increase in microglial activation as assessed by the MHC II antigen OX-6 and the no. of matrix metalloproteinase 9 (MMP-9)-immunopos. cells.  NO is a known modulator of MMP-9, and iNOS inhibition was assocd. with decreased nos. of MMP-9-immunopos. cells, culminating in a redn. in the nos. of reactive microglia.  Withdrawal of GW274150 for a further 7 days negated any neuroprotective effects of iNOS inhibition, suggesting that the damaging effects of inflammation last beyond 7 days in this model and the continued administration of the drug may be required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOlohkfL3bLVg90H21EOLACvtfcHk0lgr8iHO1hDc3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlejtbk%253D&md5=7ac55463ac877d6c20857c2d6a338569</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2010.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2010.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DBroom%26aufirst%3DL.%26aulast%3DMarinova-Mutafchieva%26aufirst%3DL.%26aulast%3DSadeghian%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DJ.%2BB.%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DDexter%26aufirst%3DD.%2BT.%26atitle%3DNeuroprotection%2520by%2520the%2520selective%2520iNOS%2520inhibitor%2520GW274150%2520in%2520a%2520model%2520of%2520Parkinson%2520disease%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2011%26volume%3D50%26spage%3D633%26epage%3D640%26doi%3D10.1016%2Fj.freeradbiomed.2010.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iravani, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashefi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mander, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span> <span> </span><span class="NLM_article-title">Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/s0306-4522(01)00562-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2FS0306-4522%2801%2900562-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=11882372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD38XhslSktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=49-58&author=M.+M.+Iravaniauthor=K.+Kashefiauthor=P.+Manderauthor=S.+Roseauthor=P.+Jenner&title=Involvement+of+inducible+nitric+oxide+synthase+in+inflammation-induced+dopaminergic+neurodegeneration&doi=10.1016%2Fs0306-4522%2801%2900562-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration</span></div><div class="casAuthors">Iravani, M. M.; Kashefi, K.; Mander, P.; Rose, S.; Jenner, P.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-58</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The loss of dopaminergic neurons in the substantia nigra with Parkinson's disease may result from inflammation-induced proliferation of microglia and reactive macrophages expressing inducible nitric oxide synthase (iNOS).  We have investigated the effects of the supranigral administration of lipopolysaccharide on iNOS-immunoreactivity, 3-nitrotyrosine formation and tyrosine hydroxylase-immunoreactive neuronal no., and retrogradely labeled fluorogold-pos. neurons in the ventral mesencephalon in male Wistar rats.  Following supranigral lipopolysaccharide injection, 16-18 h previously, there was intense expression of NADPH-diaphorase and iNOS-immunoreactivity in non-neuronal, macrophage-like cells.  This was accompanied by intense expression of glial fibrillary acidic protein-immunoreactive astrocytosis in the substantia nigra.  There were also significant redns. in the no. of tyrosine hydroxylase (50-60%)- and fluorogold (65-75%)-pos. neurons in the substantia nigra.  In contrast, tyrosine hydroxylase-immunoreactivity in the ventral tegmental area was not altered.  Pretreatment of animals with the iNOS inhibitor, S-methylisothiourea (10 mg kg-1, i.p.), led to a significant redn. of lipopolysaccharide-induced cell death.  Similar redn. of tyrosine hydroxylase-immunoreactivity and fluorogold-labeled neurons in the substantia nigra following lipopolysaccharide administration suggests dopaminergic cell death rather than down-regulation of tyrosine hydroxylase.  We conclude that the expression of iNOS- and 3-nitrotyrosine-immunoreactivity and redn. of cell death by S-methylisothiourea suggest the effects of lipopolysaccharide may be nitric oxide-mediated, although other actions of lipopolysaccharide (independent of iNOS induction) cannot be ruled out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW-MMG0a4pO7Vg90H21EOLACvtfcHk0liap2kmOrcemw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhslSktbY%253D&md5=c8baf4576918850cfc6d62489fc843c7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2801%2900562-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252801%252900562-0%26sid%3Dliteratum%253Aachs%26aulast%3DIravani%26aufirst%3DM.%2BM.%26aulast%3DKashefi%26aufirst%3DK.%26aulast%3DMander%26aufirst%3DP.%26aulast%3DRose%26aufirst%3DS.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DInvolvement%2520of%2520inducible%2520nitric%2520oxide%2520synthase%2520in%2520inflammation-induced%2520dopaminergic%2520neurodegeneration%26jtitle%3DNeuroscience%26date%3D2002%26volume%3D110%26spage%3D49%26epage%3D58%26doi%3D10.1016%2Fs0306-4522%2801%2900562-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dehmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dichgans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, J. B.</span></span> <span> </span><span class="NLM_article-title">Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">2213</span>– <span class="NLM_lpage">2216</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2000.0742213.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1046%2Fj.1471-4159.2000.0742213.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10800968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD3cXis12qsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2000&pages=2213-2216&author=T.+Dehmerauthor=J.+Lindenauauthor=S.+Haidauthor=J.+Dichgansauthor=J.+B.+Schulz&title=Deficiency+of+inducible+nitric+oxide+synthase+protects+against+MPTP+toxicity+in+vivo&doi=10.1046%2Fj.1471-4159.2000.0742213.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo</span></div><div class="casAuthors">Dehmer, Thomas; Lindenau, Jorg; Haid, Sibylle; Dichgans, Johannes; Schulz, Jorg B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2213-2216</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">MPTP produces clin., biochem., and neuropathol. changes reminiscent of those that occur in idiopathic Parkinson's disease (PD).  In the present study we show that MPTP treatment led to activation of microglia in the substantia nigra pars compacta (SNpc), which was assocd. and colocalized with an increase in inducible nitric oxide synthase (iNOS) expression.  In iNOS-deficient mice the increase of iNOS expression but not the activation of microglia was blocked.  Dopaminergic SNpc neurons of iNOS-deficient mice were almost completely protected from MPTP toxicity in a chronic paradigm of MPTP toxicity.  Because the MPTP-induced decrease in striatal concns. of dopamine and its metabolites did not differ between iNOS-deficient mice and their wild-type littermates, this protection was not assocd. with a preservation of nigrostriatal terminals.  Our results suggest that iNOS-derived nitric oxide produced in microglia plays an important role in the death of dopaminergic neurons but that other mechanisms contribute to the loss of dopaminergic terminals in MPTP neurotoxicity.  We conclude that inhibition of iNOS may be a promising target for the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodyCC8WMz33bVg90H21EOLACvtfcHk0liap2kmOrcemw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXis12qsrs%253D&md5=93ebd91bf7a481cc9009993a88d5df0d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2000.0742213.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2000.0742213.x%26sid%3Dliteratum%253Aachs%26aulast%3DDehmer%26aufirst%3DT.%26aulast%3DLindenau%26aufirst%3DJ.%26aulast%3DHaid%26aufirst%3DS.%26aulast%3DDichgans%26aufirst%3DJ.%26aulast%3DSchulz%26aufirst%3DJ.%2BB.%26atitle%3DDeficiency%2520of%2520inducible%2520nitric%2520oxide%2520synthase%2520protects%2520against%2520MPTP%2520toxicity%2520in%2520vivo%26jtitle%3DJ.%2520Neurochem.%26date%3D2000%26volume%3D74%26spage%3D2213%26epage%3D2216%26doi%3D10.1046%2Fj.1471-4159.2000.0742213.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatsuji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumanogoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichinose, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakoda, S.</span></span> <span> </span><span class="NLM_article-title">Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson’s disease</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">882</span>, <span class="refDoi"> DOI: 10.1002/jnr.20599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1002%2Fjnr.20599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=16041799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFKktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2005&pages=874-882&author=T.+Okunoauthor=Y.+Nakatsujiauthor=A.+Kumanogohauthor=M.+Moriyaauthor=H.+Ichinoseauthor=H.+Sumiauthor=H.+Fujimuraauthor=H.+Kikutaniauthor=S.+Sakoda&title=Loss+of+dopaminergic+neurons+by+the+induction+of+inducible+nitric+oxide+synthase+and+cyclooxygenase-2+via+CD+40%3A+relevance+to+Parkinson%E2%80%99s+disease&doi=10.1002%2Fjnr.20599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD40: Relevance to Parkinson's disease</span></div><div class="casAuthors">Okuno, Tatsusada; Nakatsuji, Yuji; Kumanogoh, Atsushi; Moriya, Masayuki; Ichinose, Hiroshi; Sumi, Hisae; Fujimura, Harutoshi; Kikutani, Hitoshi; Sakoda, Saburo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-882</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A glial reaction assocd. with up-regulation of inflammatory mols. has been suggested to play an important role in dopaminergic neuron loss in Parkinson's disease (PD).  Among inflammatory mols., inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) have been focused upon as key factors in the pathogenesis.  However, the mechanism of how these mols. are induced in PD brains is not clearly understood.  We focused on CD40, which is expressed on neural cells and could be implicated in the neuroinflammation by inducing inflammatory mols.  We showed that both iNOS and COX-2 were up-regulated in microglia and astrocytes by CD40 stimulation in assocn. with a low dose of interferon-γ (IFN-γ) in vitro.  Selective loss of dopaminergic neurons was induced by costimulation with CD40 and IFN-γ in mesencephalic cultures, which was protected by selective inhibitors of iNOS and/or COX-2.  We also found in CD40-stimulated astrocytes an increase of a low-affinity IgE receptor CD23, which is known to induce iNOS expression.  Together these data suggest that up-regulated iNOS and COX-2 via the CD40 pathway may lead to dopaminergic neuron loss and may participate in the neuroinflammaory pathway of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-GePctcnXT7Vg90H21EOLACvtfcHk0liap2kmOrcemw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFKktrY%253D&md5=4e077386cd149e15015a3a9c9dfbeb2f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fjnr.20599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.20599%26sid%3Dliteratum%253Aachs%26aulast%3DOkuno%26aufirst%3DT.%26aulast%3DNakatsuji%26aufirst%3DY.%26aulast%3DKumanogoh%26aufirst%3DA.%26aulast%3DMoriya%26aufirst%3DM.%26aulast%3DIchinose%26aufirst%3DH.%26aulast%3DSumi%26aufirst%3DH.%26aulast%3DFujimura%26aufirst%3DH.%26aulast%3DKikutani%26aufirst%3DH.%26aulast%3DSakoda%26aufirst%3DS.%26atitle%3DLoss%2520of%2520dopaminergic%2520neurons%2520by%2520the%2520induction%2520of%2520inducible%2520nitric%2520oxide%2520synthase%2520and%2520cyclooxygenase-2%2520via%2520CD%252040%253A%2520relevance%2520to%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2005%26volume%3D81%26spage%3D874%26epage%3D882%26doi%3D10.1002%2Fjnr.20599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minhas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, G.</span></span> <span> </span><span class="NLM_article-title">Inducible nitric oxide synthase inhibitors: A comprehensive update</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">855</span>, <span class="refDoi"> DOI: 10.1002/med.21636</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1002%2Fmed.21636" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=31502681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntlantbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=823-855&author=R.+Minhasauthor=Y.+Bansalauthor=G.+Bansal&title=Inducible+nitric+oxide+synthase+inhibitors%3A+A+comprehensive+update&doi=10.1002%2Fmed.21636"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible nitric oxide synthase inhibitors: A comprehensive update</span></div><div class="casAuthors">Minhas, Richa; Bansal, Yogita; Bansal, Gulshan</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">823-855</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Inducible nitric oxide synthase (iNOS), which is expressed in response to bacterial/proinflammatory stimuli, generates nitric oxide (NO) that provides cytoprotection.  Overexpression of iNOS increases the levels of NO, and this increased NO level is implicated in pathophysiol. of complex multifactorial diseases like Parkinson's disease, Alzheimer's disease, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease.  Selective inhibition of iNOS is an effective approach in treatment of such complex diseases.  -Arginine, being a substrate for iNOS, is the natural lead to develop iNOS inhibitors.  More than 200 research reports on development of nitric oxide synthase inhibitors by different research groups across the globe have appeared in literature so far.  In the present review, all reports on both natural and synthetic iNOS inhibitors, published 2002 onwards, are studied, classified, and discussed to provide comprehensive information on iNOS inhibitors.  The latter are further classified into amidines, five- or six-membered heterocyclics, fused cyclics, steroidal type, and chalcones analogs.  Structures of the most/significantly potent compds. from each report are provided to know the functional groups important for incurring iNOS inhibitory activity and selectivity.  This review is aimed to provide a comprehensive view to the medicinal chemists for rational designing of novel and potent iNOS inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUTlomCGpTELVg90H21EOLACvtfcHk0liap2kmOrcemw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntlantbo%253D&md5=54fe69326cbeb700ae5592beaf7fa702</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fmed.21636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21636%26sid%3Dliteratum%253Aachs%26aulast%3DMinhas%26aufirst%3DR.%26aulast%3DBansal%26aufirst%3DY.%26aulast%3DBansal%26aufirst%3DG.%26atitle%3DInducible%2520nitric%2520oxide%2520synthase%2520inhibitors%253A%2520A%2520comprehensive%2520update%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26spage%3D823%26epage%3D855%26doi%3D10.1002%2Fmed.21636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.-C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.ejmech.2018.03.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=29626798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1arsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=261-271&author=X.-L.+Huauthor=J.+Linauthor=X.-Y.+Lvauthor=J.-H.+Fengauthor=X.-Q.+Zhangauthor=H.+Wangauthor=W.-C.+Ye&title=Synthesis+and+biological+evaluation+of+clovamide+analogues+as+potent+anti-neuroinflammatory+agents+in+vitro+and+in+vivo&doi=10.1016%2Fj.ejmech.2018.03.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo</span></div><div class="casAuthors">Hu, Xiao-Long; Lin, Jun; Lv, Xian-Yu; Feng, Jia-Hao; Zhang, Xiao-Qi; Wang, Hao; Ye, Wen-Cai</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">261-271</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of clovamide analogs was synthesized and evaluated for their anti-neuroinflammatory activities using BV-2 microglia cells.  Among these compds., some compds., e.g., I, showed NO inhibition with no or weak cytotoxicity (CC50>100 μM) and showed an IC50 value of 2.67 μM.  Enzyme activity and docking assay revealed that some compds. target inducible NO synthase (iNOS) and exhibit potent inhibitory effects on iNOS with IC50 values ranging from 1.01 μM to 29.23 μM and compd. I significantly suppressed the expression of pro-inflammatory cytokines in lipopolysaccharide-stimulated cells.  Notably, the oral administration of I remarkably improved dyskinesia, reduced the expression of glial fibrillary acidic protein (GFAP)-a marker of neuroinflammation, and increased tyrosine hydroxylase-pos. cells in 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine-induced Parkinson's disease (PD) mouse models.  These observations demonstrated that I is an effective and promising candidate for PD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNfFsQ8aibZbVg90H21EOLACvtfcHk0ljh0UEBIhe0Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1arsbw%253D&md5=1b2850b92c4f62d971d5c7c7e19941db</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.081%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.-L.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DX.-Y.%26aulast%3DFeng%26aufirst%3DJ.-H.%26aulast%3DZhang%26aufirst%3DX.-Q.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DW.-C.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520clovamide%2520analogues%2520as%2520potent%2520anti-neuroinflammatory%2520agents%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D261%26epage%3D271%26doi%3D10.1016%2Fj.ejmech.2018.03.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallinan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houdek, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerome, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitzele, B. S.</span></span> <span> </span><span class="NLM_article-title">4-Fluorinated L-lysine analogs as selective i-NOS inhibitors: methodology for introducing fluorine into the lysine side chain</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">3527</span>– <span class="NLM_lpage">3534</span>, <span class="refDoi"> DOI: 10.1039/b307563j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1039%2FB307563J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=14599013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVSgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=3527-3534&author=E.+A.+Hallinanauthor=S.+W.+Kramerauthor=S.+C.+Houdekauthor=W.+M.+Mooreauthor=G.+M.+Jeromeauthor=D.+P.+Spanglerauthor=A.+M.+Stevensauthor=H.+S.+Shiehauthor=P.+T.+Manningauthor=B.+S.+Pitzele&title=4-Fluorinated+L-lysine+analogs+as+selective+i-NOS+inhibitors%3A+methodology+for+introducing+fluorine+into+the+lysine+side+chain&doi=10.1039%2Fb307563j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">4-Fluorinated L-lysine analogs as selective i-NOS inhibitors: methodology for introducing fluorine into the lysine side chain</span></div><div class="casAuthors">Hallinan, E. Ann; Kramer, Steven W.; Houdek, Stephen C.; Moore, William M.; Jerome, Gina M.; Spangler, Dale P.; Stevens, Anna M.; Shieh, Huey S.; Manning, Pamela T.; Pitzele, Barnett S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3527-3534</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In the literature, the introduction of fluorine into bioactive mols. is known to enhance the biol. activity relative to the parent mol.  Described in this article is the synthesis of 4R-fluoro-L-NIL and 4,4-difluoro-L-NIL as part of an iNOS program.  Both were found to be selective iNOS inhibitors.  Secondarily, methodol. to synthesize orthogonally protected 4-fluoro-L-lysine and 4,4-difluoro-L-lysine was developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphyjYE3sSOZbVg90H21EOLACvtfcHk0ljh0UEBIhe0Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVSgs7w%253D&md5=29fbe079287f43defd8de5f9588ea674</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2FB307563J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB307563J%26sid%3Dliteratum%253Aachs%26aulast%3DHallinan%26aufirst%3DE.%2BA.%26aulast%3DKramer%26aufirst%3DS.%2BW.%26aulast%3DHoudek%26aufirst%3DS.%2BC.%26aulast%3DMoore%26aufirst%3DW.%2BM.%26aulast%3DJerome%26aufirst%3DG.%2BM.%26aulast%3DSpangler%26aufirst%3DD.%2BP.%26aulast%3DStevens%26aufirst%3DA.%2BM.%26aulast%3DShieh%26aufirst%3DH.%2BS.%26aulast%3DManning%26aufirst%3DP.%2BT.%26aulast%3DPitzele%26aufirst%3DB.%2BS.%26atitle%3D4-Fluorinated%2520L-lysine%2520analogs%2520as%2520selective%2520i-NOS%2520inhibitors%253A%2520methodology%2520for%2520introducing%2520fluorine%2520into%2520the%2520lysine%2520side%2520chain%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2003%26volume%3D1%26spage%3D3527%26epage%3D3534%26doi%3D10.1039%2Fb307563j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cinelli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miley, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R. B.</span></span> <span> </span><span class="NLM_article-title">Inducible nitric oxide synthase: Regulation, structure, and inhibition</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1002/med.21599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1002%2Fmed.21599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=31192483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFSjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=158-189&author=M.+A.+Cinelliauthor=H.+T.+Doauthor=G.+P.+Mileyauthor=R.+B.+Silverman&title=Inducible+nitric+oxide+synthase%3A+Regulation%2C+structure%2C+and+inhibition&doi=10.1002%2Fmed.21599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible nitric oxide synthase: Regulation, structure, and inhibition</span></div><div class="casAuthors">Cinelli, Maris A.; Do, Ha T.; Miley, Galen P.; Silverman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">158-189</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  A considerable no. of human diseases have an inflammatory component, and a key mediator of immune activation and inflammation is inducible nitric oxide synthase (iNOS), which produces nitric oxide (NO) from -arginine.  Overexpressed or dysregulated iNOS has been implicated in numerous pathologies including sepsis, cancer, neurodegeneration, and various types of pain.  Addnl., X-ray crystal and cryogenic electron microscopy structures have shed new insights on the structure and regulation of this enzyme.  Many potent iNOS inhibitors with high selectivity over related NOS isoforms, neuronal NOS, and endothelial NOS, have been discovered, and these drugs have shown promise in animal models of endotoxemia, inflammatory and neuropathic pain, arthritis, and other disorders.  In addn. to assay limitations, both the dual modalities of iNOS and NO in disease states (ie, protective vs harmful effects) and the different roles and localizations of NOS isoforms create challenges for therapeutic intervention.  This review summarizes the structure, function, and regulation of iNOS, with focus on the development of iNOS inhibitors (historical and recent).  A better understanding of iNOS' complex functions is necessary before specific drug candidates can be identified for classical indications such as sepsis, heart failure, and pain; however, newer promising indications for iNOS inhibition, such as depression, neurodegenerative disorders, and epilepsy, have been discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXpaXR9kQB9LVg90H21EOLACvtfcHk0ljrfyIwM4H6CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFSjtw%253D%253D&md5=d35151e6a6e9755c2b9c0f5b0ea23e02</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fmed.21599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21599%26sid%3Dliteratum%253Aachs%26aulast%3DCinelli%26aufirst%3DM.%2BA.%26aulast%3DDo%26aufirst%3DH.%2BT.%26aulast%3DMiley%26aufirst%3DG.%2BP.%26aulast%3DSilverman%26aufirst%3DR.%2BB.%26atitle%3DInducible%2520nitric%2520oxide%2520synthase%253A%2520Regulation%252C%2520structure%252C%2520and%2520inhibition%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26spage%3D158%26epage%3D189%26doi%3D10.1002%2Fmed.21599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span> <span> </span><span class="NLM_article-title">High throughput artificial membrane permeability assay for blood-brain barrier</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/s0223-5234(03)00012-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2FS0223-5234%2803%2900012-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=12667689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=223-232&author=L.+Diauthor=E.+H.+Kernsauthor=K.+Fanauthor=O.+J.+McConnellauthor=G.+T.+Carter&title=High+throughput+artificial+membrane+permeability+assay+for+blood-brain+barrier&doi=10.1016%2Fs0223-5234%2803%2900012-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput artificial membrane permeability assay for blood-brain barrier</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Fan, Kristi; McConnell, Oliver J.; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">The recent advances in high throughput screening for biol. activities and combinatorial chem. have greatly expanded the no. of drug candidates.  Rapid screening for BBB penetration potential early in drug discovery programs provides important information for compd. selection and guidance of synthesis for desirable CNS properties.  In this paper, we discuss a modification of the parallel artificial membrane permeation assay (PAMPA) for the prediction of blood-brain barrier penetration (PAMPA-BBB).  The assay was developed with 30 structurally diverse com. drugs and validated with 14 Wyeth Research compds.  The PAMPA-BBB assay has the advantages of: predicting passive blood-brain barrier penetration with high success, high throughput, low cost, and reproducibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCg9Ka4mziLVg90H21EOLACvtfcHk0ljrfyIwM4H6CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D&md5=d228d5808ba8df23deed92c5e2bf3863</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900012-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900012-6%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DFan%26aufirst%3DK.%26aulast%3DMcConnell%26aufirst%3DO.%2BJ.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DHigh%2520throughput%2520artificial%2520membrane%2520permeability%2520assay%2520for%2520blood-brain%2520barrier%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D223%26epage%3D232%26doi%3D10.1016%2Fs0223-5234%2803%2900012-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmanic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagrovic, B.</span></span> <span> </span><span class="NLM_article-title">Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1016/j.bpj.2009.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.bpj.2009.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=20197040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1KktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2010&pages=861-871&author=A.+Kuzmanicauthor=B.+Zagrovic&title=Determination+of+ensemble-average+pairwise+root+mean-square+deviation+from+experimental+B-factors&doi=10.1016%2Fj.bpj.2009.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors</span></div><div class="casAuthors">Kuzmanic, Antonija; Zagrovic, Bojan</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">861-871</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Root mean-square deviation (RMSD) after roto-translational least-squares fitting is a commonly used measure of global structural similarity of macromols.  However, exptl. x-ray B-factors are used frequently to study local structural heterogeneity and dynamics in macromols. by providing direct information about root mean-square fluctuations (RMSF) that can also be calcd. from mol. dynamics simulations.  The authors provide a math. derivation showing that, given a set of conservative assumptions, a root mean-square ensemble-av. of an all-against-all distribution of pairwise RMSD for a single mol. species, 〈RMSD2〉1/2, is directly related to av. B-factors (〈B〉) and 〈RMSF2〉1/2.  The authors show this relation and explore its limits of validity on a heterogeneous ensemble of structures taken from mol. dynamics simulations of a villin headpiece generated using distributed-computing techniques and the <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1d5b72717974737a5d55727078">[email protected]</a> cluster.  The authors' results provide a basis for quantifying global structural diversity of macromols. in crystals directly from x-ray expts., and the authors show this on a large set of structures taken from the Protein Data Bank.  In particular, the ensemble-av. pairwise backbone RMSD for a microscopic ensemble underlying a typical protein x-ray structure is ∼1.1 Å, under the assumption that the principal contribution to exptl. B-factors is conformational variability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmaQXdWWHh7Vg90H21EOLACvtfcHk0ljrfyIwM4H6CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1KktL4%253D&md5=d4cff0514feab57795168526993f0d51</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2009.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2009.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DKuzmanic%26aufirst%3DA.%26aulast%3DZagrovic%26aufirst%3DB.%26atitle%3DDetermination%2520of%2520ensemble-average%2520pairwise%2520root%2520mean-square%2520deviation%2520from%2520experimental%2520B-factors%26jtitle%3DBiophys.%2520J.%26date%3D2010%26volume%3D98%26spage%3D861%26epage%3D871%26doi%3D10.1016%2Fj.bpj.2009.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almqvist, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axelsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatushchenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundbäck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D. M.</span></span> <span> </span><span class="NLM_article-title">The cellular thermal shift assay for evaluating drug target interactions in cells</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2100</span>– <span class="NLM_lpage">2122</span>, <span class="refDoi"> DOI: 10.1038/nprot.2014.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1038%2Fnprot.2014.138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=25101824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2100-2122&author=R.+Jafariauthor=H.+Almqvistauthor=H.+Axelssonauthor=M.+Ignatushchenkoauthor=T.+Lundb%C3%A4ckauthor=P.+Nordlundauthor=D.+M.+Molina&title=The+cellular+thermal+shift+assay+for+evaluating+drug+target+interactions+in+cells&doi=10.1038%2Fnprot.2014.138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The cellular thermal shift assay for evaluating drug target interactions in cells</span></div><div class="casAuthors">Jafari, Rozbeh; Almqvist, Helena; Axelsson, Hanna; Ignatushchenko, Marina; Lundbaeck, Thomas; Nordlund, Paer; Molina, Daniel Martinez</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2100-2122</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thermal shift assays are used to study thermal stabilization of proteins upon ligand binding.  Such assays have been used extensively on purified proteins in the drug discovery industry and in academia to detect interactions.  Recently, we published a proof-of-principle study describing the implementation of thermal shift assays in a cellular format, which we call the cellular thermal shift assay (CETSA).  The method allows studies of target engagement of drug candidates in a cellular context, herein exemplified with exptl. data on the human kinases p38α and ERK1/2.  The assay involves treatment of cells with a compd. of interest, heating to denature and ppt. proteins, cell lysis, and the sepn. of cell debris and aggregates from the sol. protein fraction.  Whereas unbound proteins denature and ppt. at elevated temps., ligand-bound proteins remain in soln.  We describe two procedures for detecting the stabilized protein in the sol. fraction of the samples.  One approach involves sample workup and detection using quant. western blotting, whereas the second is performed directly in soln. and relies on the induced proximity of two target-directed antibodies upon binding to sol. protein.  The latter protocol has been optimized to allow an increased throughput, as potential applications require large nos. of samples.  Both approaches can be completed in a day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzarqomAK6eLVg90H21EOLACvtfcHk0lhVDcDu3LMbGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ&md5=e7852e1a306bca1698a8e8463ae566b1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2014.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2014.138%26sid%3Dliteratum%253Aachs%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DAlmqvist%26aufirst%3DH.%26aulast%3DAxelsson%26aufirst%3DH.%26aulast%3DIgnatushchenko%26aufirst%3DM.%26aulast%3DLundb%25C3%25A4ck%26aufirst%3DT.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DMolina%26aufirst%3DD.%2BM.%26atitle%3DThe%2520cellular%2520thermal%2520shift%2520assay%2520for%2520evaluating%2520drug%2520target%2520interactions%2520in%2520cells%26jtitle%3DNat.%2520Protoc.%26date%3D2014%26volume%3D9%26spage%3D2100%26epage%3D2122%26doi%3D10.1038%2Fnprot.2014.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundbäck, T.</span></span> <span> </span><span class="NLM_article-title">CETSA: a target engagement assay with potential to transform drug discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">975</span>– <span class="NLM_lpage">978</span>, <span class="refDoi"> DOI: 10.4155/fmc.15.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.4155%2Ffmc.15.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=26062395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpslGgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=975-978&author=A.+J.+Jensenauthor=D.+M.+Molinaauthor=T.+Lundb%C3%A4ck&title=CETSA%3A+a+target+engagement+assay+with+potential+to+transform+drug+discovery&doi=10.4155%2Ffmc.15.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CETSA: a target engagement assay with potential to transform drug discovery</span></div><div class="casAuthors">Jensen, Annika Jenmalm; Molina, Daniel Martinez; Lundbaeck, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">975-978</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLq9NuYjGuYrVg90H21EOLACvtfcHk0lhVDcDu3LMbGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpslGgtLg%253D&md5=308cef6a198e47a4a45e28cf0d66d46f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.50%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DA.%2BJ.%26aulast%3DMolina%26aufirst%3DD.%2BM.%26aulast%3DLundb%25C3%25A4ck%26aufirst%3DT.%26atitle%3DCETSA%253A%2520a%2520target%2520engagement%2520assay%2520with%2520potential%2520to%2520transform%2520drug%2520discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D975%26epage%3D978%26doi%3D10.4155%2Ffmc.15.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olaru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffrezic-Renault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboul-Enein, H. Y.</span></span> <span> </span><span class="NLM_article-title">Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis</span>. <i>Crit. Rev. Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1080/10408347.2014.881250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1080%2F10408347.2014.881250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=25558771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvF2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=97-105&author=A.+Olaruauthor=C.+Balaauthor=N.+Jaffrezic-Renaultauthor=H.+Y.+Aboul-Enein&title=Surface+plasmon+resonance+%28SPR%29+biosensors+in+pharmaceutical+analysis&doi=10.1080%2F10408347.2014.881250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Surface Plasmon Resonance (SPR) Biosensors in Pharmaceutical Analysis</span></div><div class="casAuthors">Olaru, Andreea; Bala, Camelia; Jaffrezic-Renault, Nicole; Aboul-Enein, Hassan Y.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Analytical Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-105</span>CODEN:
                <span class="NLM_cas:coden">CCACBB</span>;
        ISSN:<span class="NLM_cas:issn">1040-8347</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  This review aims to highlight the applications of one of the most prominent optical biosensor technologies, surface plasmon resonance (SPR), in the drug discovery process and quality anal. of pharmaceutical compds. and their particularities.  SPR assay formats and exptl. issues are used for pharmacokinetic drug profiling, ADMET studies, high-throughput screening, and fragment-based drug screening, the last with an emphasis on the detection of small (drug) mols.  The classical method strengths and some applications of localized SPR and SPR imaging that are of high interest in the drug discovery process are presented, as well as possible challenges.  While similar works treat sep. the steps of drug discovery or focus only on the detection of drug residues in food or health safety, this review presents in a compact format the results and the progress obtained in both areas (drug discovery and quality anal.) based on the application of SPR biosensors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFltuwoLaZrrVg90H21EOLACvtfcHk0lhVDcDu3LMbGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvF2jsg%253D%253D&md5=e80f2bc3b0be491c441a45a67ca7fdab</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F10408347.2014.881250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10408347.2014.881250%26sid%3Dliteratum%253Aachs%26aulast%3DOlaru%26aufirst%3DA.%26aulast%3DBala%26aufirst%3DC.%26aulast%3DJaffrezic-Renault%26aufirst%3DN.%26aulast%3DAboul-Enein%26aufirst%3DH.%2BY.%26atitle%3DSurface%2520plasmon%2520resonance%2520%2528SPR%2529%2520biosensors%2520in%2520pharmaceutical%2520analysis%26jtitle%3DCrit.%2520Rev.%2520Anal.%2520Chem.%26date%3D2015%26volume%3D45%26spage%3D97%26epage%3D105%26doi%3D10.1080%2F10408347.2014.881250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span> <span> </span><span class="NLM_article-title">Development of a SPR aptasensor containing oriented aptamer for direct capture and detection of tetracycline in multiple honey samples</span>. <i>Biosens. Bioelectron.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/j.bios.2018.02.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.bios.2018.02.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=29522968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFyntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=1-7&author=S.+Wangauthor=Y.+Dongauthor=X.+Liang&title=Development+of+a+SPR+aptasensor+containing+oriented+aptamer+for+direct+capture+and+detection+of+tetracycline+in+multiple+honey+samples&doi=10.1016%2Fj.bios.2018.02.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a SPR aptasensor containing oriented aptamer for direct capture and detection of tetracycline in multiple honey samples</span></div><div class="casAuthors">Wang, Sai; Dong, Yiyang; Liang, Xingguo</div><div class="citationInfo"><span class="NLM_cas:title">Biosensors & Bioelectronics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">BBIOE4</span>;
        ISSN:<span class="NLM_cas:issn">0956-5663</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Although surface plasmon resonance (SPR) technique and aptamer technol. shows great potential in anal. and biol. chem., direct capture and anal. of small mols. using SPR remains tough.  Detection sensitivity of aptasensor and recognition ability of aptamer is limited, because direct immobilization of aptamer causes large steric hindrance and strand entanglement.  Herein, we chose a typical small mol.-tetracycline (Mw. 444.4 g/mol) as a model, and combined aptamer technol., DNA nanostructure, and com. Biacore T200 SPR instrument to develop a straightforward format SPR aptasensor.  Anti-tetracycline aptamer (Apt76) was fabricated on the top of a tetrahedron nanostructure to provide a better accessibility to tetracycline than the single-stranded Apt76 (ss-Apt76), and thus to improve sensitivity of the SPR aptasensor.  The aptasensor was then validated in real world application for tetracycline screening in multiple honey samples, achieving good recovery rates of 80.20-114.3%, intuitive sensorgrams indicating the binding kinetic properties, and high specificity towards tetracycline.  LOD of the tetrahedron-based SPR aptasensor was obtained using the real honey sample and calcd. to be 0.0069 μg/kg, which was 10-fold range lower than that of the ss-Apt76-based aptasensor.  The proof-of-concept demonstrated that aptamers of small mols. can be oriented immobilized on the SPR surface in a uniform nanoscale distance in both lateral and vertical direction, so as to achieve better conformational folding and better accessibility to small mols.  The concept is promising to be a universal and powerful tool for other ligand immobilization and SPR studies for both real world detection and mol. interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1sSUvXwxrhrVg90H21EOLACvtfcHk0lhVDcDu3LMbGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFyntbg%253D&md5=c64a636192a614f470f573992ef241a6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bios.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bios.2018.02.051%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DX.%26atitle%3DDevelopment%2520of%2520a%2520SPR%2520aptasensor%2520containing%2520oriented%2520aptamer%2520for%2520direct%2520capture%2520and%2520detection%2520of%2520tetracycline%2520in%2520multiple%2520honey%2520samples%26jtitle%3DBiosens.%2520Bioelectron.%26date%3D2018%26volume%3D109%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.bios.2018.02.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.-S.</span></span> <span> </span><span class="NLM_article-title">NADPH oxidase-derived H<sub>2</sub>O<sub>2</sub> mediates the regulatory effects of microglia on astrogliosis in experimental models of Parkinson’s disease</span>. <i>Redox Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.redox.2017.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.redox.2017.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=28237879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtl2jurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=162-170&author=L.+Houauthor=X.+Zhouauthor=C.+Zhangauthor=K.+Wangauthor=X.+Liuauthor=Y.+Cheauthor=F.+Sunauthor=H.+Liauthor=Q.+Wangauthor=D.+Zhangauthor=J.-S.+Hong&title=NADPH+oxidase-derived+H2O2+mediates+the+regulatory+effects+of+microglia+on+astrogliosis+in+experimental+models+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.redox.2017.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH oxidase-derived H2O2 mediates the regulatory effects of microglia on astrogliosis in experimental models of Parkinson's disease</span></div><div class="casAuthors">Hou, Liyan; Zhou, Xueying; Zhang, Cong; Wang, Ke; Liu, Xiaofang; Che, Yuning; Sun, Fuqiang; Li, Huihua; Wang, Qingshan; Zhang, Dan; Hong, Jau-Shyong</div><div class="citationInfo"><span class="NLM_cas:title">Redox Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">162-170</span>CODEN:
                <span class="NLM_cas:coden">RBEIB3</span>;
        ISSN:<span class="NLM_cas:issn">2213-2317</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Astrogliosis has long been recognized in Parkinson's disease (PD), the most common neurodegenerative movement disorder.  However, the mechanisms of how astroglia become activated remain unclear.  Reciprocal interactions between microglia and astroglia play a pivotal role in regulating the activities of astroglia.  The purpose of this study is to investigate the mechanism by which microglia regulate astrogliosis by using lipopolysaccharide (LPS) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse PD models.  We found that the activation of microglia preceded astroglia in the substantia nigra of mice treated with either LPS or MPTP.  Furthermore, suppression of microglial activation by pharmacol. inhibition or genetic deletion of NADPH oxidase (NOX2) in mice attenuated astrogliosis.  The important role of NOX2 in microglial regulation of astrogliosis was further mirrored in a mixed-glia culture system.  Mechanistically, H2O2, a product of microglial NOX2 activation, serves as a direct signal to regulate astrogliosis.  Astrogliosis was induced by H2O2 through a process in which extracellularly generated H2O2 diffused into the cytoplasm and subsequently stimulated activation of transcription factors, STAT1 and STAT3.  STAT1/3 activation regulated the immunol. functions of H2O2-induced astrogliosis since AG490, an inhibitor of STAT1/3, attenuated the gene expressions of both proinflammatory and neurotrophic factors in H2O2-treated astrocyte.  Our findings indicate that microglial NOX2-generated H2O2 is able to regulate the immunol. functions of astroglia via a STAT1/3-dependent manner, providing addnl. evidence for the immune pathogenesis and therapeutic studies of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3PyL18oUz6rVg90H21EOLACvtfcHk0liq0pxawYuPuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtl2jurk%253D&md5=c4de529006f34a9597ce51654701613b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.redox.2017.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.redox.2017.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHong%26aufirst%3DJ.-S.%26atitle%3DNADPH%2520oxidase-derived%2520H2O2%2520mediates%2520the%2520regulatory%2520effects%2520of%2520microglia%2520on%2520astrogliosis%2520in%2520experimental%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DRedox%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D162%26epage%3D170%26doi%3D10.1016%2Fj.redox.2017.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, H.</span></span> <span> </span><span class="NLM_article-title">Neurogenesis in Neurotoxin-induced Animal Models for Parkinson’s Disease-A Review of the Current Status</span>. <i>J. Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1293/tox.22.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1293%2Ftox.22.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=22271983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=101-108&author=X.+J.+Heauthor=H.+Nakayama&title=Neurogenesis+in+Neurotoxin-induced+Animal+Models+for+Parkinson%E2%80%99s+Disease-A+Review+of+the+Current+Status&doi=10.1293%2Ftox.22.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Neurogenesis in neurotoxin-induced animal models for Parkinson's disease - a review of the current status</span></div><div class="casAuthors">He, Xi Jun; Nakayama, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-108</span>CODEN:
                <span class="NLM_cas:coden">JTPAE7</span>;
        ISSN:<span class="NLM_cas:issn">0914-9198</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Toxicologic Pathology</span>)
        </div><div class="casAbstract">A review.  Animal models for Parkinson's disease (PD) are essential for understanding its pathogenesis and for development and testing of new therapies.  Discoveries of endogenous neurogenesis in the adult mammalian brain give new insight into the cell-based approach for treatment of neurodegenerative disorders, such as PD.  Although a great deal of interest has been focused on endogenous neurogenesis in neurotoxin-induced animal models for PD, it still remains controversial whether neural stem cells migrate into the injured area and contribute to repopulation of depleted dopaminergic neurons in neurotoxin-injured adult brains.  The purpose of this review is to examine the data available regarding neurogenesis in neurotoxin-induced animal models of PD.  It is hoped that data from the animal investigations available in the literature will promote understanding of the neurotoxin-induced animal models for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5LuHRl93aPbVg90H21EOLACvtfcHk0liq0pxawYuPuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKmt7Y%253D&md5=9d70c565c1c2cc0e28d87c7fe498d9df</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1293%2Ftox.22.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1293%252Ftox.22.101%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%2BJ.%26aulast%3DNakayama%26aufirst%3DH.%26atitle%3DNeurogenesis%2520in%2520Neurotoxin-induced%2520Animal%2520Models%2520for%2520Parkinson%25E2%2580%2599s%2520Disease-A%2520Review%2520of%2520the%2520Current%2520Status%26jtitle%3DJ.%2520Toxicol.%2520Pathol.%26date%3D2009%26volume%3D22%26spage%3D101%26epage%3D108%26doi%3D10.1293%2Ftox.22.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, L. M.</span></span> <span> </span><span class="NLM_article-title">MiR-302b-5p enhances the neuroprotective effect of IGF-1 in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease by regulating inducible nitric-oxide synthase</span>. <i>Cell Biochem. Funct.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.1002/cbf.3534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1002%2Fcbf.3534" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=1023-1035&author=X.+Cuiauthor=M.+P.+Liauthor=Z.+C.+Heauthor=L.+Huauthor=J.+P.+Liuauthor=J.+H.+Yanauthor=L.+M.+Hua&title=MiR-302b-5p+enhances+the+neuroprotective+effect+of+IGF-1+in+methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine-induced+Parkinson%E2%80%99s+disease+by+regulating+inducible+nitric-oxide+synthase&doi=10.1002%2Fcbf.3534"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcbf.3534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbf.3534%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DM.%2BP.%26aulast%3DHe%26aufirst%3DZ.%2BC.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%2BP.%26aulast%3DYan%26aufirst%3DJ.%2BH.%26aulast%3DHua%26aufirst%3DL.%2BM.%26atitle%3DMiR-302b-5p%2520enhances%2520the%2520neuroprotective%2520effect%2520of%2520IGF-1%2520in%2520methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine-induced%2520Parkinson%25E2%2580%2599s%2520disease%2520by%2520regulating%2520inducible%2520nitric-oxide%2520synthase%26jtitle%3DCell%2520Biochem.%2520Funct.%26date%3D2020%26volume%3D38%26spage%3D1023%26epage%3D1035%26doi%3D10.1002%2Fcbf.3534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Fischer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noelker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünewald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulinović, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerreiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombès, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oertel, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, A.</span></span> <span> </span><span class="NLM_article-title">Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1111/jnc.12343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1111%2Fjnc.12343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=23802648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKhu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2013&pages=782-792&author=D.+Alvarez-Fischerauthor=C.+Noelkerauthor=A.+Gr%C3%BCnewaldauthor=F.+Vulinovi%C4%87author=S.+Guerreiroauthor=J.+Fuchsauthor=L.+Luauthor=A.+Lomb%C3%A8sauthor=E.+C.+Hirschauthor=W.+H.+Oertelauthor=P.+P.+Michelauthor=A.+Hartmann&title=Probenecid+potentiates+MPTP%2FMPP%2B+toxicity+by+interference+with+cellular+energy+metabolism&doi=10.1111%2Fjnc.12343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism</span></div><div class="casAuthors">Alvarez-Fischer, Daniel; Noelker, Carmen; Gruenewald, Anne; Vulinovic, Franca; Guerreiro, Serge; Fuchs, Julia; Lu, Lixia; Lombes, Anne; Hirsch, Etienne C.; Oertel, Wolfgang H.; Michel, Patrick P.; Hartmann, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5&6</span>),
    <span class="NLM_cas:pages">782-792</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The uricosuric agent probenecid is co-administered with the dopaminergic neurotoxin MPTP to produce a chronic mouse model of Parkinson's disease.  It has been proposed that probenecid serves to elevate concns. of MPTP in the brain by reducing renal elimination of the toxin.  However, this mechanism has never been formally demonstrated to date and is questioned by the authors' previous data showing that intracerebral concns. of MPP+, the active metabolite of MPTP, are not modified by co-injection of probenecid.  In this study, the authors investigated the potentiating effects of probenecid in vivo and in vitro arguing against the possibility of altered metab. or impaired renal elimination of MPTP.  The authors find that probenecid (i) is toxic in itself to several neuronal populations apart from dopaminergic neurons, and (ii) that it also potentiates the effects of other mitochondrial complex I inhibitors such as rotenone.  On a mechanistic level, the authors show that probenecid is able to lower intracellular ATP concns. and that its toxic action on neuronal cells can be reversed by extracellular ATP.  Probenecid can potentiate the effect of mitochondrial toxins due to its impact on ATP metab. and could therefore be useful to model atypical parkinsonian syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop9u1iglGhO7Vg90H21EOLACvtfcHk0liDufzpMMzFeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKhu7jL&md5=bc619411839250d4fb387ebc18b1586b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fjnc.12343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.12343%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Fischer%26aufirst%3DD.%26aulast%3DNoelker%26aufirst%3DC.%26aulast%3DGr%25C3%25BCnewald%26aufirst%3DA.%26aulast%3DVulinovi%25C4%2587%26aufirst%3DF.%26aulast%3DGuerreiro%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DLomb%25C3%25A8s%26aufirst%3DA.%26aulast%3DHirsch%26aufirst%3DE.%2BC.%26aulast%3DOertel%26aufirst%3DW.%2BH.%26aulast%3DMichel%26aufirst%3DP.%2BP.%26aulast%3DHartmann%26aufirst%3DA.%26atitle%3DProbenecid%2520potentiates%2520MPTP%252FMPP%252B%2520toxicity%2520by%2520interference%2520with%2520cellular%2520energy%2520metabolism%26jtitle%3DJ.%2520Neurochem.%26date%3D2013%26volume%3D127%26spage%3D782%26epage%3D792%26doi%3D10.1111%2Fjnc.12343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meka, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Rischart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nidadavolu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motori, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponna, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboutalebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annamneedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finckh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miesbauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotermund, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatzelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winklhofer, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, E. R.</span></span> <span> </span><span class="NLM_article-title">Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1873</span>– <span class="NLM_lpage">1885</span>, <span class="refDoi"> DOI: 10.1172/jci79300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1172%2FJCI79300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=25822020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A280%3ADC%252BC2MnovFCntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=1873-1885&author=D.+P.+Mekaauthor=A.+K.+M%C3%BCller-Rischartauthor=P.+Nidadavoluauthor=B.+Mohammadiauthor=E.+Motoriauthor=S.+K.+Ponnaauthor=H.+Aboutalebiauthor=M.+Bassalauthor=A.+Annamneediauthor=B.+Finckhauthor=M.+Miesbauerauthor=N.+Rotermundauthor=C.+Lohrauthor=J.+Tatzeltauthor=K.+F.+Winklhoferauthor=E.+R.+Kramer&title=Parkin+cooperates+with+GDNF%2FRET+signaling+to+prevent+dopaminergic+neuron+degeneration&doi=10.1172%2Fjci79300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration</span></div><div class="casAuthors">Meka Durga Praveen; Muller-Rischart Anne Kathrin; Nidadavolu Prakash; Mohammadi Behnam; Motori Elisa; Ponna Srinivas Kumar; Aboutalebi Helia; Bassal Mahmoud; Annamneedi Anil; Finckh Barbara; Miesbauer Margit; Rotermund Natalie; Lohr Christian; Tatzelt Jorg; Winklhofer Konstanze F; Kramer Edgar R</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1873-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkin and the glial cell line-derived neurotrophic factor (GDNF) receptor RET have both been independently linked to the dopaminergic neuron degeneration that underlies Parkinson's disease (PD).  In the present study, we demonstrate that there is genetic crosstalk between parkin and the receptor tyrosine kinase RET in two different mouse models of PD.  Mice lacking both parkin and RET exhibited accelerated dopaminergic cell and axonal loss compared with parkin-deficient animals, which showed none, and RET-deficient mice, in which we found moderate degeneration.  Transgenic expression of parkin protected the dopaminergic systems of aged RET-deficient mice.  Downregulation of either parkin or RET in neuronal cells impaired mitochondrial function and morphology.  Parkin expression restored mitochondrial function in GDNF/RET-deficient cells, while GDNF stimulation rescued mitochondrial defects in parkin-deficient cells.  In both cases, improved mitochondrial function was the result of activation of the prosurvival NF-κB pathway, which was mediated by RET through the phosphoinositide-3-kinase (PI3K) pathway.  Taken together, these observations indicate that parkin and the RET signaling cascade converge to control mitochondrial integrity and thereby properly maintain substantia nigra pars compacta dopaminergic neurons and their innervation in the striatum.  The demonstration of crosstalk between parkin and RET highlights the interplay in the protein network that is altered in PD and suggests potential therapeutic targets and strategies to treat PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJ1yUqFoXEC7GbPKh4T9eAfW6udTcc2eZgalzJK3Z657ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnovFCntg%253D%253D&md5=d0c32187ee99f21afafd51d60fede891</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1172%2FJCI79300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI79300%26sid%3Dliteratum%253Aachs%26aulast%3DMeka%26aufirst%3DD.%2BP.%26aulast%3DM%25C3%25BCller-Rischart%26aufirst%3DA.%2BK.%26aulast%3DNidadavolu%26aufirst%3DP.%26aulast%3DMohammadi%26aufirst%3DB.%26aulast%3DMotori%26aufirst%3DE.%26aulast%3DPonna%26aufirst%3DS.%2BK.%26aulast%3DAboutalebi%26aufirst%3DH.%26aulast%3DBassal%26aufirst%3DM.%26aulast%3DAnnamneedi%26aufirst%3DA.%26aulast%3DFinckh%26aufirst%3DB.%26aulast%3DMiesbauer%26aufirst%3DM.%26aulast%3DRotermund%26aufirst%3DN.%26aulast%3DLohr%26aufirst%3DC.%26aulast%3DTatzelt%26aufirst%3DJ.%26aulast%3DWinklhofer%26aufirst%3DK.%2BF.%26aulast%3DKramer%26aufirst%3DE.%2BR.%26atitle%3DParkin%2520cooperates%2520with%2520GDNF%252FRET%2520signaling%2520to%2520prevent%2520dopaminergic%2520neuron%2520degeneration%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D1873%26epage%3D1885%26doi%3D10.1172%2Fjci79300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, D.-s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishizawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichinose, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtzman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, K.</span></span> <span> </span><span class="NLM_article-title">Prevention of dopaminergic neuron death by adeno-associated virus vector-mediated GDNF gene transfer in rat mesencephalic cells in vitro</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1016/s0304-3940(98)00313-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2FS0304-3940%2898%2900313-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=9665664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADyaK1cXivVGhtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1998&pages=61-64&author=D.-s.+Fanauthor=M.+Ogawaauthor=K.+Ikeguchiauthor=K.-i.+Fujimotoauthor=M.+Urabeauthor=A.+Kumeauthor=M.+Nishizawaauthor=N.+Matsushitaauthor=K.+Kiuchiauthor=H.+Ichinoseauthor=T.+Nagatsuauthor=G.+J.+Kurtzmanauthor=I.+Nakanoauthor=K.+Ozawa&title=Prevention+of+dopaminergic+neuron+death+by+adeno-associated+virus+vector-mediated+GDNF+gene+transfer+in+rat+mesencephalic+cells+in+vitro&doi=10.1016%2Fs0304-3940%2898%2900313-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of dopaminergic neuron death by adeno-associated virus vector-mediated GDNF gene transfer in rat mesencephalic cells in vitro</span></div><div class="casAuthors">Fan, Dong-sheng; Ogawa, Matsuo; Ikeguchi, Kunihiko; Fujimoto, Ken-ichi; Urabe, Masashi; Kume, Akihiro; Nishizawa, Masatoyo; Matsushita, Natsuki; Kiuchi, Kazutoshi; Ichinose, Hiroshi; Nagatsu, Toshiharu; Kurtzman, Gary J.; Nakano, Imaharu; Ozawa, Keiya</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-64</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Glial cell line-derived neurotrophic factor (GDNF) is known as a potent neurotrophic factor for dopaminergic neurons.  Since adeno-assocd. virus (AAV) vector is a suitable vehicle for gene transfer into neurons, rat E14 mesencephalic cells were transduced with an AAV vector expressing GDNF.  When compared with mock transduction, a larger no. of dopaminergic neurons survived in AAV-GDNF-transduced cultures (234% and 325% of controls at 1 and 2 wk, resp.; P<0.01).  Furthermore, the dopaminergic neurons in the latter cultures grew more prominent neurites than those in the former.  These findings suggest that AAV vector-mediated GDNF gene transfer may prevent dopaminergic neuron death, and is therefore a logical approach for the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTyKTiVh7u9rVg90H21EOLACvtfcHk0liDufzpMMzFeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivVGhtLk%253D&md5=4060ee638e4e7400c1b24b5afd010e72</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0304-3940%2898%2900313-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3940%252898%252900313-9%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DD.-s.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DIkeguchi%26aufirst%3DK.%26aulast%3DFujimoto%26aufirst%3DK.-i.%26aulast%3DUrabe%26aufirst%3DM.%26aulast%3DKume%26aufirst%3DA.%26aulast%3DNishizawa%26aufirst%3DM.%26aulast%3DMatsushita%26aufirst%3DN.%26aulast%3DKiuchi%26aufirst%3DK.%26aulast%3DIchinose%26aufirst%3DH.%26aulast%3DNagatsu%26aufirst%3DT.%26aulast%3DKurtzman%26aufirst%3DG.%2BJ.%26aulast%3DNakano%26aufirst%3DI.%26aulast%3DOzawa%26aufirst%3DK.%26atitle%3DPrevention%2520of%2520dopaminergic%2520neuron%2520death%2520by%2520adeno-associated%2520virus%2520vector-mediated%2520GDNF%2520gene%2520transfer%2520in%2520rat%2520mesencephalic%2520cells%2520in%2520vitro%26jtitle%3DNeurosci.%2520Lett.%26date%3D1998%26volume%3D248%26spage%3D61%26epage%3D64%26doi%3D10.1016%2Fs0304-3940%2898%2900313-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hevel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marletta, M. A.</span></span> <span> </span><span class="NLM_article-title">Nitric-Oxide Synthase Assays</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>233</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1016/s0076-6879(94)33028-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2FS0076-6879%2894%2933028-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=7516999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADyaK2MXitlSksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=1994&pages=250-258&author=J.+M.+Hevelauthor=M.+A.+Marletta&title=Nitric-Oxide+Synthase+Assays&doi=10.1016%2Fs0076-6879%2894%2933028-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide synthase assays</span></div><div class="casAuthors">Hevel, Joan M.; Marletta, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">233</span>
        (<span class="NLM_cas:issue">OXYGEN RADICALS IN BIOLOGICAL SYSTEMS, PT. C</span>),
    <span class="NLM_cas:pages">250-8</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    </div><div class="casAbstract">Several procedures are described for the anal. of nitric oxide synthase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmUa1x0Pt2JrVg90H21EOLACvtfcHk0lixENIF--Ly5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitlSksw%253D%253D&md5=29ca8a48095d9da8ec8d9421f43de0ea</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2894%2933028-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252894%252933028-X%26sid%3Dliteratum%253Aachs%26aulast%3DHevel%26aufirst%3DJ.%2BM.%26aulast%3DMarletta%26aufirst%3DM.%2BA.%26atitle%3DNitric-Oxide%2520Synthase%2520Assays%26jtitle%3DMethods%2520Enzymol.%26date%3D1994%26volume%3D233%26spage%3D250%26epage%3D258%26doi%3D10.1016%2Fs0076-6879%2894%2933028-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bourdonnec, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seida, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuthill, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeHaven, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolle, R. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of a series of aminopiperidines as novel iNOS inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.10.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.bmcl.2007.10.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=18024030" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=336-343&author=B.+L.+Bourdonnecauthor=L.+K.+Leisterauthor=C.+A.+Ajelloauthor=J.+A.+Casselauthor=P.+R.+Seidaauthor=H.+O%E2%80%99Hareauthor=M.+Guauthor=G.-H.+Chuauthor=P.+A.+Tuthillauthor=R.+N.+DeHavenauthor=R.+E.+Dolle&title=Discovery+of+a+series+of+aminopiperidines+as+novel+iNOS+inhibitors&doi=10.1016%2Fj.bmcl.2007.10.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.10.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.10.073%26sid%3Dliteratum%253Aachs%26aulast%3DBourdonnec%26aufirst%3DB.%2BL.%26aulast%3DLeister%26aufirst%3DL.%2BK.%26aulast%3DAjello%26aufirst%3DC.%2BA.%26aulast%3DCassel%26aufirst%3DJ.%2BA.%26aulast%3DSeida%26aufirst%3DP.%2BR.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DM.%26aulast%3DChu%26aufirst%3DG.-H.%26aulast%3DTuthill%26aufirst%3DP.%2BA.%26aulast%3DDeHaven%26aufirst%3DR.%2BN.%26aulast%3DDolle%26aufirst%3DR.%2BE.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%2520aminopiperidines%2520as%2520novel%2520iNOS%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D336%26epage%3D343%26doi%3D10.1016%2Fj.bmcl.2007.10.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chreifi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R. B.</span></span> <span> </span><span class="NLM_article-title">Optimization of blood-brain barrier permeability with potent and selective human neuronal nitric oxide synthase inhibitors having a 2-Aminopyridine scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2690</span>– <span class="NLM_lpage">2707</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b02032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b02032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFeruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2690-2707&author=H.+T.+Doauthor=H.+Liauthor=G.+Chreifiauthor=T.+L.+Poulosauthor=R.+B.+Silverman&title=Optimization+of+blood-brain+barrier+permeability+with+potent+and+selective+human+neuronal+nitric+oxide+synthase+inhibitors+having+a+2-Aminopyridine+scaffold&doi=10.1021%2Facs.jmedchem.8b02032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold</span></div><div class="casAuthors">Do, Ha T.; Li, Huiying; Chreifi, Georges; Poulos, Thomas L.; Silverman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2690-2707</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Effective delivery of therapeutic drugs into the human brain is one of the most challenging tasks in central nervous system drug development because of the blood-brain barrier (BBB).  To overcome the BBB, both passive permeability and efflux transporter liability of a compd. must be addressed.  Herein, we report our optimization related to BBB penetration of neuronal nitric oxide synthase (nNOS) inhibitors toward the development of new drugs for neurodegenerative diseases.  Various approaches, including enhancing lipophilicity and rigidity of new inhibitors and modulating the pKa of amino groups, have been employed.  In addn. to detg. inhibitor potency and selectivity, crystal structures of most newly designed compds. complexed to various nitric oxide synthase isoforms have been detd.  We have discovered a new analog (21), which exhibits not only excellent potency (Ki < 30 nM) in nNOS inhibition but also a significantly low P-glycoprotein and breast-cancer-resistant protein substrate liability as indicated by an efflux ratio of 0.8 in the Caco-2 bidirectional assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8cFYB2VOYWLVg90H21EOLACvtfcHk0lixENIF--Ly5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFeruro%253D&md5=1c357353833e5786f82ec591f51fd0f3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b02032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b02032%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DH.%2BT.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DChreifi%26aufirst%3DG.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26aulast%3DSilverman%26aufirst%3DR.%2BB.%26atitle%3DOptimization%2520of%2520blood-brain%2520barrier%2520permeability%2520with%2520potent%2520and%2520selective%2520human%2520neuronal%2520nitric%2520oxide%2520synthase%2520inhibitors%2520having%2520a%25202-Aminopyridine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2690%26epage%3D2707%26doi%3D10.1021%2Facs.jmedchem.8b02032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of Kukoamine A on neurotoxin-induced Parkinson’s model through apoptosis inhibition and autophagy enhancement</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.02.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.neuropharm.2017.02.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=28238714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Wht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=352-363&author=X.+Huauthor=Q.+Songauthor=X.+Liauthor=D.+Liauthor=Q.+Zhangauthor=W.+Mengauthor=Q.+Zhao&title=Neuroprotective+effects+of+Kukoamine+A+on+neurotoxin-induced+Parkinson%E2%80%99s+model+through+apoptosis+inhibition+and+autophagy+enhancement&doi=10.1016%2Fj.neuropharm.2017.02.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of Kukoamine A on neurotoxin-induced Parkinson's model through apoptosis inhibition and autophagy enhancement</span></div><div class="casAuthors">Hu, Xiao Long; Song, Qi; Li, Xin; Li, Dan Dan; Zhang, Qiao; Meng, Wei Hong; Zhao, Qing Chun</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">352-363</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in substantia nigra (SN).  Our previous study demonstrated Kukoamine A to exhibit strong neuroprotective effects through anti-oxidative stress, anti-inflammation, anti-excitoxicity.  In the present study, MPP+ and MPTP-induced PD models of cell and animal were used to investigate the effects of KuA on PD.  Our results demonstrated that KuA ameliorated cell loss and mitochondrial membrane potential (MMP) loss, and inhibited Bax/Bcl-2 ratio and MAPKs family that were induced by MPP+.  In addn., animal expts. showed that KuA improved the motor function and neuronal activity, and increased the pos. cells of tyrosine hydroxylase (TH) both in substantia nigra (SN) and striatum (Str).  Moreover, KuA could decrease the expression of α-synuclein in brain.  Finally, KuA exerted apparent autophagy enhancement both in vitro and in vivo.  In conclusion, KuA protected against neurotoxin-induced PD due to the apoptosis inhibition and autophagy enhancement, suggesting that KuA treatment might represent a neuroprotective treatment for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZhR9WcUXI0bVg90H21EOLACvtfcHk0ljg_jo3INQJRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Wht7g%253D&md5=95f453a39449d7bb633acd19c387bf62</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.02.022%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMeng%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DNeuroprotective%2520effects%2520of%2520Kukoamine%2520A%2520on%2520neurotoxin-induced%2520Parkinson%25E2%2580%2599s%2520model%2520through%2520apoptosis%2520inhibition%2520and%2520autophagy%2520enhancement%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D117%26spage%3D352%26epage%3D363%26doi%3D10.1016%2Fj.neuropharm.2017.02.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capitelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sereniki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, M. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reksidler, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tufik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vital, M. A. B. F.</span></span> <span> </span><span class="NLM_article-title">Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>594</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2008.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.ejphar.2008.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=18674531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVynurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=594&publication_year=2008&pages=101-108&author=C.+Capitelliauthor=A.+Serenikiauthor=M.+M.+S.+Limaauthor=A.+B.+Reksidlerauthor=S.+Tufikauthor=M.+A.+B.+F.+Vital&title=Melatonin+attenuates+tyrosine+hydroxylase+loss+and+hypolocomotion+in+MPTP-lesioned+rats&doi=10.1016%2Fj.ejphar.2008.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats</span></div><div class="casAuthors">Capitelli, Caroline; Sereniki, Adriana; Lima, Marcelo Meira Santos; Reksidler, Angela Braga; Tufik, Sergio; Vital, Maria Aparecida Barbato Frazao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">594</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">101-108</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Parkinson's disease is a chronic neurol. disease characterized by dopaminergic neuron degeneration in the substantia nigra pars compacta.  Melatonin is a powerful antioxidant agent secreted by the pineal gland which has numerous physiol. functions and seems to exert an important neuroprotective effect.  The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model has been used to understand the pathophysiol. of the disease because of its capacity to mimic biochem. and histol. features obsd. in Parkinson's disease.  This study investigated the effect of pretreatment with melatonin (50 mg/kg) on MPTP-lesioned animals 24 h and 7 days after neurotoxin infusion using the open-field test, two-way avoidance task and immunohistochem.  Twenty-four hours after lesioning, the MPTP + vehicle group exhibited hypolocomotion and significant loss of tyrosine hydroxylase-immunoreactive cells, whereas no differences in these parameters were obsd. in lesioned animals receiving melatonin.  Seven days after surgery, the MPTP-lesioned rats did not show hypolocomotion compared to control animals, while there was a significant dopaminergic neuronal loss.  In the two-way avoidance task, MPTP-treated animals presented a cognitive deficit compared to the control groups and melatonin administration did not repair this defect.  The present results suggest that melatonin reduces neuronal loss in the MPTP animal model of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWUUDQthb4SLVg90H21EOLACvtfcHk0ljg_jo3INQJRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVynurzK&md5=fc576dee7ba2fffcb4509ea54910a4e5</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2008.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2008.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DCapitelli%26aufirst%3DC.%26aulast%3DSereniki%26aufirst%3DA.%26aulast%3DLima%26aufirst%3DM.%2BM.%2BS.%26aulast%3DReksidler%26aufirst%3DA.%2BB.%26aulast%3DTufik%26aufirst%3DS.%26aulast%3DVital%26aufirst%3DM.%2BA.%2BB.%2BF.%26atitle%3DMelatonin%2520attenuates%2520tyrosine%2520hydroxylase%2520loss%2520and%2520hypolocomotion%2520in%2520MPTP-lesioned%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D594%26spage%3D101%26epage%3D108%26doi%3D10.1016%2Fj.ejphar.2008.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Strategies for further structural optimization of <b>4b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>1</b>–<b>20</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of compounds <b>1</b>–<b>20</b> and <b>4b</b> on NO release in BV-2 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. 3D-QSAR model. (A) 3D-QSAR model coefficients on electrostatic potential grids. Blue represents positive coefficients and red represents negative coefficients. (B) 3D-QSAR model coefficients on van der Waals grids. Green represents positive coefficients and yellow represents negative coefficients.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Molecular docking and MD simulation. (A) Predicted 3D binding mode of <b>18</b> with the iNOS crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R35">1R35</a>). Hydrogen bonds between inhibitors and amino acid residues are indicated by green dashed lines. (B) Predicted two-dimensional binding mode of <b>18</b> toward iNOS. (C) RMSD plot of native iNOS and complexed with EuC in black and red colors, respectively. (D) <i>R</i><sub>g</sub> plot of native iNOS and complexed with <b>18</b> in black and red colors, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Thermodynamic and kinetic experiments of <b>18</b> toward iNOS. (A,B) CETSA and ITDRF<sub>cesta</sub> were used to evaluate the binding between <b>18</b> and iNOS at the thermodynamic level. (C) SPR was used to assess the binding between <b>18</b> and iNOS at the kinetic level. (D) Effects of <b>18</b> on iNOS activity at different time points (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>18</b> protected DAergic neurons from neurotoxicity induced by microglial activation. SH-SY5Y cells were incubated for 24 h with conditioned medium derived from cultures of BV-2 cells. Before collecting culture media, BV-2 cells were pre-treated with <b>18</b> (0.1, 1, or 10 μM) for 2 h and incubated with LPS (0 or 500 ng/mL). (A) Cell viability measured with the MTT assay (<i>n</i> = 6). (B) LDH leakage assay (<i>n</i> = 6). (C) Morphological observation. (D) Cell nuclei stained with Hoechst 33258 (blue). (E) Apoptosis of SH-SY5Y cells evaluated by FCM detection of annexin V–PI double staining [distribution of viable (lower left), necrotic (upper left), late apoptotic (upper right), and early apoptotic (lower right) cells]. (F) Statistical analysis of three independent experiments of annexin V–PI double staining. All data are presented as means ± SD or SEM. **<i>p</i> < 0.01 or ***<i>p</i> < 0.001, compared with the control group; #<i>p</i> < 0.05, ##<i>p</i> < 0.01, or ###<i>p</i> < 0.001, compared with the LPS group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Prevention of <b>18</b> on MPTP-induced acute PD motor deficits. The behavioral measurements were carried out in the 4th, 24th, 48th, and 72nd h after the last injection of MPTP. (A) Experimental procedure and drug administration scheme. (B) Traction test. (C) Rotarod test. (D) Motion trail of the first three mice in each group in the open-field test (<i>n</i> = 8 mice/group). (E) Total distance of mice in the open-field test (<i>n</i> = 8 mice). (F) Mean velocity of mice in the open-field test (<i>n</i> = 8 mice). All data are presented as means ± SD. **<i>p</i> < 0.01 or ***<i>p</i> < 0.001, compared with the control group; #<i>p</i> < 0.05, ##<i>p</i> < 0.01, or ###<i>p</i> < 0.001, compared with the MPTP treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Prevention of <b>18</b> on MPTP-induced nigrostriatal DAergic injury. (A) Level of NO in SNpc and STR. (B) Level of DA in SNpc and STR. (C) Immunohistochemical staining showing TH positive cells in the SNpc and STR (scale bar: 200 μm). (D) Stereological counting of TH positive cells (<i>n</i> = 6). (E) Western blot analysis of the changes in the protein level of TH in both SNpc and STR. All data are presented as means ± SEM. **<i>p</i> < 0.01 or ***<i>p</i> < 0.001, compared with the control group; #<i>p</i> < 0.05, ##<i>p</i> < 0.01, or ###<i>p</i> < 0.001, compared with MPTP treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <b>18</b> alleviated the apoptosis of the SNpc neuron in the MPTP-induced acute PD model. (A,D) Original bands of Bax and Bcl-2 in SNpc and STR, β-actin served as control. (B,E) Quantitative analysis of blots. (C,F) Caspase-3 and caspase-9 activities in SNpc and STR. All data are presented as means ± SEM. ***<i>p</i> < 0.001, compared with the control group; ##<i>p</i> < 0.01 or ###<i>p</i> < 0.001, compared with the MPTP treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Therapeutic effects of <b>18</b> on MPTP/probenecid-induced chronic PD motor deficits. (A) Experimental procedure and drug administration scheme. (B) Traction test. (C) Rotarod test. (D) Motion trail of the first three mice in each group (no. 1, 2, and 3) in the open-field test (<i>n</i> = 8 mice/group). (E) Total distance of mice in the open-field test (<i>n</i> = 8 mice). (F) Mean velocity of mice in the open-field test (<i>n</i> = 8). (F) Mean speed of mice in the open-field test (<i>n</i> = 8). All data are presented as means ± SEM. ***<i>p</i> < 0.001, compared with the control group; ##<i>p</i> < 0.01 or ###<i>p</i> < 0.001, compared with the MPTP treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/medium/jm1c00578_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effects of <b>18</b> on the repair of DAergic neurons. (A) Immunohistochemical staining showing TH and DOPA decarboxylase-positive cells in the SN (scale bar: 200 μm). (B,C) Stereological counting of TH and DOPA decarboxylase-positive cells (<i>n</i> = 3). (D) Western blot analysis of the changes in the protein level of TH in SNpc. (E) Western blot analysis of the changes in the protein level of DOPA in SNpc. (F,G) Immunofluorescence staining showing GDNF in microglia of mice. All data are presented as means ± SEM. ***<i>p</i> < 0.001, compared with the control group; ##<i>p</i> < 0.01 or ###<i>p</i> < 0.001, compared with the MPTP treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00578/20210602/images/large/jm1c00578_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00578&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77780" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77780" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dostrovsky, J. O.</span></span> <span> </span><span class="NLM_article-title">New developments in understanding the etiology of Parkinson’s disease and in its treatment</span>. <i>Curr. Opin. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1016/s0959-4388(98)80122-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2FS0959-4388%2898%2980122-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=9914234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADyaK1MXhs12rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=783-790&author=A.+M.+Lozanoauthor=A.+E.+Langauthor=W.+D.+Hutchisonauthor=J.+O.+Dostrovsky&title=New+developments+in+understanding+the+etiology+of+Parkinson%E2%80%99s+disease+and+in+its+treatment&doi=10.1016%2Fs0959-4388%2898%2980122-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">New developments in understanding the etiology of Parkinson's disease and in its treatment</span></div><div class="casAuthors">Lozano, Andres M.; Lang, Anthony E.; Hutchison, William D.; Dostrovsky, Jonathon O.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurobiology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">783-790</span>CODEN:
                <span class="NLM_cas:coden">COPUEN</span>;
        ISSN:<span class="NLM_cas:issn">0959-4388</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">A review, with 68 refs.  Important recent advances have been made in understanding the etiol. and pathogenesis of Parkinson's disease, as well as in developing novel treatments.  Two newly identified genes, α-synuclein and parkin, have been linked to parkinsonism.  In addn., disturbances to the normal basal ganglia circuits in Parkinson's patients are being described at both anatomical and physiol. levels.  These developments provide a strong scientific basis for novel medical and surgical strategies to treat the profound motor disturbances in patients with Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodlpVrZ3PxRbVg90H21EOLACvtfcHk0liM_zOD2YsFHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhs12rtw%253D%253D&md5=92603a33810b19c8c3b1eb2b23e470ae</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0959-4388%2898%2980122-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-4388%252898%252980122-0%26sid%3Dliteratum%253Aachs%26aulast%3DLozano%26aufirst%3DA.%2BM.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DHutchison%26aufirst%3DW.%2BD.%26aulast%3DDostrovsky%26aufirst%3DJ.%2BO.%26atitle%3DNew%2520developments%2520in%2520understanding%2520the%2520etiology%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520in%2520its%2520treatment%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D1998%26volume%3D8%26spage%3D783%26epage%3D790%26doi%3D10.1016%2Fs0959-4388%2898%2980122-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcão, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease</span>. <i>Eur. J. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">815</span>, <span class="refDoi"> DOI: 10.1111/ene.12666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1111%2Fene.12666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=25649051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A280%3ADC%252BC2MritlCqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=815&author=J.+J.+Ferreiraauthor=J.-F.+Rochaauthor=A.+Falc%C3%A3oauthor=A.+Santosauthor=R.+Pintoauthor=T.+Nunesauthor=P.+Soares-da-Silva&title=Effect+of+opicapone+on+levodopa+pharmacokinetics%2C+catechol-O-methyltransferase+activity+and+motor+fluctuations+in+patients+with+Parkinson%E2%80%99s+disease&doi=10.1111%2Fene.12666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease</span></div><div class="casAuthors">Ferreira J J; Rocha J-F; Falcao A; Santos A; Pinto R; Nunes T; Soares-da-Silva P</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">815-25, e56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Opicapone (OPC) is a novel third generation catechol-O-methyltransferase (COMT) inhibitor that enhances levodopa availability.  This study investigated the effects of OPC in comparison with placebo on levodopa pharmacokinetics, tolerability and safety, COMT activity and motor response to levodopa in Parkinson's disease (PD) patients with motor fluctuations.  METHODS:  This was a randomized, multicentre, double-blind and placebo-controlled study in four parallel groups of PD patients treated with standard-release 100/25 mg levodopa/carbidopa or levodopa/benserazide and with motor fluctuations (wearing-OFF phenomenon).  Subjects were sequentially assigned to be administered, once-daily, up to 28 days (maintenance phase), placebo (n = 10) or 5 (n = 10), 15 (n = 10) and 30 mg (n = 10) OPC.  Two levodopa tests were performed, one at baseline and another following the maintenance phase.  Subjects kept a diary to record motor fluctuations (ON/OFF periods) throughout the study.  RESULTS:  In relation to placebo, levodopa exposure (AUC0-6) increased 24.7%, 53.9% and 65.6% following 5, 15 and 30 mg OPC, respectively.  Maximum COMT inhibition (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg OPC).  The study was not designed to detect any significant differences in motor performance, but the exploratory analysis performed shows improvement in various motor outcomes, including a dose-dependent change in absolute OFF time corresponding to a percentage decrease of 4.16% (P > 0.05), 29.55% (P > 0.05) and 32.71% (P < 0.05) with 5, 15 and 30 mg OPC, respectively.  Treatments were generally well tolerated and safe.  CONCLUSIONS:  OPC is a promising new COMT inhibitor that significantly decreased COMT activity, increased systemic exposure to levodopa and improved motor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEuvMtwfdhHOQ4Pl9hzjQhfW6udTcc2eYECUerNnDp7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MritlCqsA%253D%253D&md5=7b33ae752bc6ace3867a38b8f9e6e9c8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fene.12666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fene.12666%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DJ.%2BJ.%26aulast%3DRocha%26aufirst%3DJ.-F.%26aulast%3DFalc%25C3%25A3o%26aufirst%3DA.%26aulast%3DSantos%26aufirst%3DA.%26aulast%3DPinto%26aufirst%3DR.%26aulast%3DNunes%26aufirst%3DT.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26atitle%3DEffect%2520of%2520opicapone%2520on%2520levodopa%2520pharmacokinetics%252C%2520catechol-O-methyltransferase%2520activity%2520and%2520motor%2520fluctuations%2520in%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Neurol.%26date%3D2015%26volume%3D22%26spage%3D815%26doi%3D10.1111%2Fene.12666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, A. H. V.</span></span> <span> </span><span class="NLM_article-title">Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1071</span>, <span class="refDoi"> DOI: 10.2165/11596310-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.2165%2F11596310-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=22133327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1061-1071&author=A.+H.+V.+Schapira&title=Monoamine+oxidase+B+inhibitors+for+the+treatment+of+Parkinson%E2%80%99s+disease%3A+a+review+of+symptomatic+and+potential+disease-modifying+effects&doi=10.2165%2F11596310-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects</span></div><div class="casAuthors">Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1061-1071</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease is a disorder characterized pathol. by progressive neurodegeneration of the dopaminergic cells of the nigrostriatal pathway.  Although the resulting dopamine deficiency is the cause of the typical motor features of Parkinson's disease (bradykinesia, rigidity, tremor), addnl. non-motor symptoms appear at various timepoints and are the result of non-dopamine nerve degeneration.  Monoamine oxidase B (MAO-B) inhibitors are used in the symptomatic treatment of Parkinson's disease as they increase synaptic dopamine by blocking its degrdn.  Two MAO-B inhibitors, selegiline and rasagiline, are currently licensed in Europe and North America for the symptomatic improvement of early Parkinson's disease and to reduce off-time in patients with more advanced Parkinson's disease and motor fluctuations related to levodopa.  A third MAO-B inhibitor (safinamide), which also combines addnl. non-dopaminergic properties of potential benefit to Parkinson's disease, is currently under development in phase III clin. trials as adjuvant therapy to either a dopamine agonist or levodopa.  MAO-B inhibitors have also been studied extensively for possible neuroprotective or disease-modifying actions.  There is considerable lab. evidence that MAO-B inhibitors do exert some neuroprotective properties, at least in the Parkinson's disease models currently available.  However, these models have significant limitations and caution is required in assuming that such results may easily be extrapolated to clin. trials.  Rasagiline 1 mg/day has been shown to provide improved motor control in terms of Unified Parkinson's Disease Rating Scale (UPDRS) score at 18 mo in those patients with early disease who began the drag 9 mo before a second group.  There are a no. of possible explanations for this effect that may include a disease-modifying action; however, the US FDA recently declined an application for the licence of rasagiline to be extended to cover disease modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2AHDUDO6Ch7Vg90H21EOLACvtfcHk0litutUkQR_Dmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D&md5=a6c6a9380eaa9056a877fa0df9e39446</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2165%2F11596310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26atitle%3DMonoamine%2520oxidase%2520B%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520review%2520of%2520symptomatic%2520and%2520potential%2520disease-modifying%2520effects%26jtitle%3DCNS%2520Drugs%26date%3D2011%26volume%3D25%26spage%3D1061%26epage%3D1071%26doi%3D10.2165%2F11596310-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koprich, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piggott, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotchie, J. M.</span></span> <span> </span><span class="NLM_article-title">UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2014.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.neuropharm.2014.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=24447715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFynt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=76-87&author=P.+Huotauthor=T.+H.+Johnstonauthor=K.+D.+Lewisauthor=J.+B.+Koprichauthor=M.+G.+Reyesauthor=S.+H.+Foxauthor=M.+J.+Piggottauthor=J.+M.+Brotchie&title=UWA-121%2C+a+mixed+dopamine+and+serotonin+re-uptake+inhibitor%2C+enhances+L-DOPA+anti-parkinsonian+action+without+worsening+dyskinesia+or+psychosis-like+behaviours+in+the+MPTP-lesioned+common+marmoset&doi=10.1016%2Fj.neuropharm.2014.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset</span></div><div class="casAuthors">Huot, Philippe; Johnston, Tom H.; Lewis, Katie D.; Koprich, James B.; Reyes, M. Gabriela; Fox, Susan H.; Piggott, Matthew J.; Brotchie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-87</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease (PD), but its long-term administration is complicated by wearing-off and dyskinesia.  UWA-101, a dual, equipotent inhibitor of dopamine (DAT) and serotonin (SERT) transporters, has previously been shown to successfully extend duration of anti-parkinsonian benefit of L-DOPA (ON-time), without exacerbating dyskinesia, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset.  However, UWA-101 is racemic and it is unclear whether one or both enantiomers contribute to its actions, and whether a better therapeutic effect might be attained by using a single antipode.  In the current study, we synthesized the two enantiomers of UWA-101, R-101 (UWA-121) and S-101 (UWA-122), characterized their pharmacol. profiles and administered them to MPTP-lesioned marmosets.  Parkinsonism, dyskinesia, psychosis-like behaviors and duration of ON-time were evaluated.  UWA-121 is a dual DAT > SERT inhibitor, with an approx. 10:1 DAT:SERT affinity ratio (inhibitory consts. (Ki) of 307 and 3830 nM, resp.).  In combination with L-DOPA, UWA-121 extended duration of ON-time when compared to L-DOPA/vehicle treatment (by 40%, P < 0.01).  UWA-121 also extended duration of ON-time without dyskinesia (by 215%, P < 0.05) and ON-time without psychosis-like behaviors when compared to L-DOPA/vehicle treatment (by 345%, P < 0.01).  UWA-121 did not worsen the severity of dyskinesia or psychosis-like behaviors (P > 0.05).  UWA-122 is a selective SERT inhibitor (Ki 120 nM, Ki at DAT > 50 μM) and, in combination with L-DOPA, had no effect on ON-time, dyskinesia or psychosis-like behaviors (P > 0.05).  These data indicate that dual DAT and SERT inhibitors effectively enhance L-DOPA anti-parkinsonian action without worsening dyskinesia and that compds. with such a pharmacol. profile represent promising agents against wearing-off in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbiBB5fc-TBrVg90H21EOLACvtfcHk0litutUkQR_Dmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFynt7o%253D&md5=2c88b90b665cabea18d5116c44878d9b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DHuot%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DT.%2BH.%26aulast%3DLewis%26aufirst%3DK.%2BD.%26aulast%3DKoprich%26aufirst%3DJ.%2BB.%26aulast%3DReyes%26aufirst%3DM.%2BG.%26aulast%3DFox%26aufirst%3DS.%2BH.%26aulast%3DPiggott%26aufirst%3DM.%2BJ.%26aulast%3DBrotchie%26aufirst%3DJ.%2BM.%26atitle%3DUWA-121%252C%2520a%2520mixed%2520dopamine%2520and%2520serotonin%2520re-uptake%2520inhibitor%252C%2520enhances%2520L-DOPA%2520anti-parkinsonian%2520action%2520without%2520worsening%2520dyskinesia%2520or%2520psychosis-like%2520behaviours%2520in%2520the%2520MPTP-lesioned%2520common%2520marmoset%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D82%26spage%3D76%26epage%3D87%26doi%3D10.1016%2Fj.neuropharm.2014.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chunfeng, L.</span></span> <span> </span><span class="NLM_article-title">Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">S168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=S168&author=J.+Chenauthor=J.+Hongauthor=L.+Chunfeng&title=Effect+of+dopamine+agonists+versus+levodopa+as+initial+treatment+in+Parkinson%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DChunfeng%26aufirst%3DL.%26atitle%3DEffect%2520of%2520dopamine%2520agonists%2520versus%2520levodopa%2520as%2520initial%2520treatment%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DMov.%2520Disord.%26date%3D2018%26volume%3D33%26spage%3DS168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A. E.</span></span> <span> </span><span class="NLM_article-title">Pharmacological treatment of Parkinson disease: a review</span>. <i>J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1683</span>, <span class="refDoi"> DOI: 10.1001/jama.2014.3654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1001%2Fjama.2014.3654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=24756517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFems7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2014&pages=1670-1683&author=B.+S.+Connollyauthor=A.+E.+Lang&title=Pharmacological+treatment+of+Parkinson+disease%3A+a+review&doi=10.1001%2Fjama.2014.3654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment of Parkinson disease: a review</span></div><div class="casAuthors">Connolly, Barbara S.; Lang, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1670-1683, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">A review.  Importance: Parkinson disease is the second most common neurodegenerative disease worldwide.  Although no available therapies alter the underlying neurodegenerative process, symptomatic therapies can improve patient quality of life.  Objective: To provide an evidence-based review of the initial pharmacol. management of the classic motor symptoms of Parkinson disease; describe management of medication-related motor complications (such as motor fluctuations and dyskinesia), and other medication adverse effects (nausea, psychosis, and impulse control disorders and related behaviors); and discuss the management of selected nonmotor symptoms of Parkinson disease, including rapid eye movement sleep behavior disorder, cognitive impairment, depression, orthostatic hypotension, and sialorrhea.  Evidence Review: Refs. were identified using searches of PubMed between Jan. 1985 and Feb. 2014 for English-language human studies and the full database of the Cochrane Library.  The classification of studies by quality (classes I-IV) was assessed using the levels of evidence guidelines from the American Academy of Neurol. and the highest-quality data for each topic.  Results: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.  Motor fluctuations may be managed by modifying the levodopa dosing regimen or by adding several other medications, such as MAOBIs, catechol-O-methyltransferase inhibitors, or dopamine agonists.  Impulse control disorders are typically managed by reducing or withdrawing dopaminergic medication, particularly dopamine agonists.  Evidence-based management of some nonmotor symptoms is limited by a paucity of high-quality pos. studies.  Conclusions and Relevance: Strong evidence supports using levodopa and dopamine agonists for motor symptoms at all stages of Parkinson disease.  Dopamine agonists and drugs that block dopamine metab. are effective for motor fluctuations and clozapine is effective for hallucinations.  Cholinesterase inhibitors may improve symptoms of dementia and antidepressants and pramipexole may improve depression.  Evidence supporting other therapies for motor and nonmotor features is less well established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq4bHOyyI7XrVg90H21EOLACvtfcHk0ljvHqIazGjBsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFems7rP&md5=a3faf879f5febdfc11a8992db89f2e67</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.3654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.3654%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DB.%2BS.%26aulast%3DLang%26aufirst%3DA.%2BE.%26atitle%3DPharmacological%2520treatment%2520of%2520Parkinson%2520disease%253A%2520a%2520review%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2014%26volume%3D311%26spage%3D1670%26epage%3D1683%26doi%3D10.1001%2Fjama.2014.3654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beitz, J. M.</span></span> <span> </span><span class="NLM_article-title">Parkinson’s disease: a review</span>. <i>Front. Biosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>S6</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.2741/s415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.2741%2FS415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2rsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=S6&publication_year=2014&pages=65-74&author=J.+M.+Beitz&title=Parkinson%E2%80%99s+disease%3A+a+review&doi=10.2741%2Fs415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's disease: a review</span></div><div class="casAuthors">Beitz, Janice M.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience, Scholar Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">S6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-74, 10</span>CODEN:
                <span class="NLM_cas:coden">FBSEAU</span>;
        ISSN:<span class="NLM_cas:issn">1945-0524</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Parkinson's Disease is the second most common progressive neurodegenerative disorder affecting older American adults and is predicted to increase in prevalence as the United States population ages.  Resulting from a pathophysiol. loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain and the development of neuronal Lewy Bodies, idiopathic Parkinson's Disease is assocd. with risk factors including aging, family history, pesticide exposure and environmental chems. (e.g., synthetic heroin use).  Its ultimate cause(s) is (are) unknown.  Characterized by both motor and non-motor symptoms, PD patients classically display rest tremor, rigidity, bradykinesia, and stooping posture.  PD can also be assocd. with neurobehavioral disorders (depression, anxiety), cognitive impairment (dementia), and autonomic dysfunction (e.g., orthostasis and hyperhidrosis).  Recent decades have witnessed a proliferation of medical pharmacol. therapies and innovative surgical interventions like deep brain stimulation (DBS).  However, definitive disease-modifying therapy is still lacking.  Exptl. therapies are being developed and tested with limited results.  Knowledge of strategies to promote optimal quality of life for PD patients is of paramount importance for caregivers, health providers and patients themselves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB281kduGUebVg90H21EOLACvtfcHk0ljvHqIazGjBsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2rsL3P&md5=b9b2b61a02391bbc113185f2b4f99e53</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2741%2FS415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252FS415%26sid%3Dliteratum%253Aachs%26aulast%3DBeitz%26aufirst%3DJ.%2BM.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%253A%2520a%2520review%26jtitle%3DFront.%2520Biosci.%26date%3D2014%26volume%3DS6%26spage%3D65%26epage%3D74%26doi%3D10.2741%2Fs415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagotti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targa, A.D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noseda, A. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilkiwa, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuproski, A. P.</span></span> <span> </span><span class="NLM_article-title">Potential new therapies against a toxic relationship: neuroinflammation and Parkinson’s disease</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1097/fbp.0000000000000512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1097%2FFBP.0000000000000512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=31703030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlygtb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=676-688&author=L.+S.+Rodriguesauthor=J.+Fagottiauthor=A.D.+S.+Targaauthor=A.+C.+D.+Nosedaauthor=J.+L.+Ilkiwaauthor=A.+P.+Chuproski&title=Potential+new+therapies+against+a+toxic+relationship%3A+neuroinflammation+and+Parkinson%E2%80%99s+disease&doi=10.1097%2Ffbp.0000000000000512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Potential new therapies against a toxic relationship: neuroinflammation and Parkinson's disease</span></div><div class="casAuthors">Rodrigues, Lais S.; Fagotti, Juliane; D. S. Targa, Adriano; D. Noseda, Ana Carolina; L. Ilkiwa, Jessica; Chuproski, Ana Paula; W. C. Dorieux, Flavia; D. dos Santos, Patricia; M. S. Lima, Marcelo</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">676-688</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Parkinsons disease (PD) is a neurodegenerative disorder classically assocd. with motor symptoms, but several nonmotor disturbances appear decades before the clin. diagnosis of the disease.  A variety of hypotheses exist to explain the onset of PD, and neuroinflammation is one of the most investigated processes.  In fact, strong evidence suggests that PD begins with an inflammatory process; currently, however, no anti-inflammatory therapy is clin. employed to alleviate the typical motor and the prodromal disturbances such as olfactory loss, cognitive impairments, depression and anxiety, sleep disturbances, and autonomic disorders.  In fact, the classical dopaminergic therapies are not effective in alleviating these symptoms and there is no other specific therapy for these outcomes.  Therefore, in this review, we will discuss novel potential pharmacol. therapeutic strategies focusing on cannabinoids, caffeine, melatonin, and dietary compds., which could act as adjuvants to regular PD therapy.  These described chems. have been extensively investigated as anti-inflammatory agents possibly promoting beneficial effects on nonmotor symptoms of PD.  The investigation of the inflammatory process at different stages of PD progression should give us a better view of the therapeutic scenario and could improve our understanding of the mechanisms of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Qvtpyqa707Vg90H21EOLACvtfcHk0ljvHqIazGjBsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlygtb7K&md5=55684104a98ce4c4b229ef6a0a4e6a32</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1097%2FFBP.0000000000000512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0000000000000512%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DL.%2BS.%26aulast%3DFagotti%26aufirst%3DJ.%26aulast%3DTarga%26aufirst%3DA.D.%2BS.%26aulast%3DNoseda%26aufirst%3DA.%2BC.%2BD.%26aulast%3DIlkiwa%26aufirst%3DJ.%2BL.%26aulast%3DChuproski%26aufirst%3DA.%2BP.%26atitle%3DPotential%2520new%2520therapies%2520against%2520a%2520toxic%2520relationship%253A%2520neuroinflammation%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2019%26volume%3D30%26spage%3D676%26epage%3D688%26doi%3D10.1097%2Ffbp.0000000000000512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miscusi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germanò, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuzzocrea, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasello, F.</span></span> <span> </span><span class="NLM_article-title">Nitric oxide in the injured spinal cord: synthases cross-talk, oxidative stress and inflammation</span>. <i>Brain Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.brainresrev.2007.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.brainresrev.2007.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=17500094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Kqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2007&pages=205-218&author=A.+Contiauthor=M.+Miscusiauthor=S.+Cardaliauthor=A.+German%C3%B2author=H.+Suzukiauthor=S.+Cuzzocreaauthor=F.+Tomasello&title=Nitric+oxide+in+the+injured+spinal+cord%3A+synthases+cross-talk%2C+oxidative+stress+and+inflammation&doi=10.1016%2Fj.brainresrev.2007.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide in the injured spinal cord: Synthases cross-talk, oxidative stress and inflammation</span></div><div class="casAuthors">Conti, Alfredo; Miscusi, Massimo; Cardali, Salvatore; Germano, Antonino; Suzuki, Hisanori; Cuzzocrea, Salvatore; Tomasello, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">205-218</span>CODEN:
                <span class="NLM_cas:coden">BRERD2</span>;
        ISSN:<span class="NLM_cas:issn">0165-0173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) is a unique informational mol. involved in a variety of physiol. processes in the central nervous system (CNS).  It has been demonstrated that it can exert both protective and detrimental effects in several disease states of the CNS, including spinal cord injury (SCI).  The effects of NO on the spinal cord depend on several factors such as: concn. of produced NO, activity of different synthase isoforms, cellular source of prodn. and time of release.  Basically, it has been shown that low NO concns. may play a role in physiol. processes, whereas large amts. of NO may be detrimental by increasing oxidative stress.  However, this does not explain all the discrepancies evidenced studying the effects of NO in SCI models.  The anal. of the different synthase isoforms, of their temporal profile of activation and cellular source has shed light on this topic.  Two post-injury time intervals can be defined with ref. to the NO prodn.: immediately after injury and several hours-to-days later.  The initial immediate peak of NO prodn. after injury is due to the up-regulation of the neuronal NO synthase (nNOS) in resident spinal cord cells.  The late peak is due primarily to the activity of inducible NOS (iNOS) produced by inflammatory infiltrating cells.  High NO levels produced by up-regulated nNOS and iNOS are neurotoxic; the down-regulation of nNOS corresponds temporally to the expression of iNOS.  On the bases of those evidence, therapeutic approaches should be aimed: (1) to reduce the NO-elicited damage by inhibition of specific synthases according to the temporal profile of activation; (2) by maintaining physiol. amt. of NO to keep the induction of iNOS expression suppressed and avoiding ischemia/reperfusion injuries; (3) by using scavengers of oxygen and nitrogen reactive species or using inhibitors of the specific kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAtVKal9OJ1LVg90H21EOLACvtfcHk0lhqFsyzHSA2gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Kqtrw%253D&md5=8edc09dcea5634e9ba2015d3791e34c3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2007.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2007.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DConti%26aufirst%3DA.%26aulast%3DMiscusi%26aufirst%3DM.%26aulast%3DCardali%26aufirst%3DS.%26aulast%3DGerman%25C3%25B2%26aufirst%3DA.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DCuzzocrea%26aufirst%3DS.%26aulast%3DTomasello%26aufirst%3DF.%26atitle%3DNitric%2520oxide%2520in%2520the%2520injured%2520spinal%2520cord%253A%2520synthases%2520cross-talk%252C%2520oxidative%2520stress%2520and%2520inflammation%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2007%26volume%3D54%26spage%3D205%26epage%3D218%26doi%3D10.1016%2Fj.brainresrev.2007.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hague, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peuralinna, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eerola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tienari, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, A. B.</span></span> <span> </span><span class="NLM_article-title">Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1212/01.wnl.0000110191.38152.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1212%2F01.WNL.0000110191.38152.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=14981185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FptFOguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2004&pages=635-636&author=S.+Hagueauthor=T.+Peuralinnaauthor=J.+Eerolaauthor=O.+Hellstromauthor=P.+J.+Tienariauthor=A.+B.+Singleton&title=Confirmation+of+the+protective+effect+of+iNOS+in+an+independent+cohort+of+Parkinson+disease&doi=10.1212%2F01.wnl.0000110191.38152.29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease</span></div><div class="casAuthors">Hague S; Peuralinna T; Eerola J; Hellstrom O; Tienari P J; Singleton A B</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">635-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nitric oxide is a biologic messenger molecule involved in a diverse range of physiologic processes.  An exon 22 inducible nitric oxide synthase genotype has recently been reported to be protective against Parkinson disease in a European cohort.  The authors confirm the protective effect of this genotype (OR = 0.5, 95% CI 0.27 to 0.93) in an independent Finnish case-control series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHx6fXWaFfSFf1XRtfYM0dfW6udTcc2eZzqp7mPJOourntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FptFOguw%253D%253D&md5=228e7ceebcd75e9282bd66b2de32558e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1212%2F01.WNL.0000110191.38152.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252F01.WNL.0000110191.38152.29%26sid%3Dliteratum%253Aachs%26aulast%3DHague%26aufirst%3DS.%26aulast%3DPeuralinna%26aufirst%3DT.%26aulast%3DEerola%26aufirst%3DJ.%26aulast%3DHellstrom%26aufirst%3DO.%26aulast%3DTienari%26aufirst%3DP.%2BJ.%26aulast%3DSingleton%26aufirst%3DA.%2BB.%26atitle%3DConfirmation%2520of%2520the%2520protective%2520effect%2520of%2520iNOS%2520in%2520an%2520independent%2520cohort%2520of%2520Parkinson%2520disease%26jtitle%3DNeurology%26date%3D2004%26volume%3D62%26spage%3D635%26epage%3D636%26doi%3D10.1212%2F01.wnl.0000110191.38152.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boissière, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucheux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouatt-Prigent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agid, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E. C.</span></span> <span> </span><span class="NLM_article-title">Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/0306-4522(95)00578-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2F0306-4522%2895%2900578-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=8737406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADyaK28XisFCksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1996&pages=355-363&author=S.+Hunotauthor=F.+Boissi%C3%A8reauthor=B.+Faucheuxauthor=B.+Bruggauthor=A.+Mouatt-Prigentauthor=Y.+Agidauthor=E.+C.+Hirsch&title=Nitric+oxide+synthase+and+neuronal+vulnerability+in+Parkinson%E2%80%99s+disease&doi=10.1016%2F0306-4522%2895%2900578-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide synthase and neuronal vulnerability in Parkinson's disease</span></div><div class="casAuthors">Hunot, S.; Boissiere, F.; Faucheux, B.; Brugg, B.; Mouatt-Prigent, A.; Agid, Y.; Hirsch, E. C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">355-63</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Parkinson's disease is characterized by a loss of dopaminergic neurons in the mesencephalon.  Although the mechanism of this neuronal loss is still unknown, oxidative stress is very likely involved in the cascade of events leading to nerve cell death.  Since nitric oxide could be involved in the prodn. of free radicals, we analyzed, using immunohistochem. and histochem., the prodn. systems of nitric oxide in the mesencephalon of four patients with idiopathic Parkinson's disease and three matched control subjects.  Using specific antibodies directed against the inducible isoform of nitric oxide synthase (the enzyme involved in the synthesis of nitric oxide), we found evidence to suggest that this isoform was present solely in glial cells displaying the morphol. characteristics of activated macrophages.  Immunohistochem. anal. performed with antibodies against the neuronal isoform of nitric oxide synthase, however, revealed perikarya and processes of neurons but o glial cell staining.  The no. of nitric oxide synthase-contg. cells was investigated by histoenzymol., using the NADPH-diaphorase activity of nitric oxide synthase.  Histochem. revealed (i) a significant increase in NADPH-diaphorase-pos. glial cell d. in the dopaminergic cell groups characterized by neuronal loss in Parkinson's disease and (ii) a neuronal loss in Parkinson's disease that was two-fold greater for pigmented NADPH-diaphorase-neg. neurons than for pigmented NADPH-diaphorase-pos. neurons.  These data suggest a potentially deleterious role of glial cells producing excessive levels of nitric oxide in Parkinson's disease, which may be neurotoxic for a subpopulation of dopaminergic neurons, esp. those not expressing NADPH-diaphorase activity.  However, it cannot be excluded that the presence of glial cells expressing nitric oxide synthase in the substantia nigra of patients with Parkinson's disease represents a consequence of dopaminergic neuronal loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4SORDlRL1TrVg90H21EOLACvtfcHk0lhqFsyzHSA2gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XisFCksro%253D&md5=2096cb70025e015e0d53dc14503b8aa8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2F0306-4522%2895%2900578-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0306-4522%252895%252900578-1%26sid%3Dliteratum%253Aachs%26aulast%3DHunot%26aufirst%3DS.%26aulast%3DBoissi%25C3%25A8re%26aufirst%3DF.%26aulast%3DFaucheux%26aufirst%3DB.%26aulast%3DBrugg%26aufirst%3DB.%26aulast%3DMouatt-Prigent%26aufirst%3DA.%26aulast%3DAgid%26aufirst%3DY.%26aulast%3DHirsch%26aufirst%3DE.%2BC.%26atitle%3DNitric%2520oxide%2520synthase%2520and%2520neuronal%2520vulnerability%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeuroscience%26date%3D1996%26volume%3D72%26spage%3D355%26epage%3D363%26doi%3D10.1016%2F0306-4522%2895%2900578-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broom, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinova-Mutafchieva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medhurst, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dexter, D. T.</span></span> <span> </span><span class="NLM_article-title">Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">633</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2010.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.freeradbiomed.2010.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=21185368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlejtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=633-640&author=L.+Broomauthor=L.+Marinova-Mutafchievaauthor=M.+Sadeghianauthor=J.+B.+Davisauthor=A.+D.+Medhurstauthor=D.+T.+Dexter&title=Neuroprotection+by+the+selective+iNOS+inhibitor+GW274150+in+a+model+of+Parkinson+disease&doi=10.1016%2Fj.freeradbiomed.2010.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease</span></div><div class="casAuthors">Broom, Lauren; Marinova-Mutafchieva, Lilia; Sadeghian, Mona; Davis, John B.; Medhurst, Andrew D.; Dexter, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">633-640</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neuroinflammation and the activation of inducible nitric oxide synthase (iNOS) have been proposed to play a role in the pathogenesis of Parkinson disease (PD).  In this study we investigated the effects of the selective iNOS inhibitor GW274150 in the 6-OHDA model of PD.  6-OHDA administration was assocd. with increased nos. of cells expressing iNOS.  Administration of the iNOS inhibitor twice daily for 7 days, beginning 2 days after the 6-OHDA lesioning, led to a significant neuroprotection as shown by assessment of the integrity of the nigrostriatal system by tyrosine hydroxylase immunocytochem. and HPLC assessment of striatal dopamine content.  However, GW274150 displayed a bell-shaped neuroprotective profile, being ineffective at high doses.  6-OHDA lesioning was assocd. with an increase in microglial activation as assessed by the MHC II antigen OX-6 and the no. of matrix metalloproteinase 9 (MMP-9)-immunopos. cells.  NO is a known modulator of MMP-9, and iNOS inhibition was assocd. with decreased nos. of MMP-9-immunopos. cells, culminating in a redn. in the nos. of reactive microglia.  Withdrawal of GW274150 for a further 7 days negated any neuroprotective effects of iNOS inhibition, suggesting that the damaging effects of inflammation last beyond 7 days in this model and the continued administration of the drug may be required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOlohkfL3bLVg90H21EOLACvtfcHk0lhVICyc5_tkzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlejtbk%253D&md5=7ac55463ac877d6c20857c2d6a338569</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2010.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2010.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DBroom%26aufirst%3DL.%26aulast%3DMarinova-Mutafchieva%26aufirst%3DL.%26aulast%3DSadeghian%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DJ.%2BB.%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DDexter%26aufirst%3DD.%2BT.%26atitle%3DNeuroprotection%2520by%2520the%2520selective%2520iNOS%2520inhibitor%2520GW274150%2520in%2520a%2520model%2520of%2520Parkinson%2520disease%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2011%26volume%3D50%26spage%3D633%26epage%3D640%26doi%3D10.1016%2Fj.freeradbiomed.2010.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iravani, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashefi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mander, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span> <span> </span><span class="NLM_article-title">Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/s0306-4522(01)00562-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2FS0306-4522%2801%2900562-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=11882372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD38XhslSktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=49-58&author=M.+M.+Iravaniauthor=K.+Kashefiauthor=P.+Manderauthor=S.+Roseauthor=P.+Jenner&title=Involvement+of+inducible+nitric+oxide+synthase+in+inflammation-induced+dopaminergic+neurodegeneration&doi=10.1016%2Fs0306-4522%2801%2900562-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration</span></div><div class="casAuthors">Iravani, M. M.; Kashefi, K.; Mander, P.; Rose, S.; Jenner, P.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-58</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The loss of dopaminergic neurons in the substantia nigra with Parkinson's disease may result from inflammation-induced proliferation of microglia and reactive macrophages expressing inducible nitric oxide synthase (iNOS).  We have investigated the effects of the supranigral administration of lipopolysaccharide on iNOS-immunoreactivity, 3-nitrotyrosine formation and tyrosine hydroxylase-immunoreactive neuronal no., and retrogradely labeled fluorogold-pos. neurons in the ventral mesencephalon in male Wistar rats.  Following supranigral lipopolysaccharide injection, 16-18 h previously, there was intense expression of NADPH-diaphorase and iNOS-immunoreactivity in non-neuronal, macrophage-like cells.  This was accompanied by intense expression of glial fibrillary acidic protein-immunoreactive astrocytosis in the substantia nigra.  There were also significant redns. in the no. of tyrosine hydroxylase (50-60%)- and fluorogold (65-75%)-pos. neurons in the substantia nigra.  In contrast, tyrosine hydroxylase-immunoreactivity in the ventral tegmental area was not altered.  Pretreatment of animals with the iNOS inhibitor, S-methylisothiourea (10 mg kg-1, i.p.), led to a significant redn. of lipopolysaccharide-induced cell death.  Similar redn. of tyrosine hydroxylase-immunoreactivity and fluorogold-labeled neurons in the substantia nigra following lipopolysaccharide administration suggests dopaminergic cell death rather than down-regulation of tyrosine hydroxylase.  We conclude that the expression of iNOS- and 3-nitrotyrosine-immunoreactivity and redn. of cell death by S-methylisothiourea suggest the effects of lipopolysaccharide may be nitric oxide-mediated, although other actions of lipopolysaccharide (independent of iNOS induction) cannot be ruled out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW-MMG0a4pO7Vg90H21EOLACvtfcHk0lhVICyc5_tkzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhslSktbY%253D&md5=c8baf4576918850cfc6d62489fc843c7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2801%2900562-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252801%252900562-0%26sid%3Dliteratum%253Aachs%26aulast%3DIravani%26aufirst%3DM.%2BM.%26aulast%3DKashefi%26aufirst%3DK.%26aulast%3DMander%26aufirst%3DP.%26aulast%3DRose%26aufirst%3DS.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DInvolvement%2520of%2520inducible%2520nitric%2520oxide%2520synthase%2520in%2520inflammation-induced%2520dopaminergic%2520neurodegeneration%26jtitle%3DNeuroscience%26date%3D2002%26volume%3D110%26spage%3D49%26epage%3D58%26doi%3D10.1016%2Fs0306-4522%2801%2900562-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dehmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dichgans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, J. B.</span></span> <span> </span><span class="NLM_article-title">Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">2213</span>– <span class="NLM_lpage">2216</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2000.0742213.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1046%2Fj.1471-4159.2000.0742213.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10800968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD3cXis12qsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2000&pages=2213-2216&author=T.+Dehmerauthor=J.+Lindenauauthor=S.+Haidauthor=J.+Dichgansauthor=J.+B.+Schulz&title=Deficiency+of+inducible+nitric+oxide+synthase+protects+against+MPTP+toxicity+in+vivo&doi=10.1046%2Fj.1471-4159.2000.0742213.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo</span></div><div class="casAuthors">Dehmer, Thomas; Lindenau, Jorg; Haid, Sibylle; Dichgans, Johannes; Schulz, Jorg B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2213-2216</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">MPTP produces clin., biochem., and neuropathol. changes reminiscent of those that occur in idiopathic Parkinson's disease (PD).  In the present study we show that MPTP treatment led to activation of microglia in the substantia nigra pars compacta (SNpc), which was assocd. and colocalized with an increase in inducible nitric oxide synthase (iNOS) expression.  In iNOS-deficient mice the increase of iNOS expression but not the activation of microglia was blocked.  Dopaminergic SNpc neurons of iNOS-deficient mice were almost completely protected from MPTP toxicity in a chronic paradigm of MPTP toxicity.  Because the MPTP-induced decrease in striatal concns. of dopamine and its metabolites did not differ between iNOS-deficient mice and their wild-type littermates, this protection was not assocd. with a preservation of nigrostriatal terminals.  Our results suggest that iNOS-derived nitric oxide produced in microglia plays an important role in the death of dopaminergic neurons but that other mechanisms contribute to the loss of dopaminergic terminals in MPTP neurotoxicity.  We conclude that inhibition of iNOS may be a promising target for the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodyCC8WMz33bVg90H21EOLACvtfcHk0lhVICyc5_tkzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXis12qsrs%253D&md5=93ebd91bf7a481cc9009993a88d5df0d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2000.0742213.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2000.0742213.x%26sid%3Dliteratum%253Aachs%26aulast%3DDehmer%26aufirst%3DT.%26aulast%3DLindenau%26aufirst%3DJ.%26aulast%3DHaid%26aufirst%3DS.%26aulast%3DDichgans%26aufirst%3DJ.%26aulast%3DSchulz%26aufirst%3DJ.%2BB.%26atitle%3DDeficiency%2520of%2520inducible%2520nitric%2520oxide%2520synthase%2520protects%2520against%2520MPTP%2520toxicity%2520in%2520vivo%26jtitle%3DJ.%2520Neurochem.%26date%3D2000%26volume%3D74%26spage%3D2213%26epage%3D2216%26doi%3D10.1046%2Fj.1471-4159.2000.0742213.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatsuji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumanogoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichinose, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakoda, S.</span></span> <span> </span><span class="NLM_article-title">Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson’s disease</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">882</span>, <span class="refDoi"> DOI: 10.1002/jnr.20599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1002%2Fjnr.20599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=16041799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFKktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2005&pages=874-882&author=T.+Okunoauthor=Y.+Nakatsujiauthor=A.+Kumanogohauthor=M.+Moriyaauthor=H.+Ichinoseauthor=H.+Sumiauthor=H.+Fujimuraauthor=H.+Kikutaniauthor=S.+Sakoda&title=Loss+of+dopaminergic+neurons+by+the+induction+of+inducible+nitric+oxide+synthase+and+cyclooxygenase-2+via+CD+40%3A+relevance+to+Parkinson%E2%80%99s+disease&doi=10.1002%2Fjnr.20599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD40: Relevance to Parkinson's disease</span></div><div class="casAuthors">Okuno, Tatsusada; Nakatsuji, Yuji; Kumanogoh, Atsushi; Moriya, Masayuki; Ichinose, Hiroshi; Sumi, Hisae; Fujimura, Harutoshi; Kikutani, Hitoshi; Sakoda, Saburo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-882</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A glial reaction assocd. with up-regulation of inflammatory mols. has been suggested to play an important role in dopaminergic neuron loss in Parkinson's disease (PD).  Among inflammatory mols., inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) have been focused upon as key factors in the pathogenesis.  However, the mechanism of how these mols. are induced in PD brains is not clearly understood.  We focused on CD40, which is expressed on neural cells and could be implicated in the neuroinflammation by inducing inflammatory mols.  We showed that both iNOS and COX-2 were up-regulated in microglia and astrocytes by CD40 stimulation in assocn. with a low dose of interferon-γ (IFN-γ) in vitro.  Selective loss of dopaminergic neurons was induced by costimulation with CD40 and IFN-γ in mesencephalic cultures, which was protected by selective inhibitors of iNOS and/or COX-2.  We also found in CD40-stimulated astrocytes an increase of a low-affinity IgE receptor CD23, which is known to induce iNOS expression.  Together these data suggest that up-regulated iNOS and COX-2 via the CD40 pathway may lead to dopaminergic neuron loss and may participate in the neuroinflammaory pathway of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-GePctcnXT7Vg90H21EOLACvtfcHk0lh0dNEta0WZVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFKktrY%253D&md5=4e077386cd149e15015a3a9c9dfbeb2f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fjnr.20599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.20599%26sid%3Dliteratum%253Aachs%26aulast%3DOkuno%26aufirst%3DT.%26aulast%3DNakatsuji%26aufirst%3DY.%26aulast%3DKumanogoh%26aufirst%3DA.%26aulast%3DMoriya%26aufirst%3DM.%26aulast%3DIchinose%26aufirst%3DH.%26aulast%3DSumi%26aufirst%3DH.%26aulast%3DFujimura%26aufirst%3DH.%26aulast%3DKikutani%26aufirst%3DH.%26aulast%3DSakoda%26aufirst%3DS.%26atitle%3DLoss%2520of%2520dopaminergic%2520neurons%2520by%2520the%2520induction%2520of%2520inducible%2520nitric%2520oxide%2520synthase%2520and%2520cyclooxygenase-2%2520via%2520CD%252040%253A%2520relevance%2520to%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2005%26volume%3D81%26spage%3D874%26epage%3D882%26doi%3D10.1002%2Fjnr.20599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minhas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, G.</span></span> <span> </span><span class="NLM_article-title">Inducible nitric oxide synthase inhibitors: A comprehensive update</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">855</span>, <span class="refDoi"> DOI: 10.1002/med.21636</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1002%2Fmed.21636" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=31502681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntlantbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=823-855&author=R.+Minhasauthor=Y.+Bansalauthor=G.+Bansal&title=Inducible+nitric+oxide+synthase+inhibitors%3A+A+comprehensive+update&doi=10.1002%2Fmed.21636"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible nitric oxide synthase inhibitors: A comprehensive update</span></div><div class="casAuthors">Minhas, Richa; Bansal, Yogita; Bansal, Gulshan</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">823-855</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Inducible nitric oxide synthase (iNOS), which is expressed in response to bacterial/proinflammatory stimuli, generates nitric oxide (NO) that provides cytoprotection.  Overexpression of iNOS increases the levels of NO, and this increased NO level is implicated in pathophysiol. of complex multifactorial diseases like Parkinson's disease, Alzheimer's disease, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease.  Selective inhibition of iNOS is an effective approach in treatment of such complex diseases.  -Arginine, being a substrate for iNOS, is the natural lead to develop iNOS inhibitors.  More than 200 research reports on development of nitric oxide synthase inhibitors by different research groups across the globe have appeared in literature so far.  In the present review, all reports on both natural and synthetic iNOS inhibitors, published 2002 onwards, are studied, classified, and discussed to provide comprehensive information on iNOS inhibitors.  The latter are further classified into amidines, five- or six-membered heterocyclics, fused cyclics, steroidal type, and chalcones analogs.  Structures of the most/significantly potent compds. from each report are provided to know the functional groups important for incurring iNOS inhibitory activity and selectivity.  This review is aimed to provide a comprehensive view to the medicinal chemists for rational designing of novel and potent iNOS inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUTlomCGpTELVg90H21EOLACvtfcHk0lh0dNEta0WZVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntlantbo%253D&md5=54fe69326cbeb700ae5592beaf7fa702</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fmed.21636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21636%26sid%3Dliteratum%253Aachs%26aulast%3DMinhas%26aufirst%3DR.%26aulast%3DBansal%26aufirst%3DY.%26aulast%3DBansal%26aufirst%3DG.%26atitle%3DInducible%2520nitric%2520oxide%2520synthase%2520inhibitors%253A%2520A%2520comprehensive%2520update%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26spage%3D823%26epage%3D855%26doi%3D10.1002%2Fmed.21636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.-C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.ejmech.2018.03.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=29626798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1arsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=261-271&author=X.-L.+Huauthor=J.+Linauthor=X.-Y.+Lvauthor=J.-H.+Fengauthor=X.-Q.+Zhangauthor=H.+Wangauthor=W.-C.+Ye&title=Synthesis+and+biological+evaluation+of+clovamide+analogues+as+potent+anti-neuroinflammatory+agents+in+vitro+and+in+vivo&doi=10.1016%2Fj.ejmech.2018.03.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo</span></div><div class="casAuthors">Hu, Xiao-Long; Lin, Jun; Lv, Xian-Yu; Feng, Jia-Hao; Zhang, Xiao-Qi; Wang, Hao; Ye, Wen-Cai</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">261-271</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of clovamide analogs was synthesized and evaluated for their anti-neuroinflammatory activities using BV-2 microglia cells.  Among these compds., some compds., e.g., I, showed NO inhibition with no or weak cytotoxicity (CC50>100 μM) and showed an IC50 value of 2.67 μM.  Enzyme activity and docking assay revealed that some compds. target inducible NO synthase (iNOS) and exhibit potent inhibitory effects on iNOS with IC50 values ranging from 1.01 μM to 29.23 μM and compd. I significantly suppressed the expression of pro-inflammatory cytokines in lipopolysaccharide-stimulated cells.  Notably, the oral administration of I remarkably improved dyskinesia, reduced the expression of glial fibrillary acidic protein (GFAP)-a marker of neuroinflammation, and increased tyrosine hydroxylase-pos. cells in 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine-induced Parkinson's disease (PD) mouse models.  These observations demonstrated that I is an effective and promising candidate for PD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNfFsQ8aibZbVg90H21EOLACvtfcHk0lh0dNEta0WZVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1arsbw%253D&md5=1b2850b92c4f62d971d5c7c7e19941db</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.081%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.-L.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DX.-Y.%26aulast%3DFeng%26aufirst%3DJ.-H.%26aulast%3DZhang%26aufirst%3DX.-Q.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DW.-C.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520clovamide%2520analogues%2520as%2520potent%2520anti-neuroinflammatory%2520agents%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D261%26epage%3D271%26doi%3D10.1016%2Fj.ejmech.2018.03.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallinan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houdek, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerome, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitzele, B. S.</span></span> <span> </span><span class="NLM_article-title">4-Fluorinated L-lysine analogs as selective i-NOS inhibitors: methodology for introducing fluorine into the lysine side chain</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">3527</span>– <span class="NLM_lpage">3534</span>, <span class="refDoi"> DOI: 10.1039/b307563j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1039%2FB307563J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=14599013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVSgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=3527-3534&author=E.+A.+Hallinanauthor=S.+W.+Kramerauthor=S.+C.+Houdekauthor=W.+M.+Mooreauthor=G.+M.+Jeromeauthor=D.+P.+Spanglerauthor=A.+M.+Stevensauthor=H.+S.+Shiehauthor=P.+T.+Manningauthor=B.+S.+Pitzele&title=4-Fluorinated+L-lysine+analogs+as+selective+i-NOS+inhibitors%3A+methodology+for+introducing+fluorine+into+the+lysine+side+chain&doi=10.1039%2Fb307563j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">4-Fluorinated L-lysine analogs as selective i-NOS inhibitors: methodology for introducing fluorine into the lysine side chain</span></div><div class="casAuthors">Hallinan, E. Ann; Kramer, Steven W.; Houdek, Stephen C.; Moore, William M.; Jerome, Gina M.; Spangler, Dale P.; Stevens, Anna M.; Shieh, Huey S.; Manning, Pamela T.; Pitzele, Barnett S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3527-3534</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In the literature, the introduction of fluorine into bioactive mols. is known to enhance the biol. activity relative to the parent mol.  Described in this article is the synthesis of 4R-fluoro-L-NIL and 4,4-difluoro-L-NIL as part of an iNOS program.  Both were found to be selective iNOS inhibitors.  Secondarily, methodol. to synthesize orthogonally protected 4-fluoro-L-lysine and 4,4-difluoro-L-lysine was developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphyjYE3sSOZbVg90H21EOLACvtfcHk0lgFFDosXsULJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVSgs7w%253D&md5=29fbe079287f43defd8de5f9588ea674</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2FB307563J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB307563J%26sid%3Dliteratum%253Aachs%26aulast%3DHallinan%26aufirst%3DE.%2BA.%26aulast%3DKramer%26aufirst%3DS.%2BW.%26aulast%3DHoudek%26aufirst%3DS.%2BC.%26aulast%3DMoore%26aufirst%3DW.%2BM.%26aulast%3DJerome%26aufirst%3DG.%2BM.%26aulast%3DSpangler%26aufirst%3DD.%2BP.%26aulast%3DStevens%26aufirst%3DA.%2BM.%26aulast%3DShieh%26aufirst%3DH.%2BS.%26aulast%3DManning%26aufirst%3DP.%2BT.%26aulast%3DPitzele%26aufirst%3DB.%2BS.%26atitle%3D4-Fluorinated%2520L-lysine%2520analogs%2520as%2520selective%2520i-NOS%2520inhibitors%253A%2520methodology%2520for%2520introducing%2520fluorine%2520into%2520the%2520lysine%2520side%2520chain%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2003%26volume%3D1%26spage%3D3527%26epage%3D3534%26doi%3D10.1039%2Fb307563j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cinelli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miley, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R. B.</span></span> <span> </span><span class="NLM_article-title">Inducible nitric oxide synthase: Regulation, structure, and inhibition</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1002/med.21599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1002%2Fmed.21599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=31192483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFSjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=158-189&author=M.+A.+Cinelliauthor=H.+T.+Doauthor=G.+P.+Mileyauthor=R.+B.+Silverman&title=Inducible+nitric+oxide+synthase%3A+Regulation%2C+structure%2C+and+inhibition&doi=10.1002%2Fmed.21599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible nitric oxide synthase: Regulation, structure, and inhibition</span></div><div class="casAuthors">Cinelli, Maris A.; Do, Ha T.; Miley, Galen P.; Silverman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">158-189</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  A considerable no. of human diseases have an inflammatory component, and a key mediator of immune activation and inflammation is inducible nitric oxide synthase (iNOS), which produces nitric oxide (NO) from -arginine.  Overexpressed or dysregulated iNOS has been implicated in numerous pathologies including sepsis, cancer, neurodegeneration, and various types of pain.  Addnl., X-ray crystal and cryogenic electron microscopy structures have shed new insights on the structure and regulation of this enzyme.  Many potent iNOS inhibitors with high selectivity over related NOS isoforms, neuronal NOS, and endothelial NOS, have been discovered, and these drugs have shown promise in animal models of endotoxemia, inflammatory and neuropathic pain, arthritis, and other disorders.  In addn. to assay limitations, both the dual modalities of iNOS and NO in disease states (ie, protective vs harmful effects) and the different roles and localizations of NOS isoforms create challenges for therapeutic intervention.  This review summarizes the structure, function, and regulation of iNOS, with focus on the development of iNOS inhibitors (historical and recent).  A better understanding of iNOS' complex functions is necessary before specific drug candidates can be identified for classical indications such as sepsis, heart failure, and pain; however, newer promising indications for iNOS inhibition, such as depression, neurodegenerative disorders, and epilepsy, have been discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXpaXR9kQB9LVg90H21EOLACvtfcHk0lgFFDosXsULJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFSjtw%253D%253D&md5=d35151e6a6e9755c2b9c0f5b0ea23e02</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fmed.21599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21599%26sid%3Dliteratum%253Aachs%26aulast%3DCinelli%26aufirst%3DM.%2BA.%26aulast%3DDo%26aufirst%3DH.%2BT.%26aulast%3DMiley%26aufirst%3DG.%2BP.%26aulast%3DSilverman%26aufirst%3DR.%2BB.%26atitle%3DInducible%2520nitric%2520oxide%2520synthase%253A%2520Regulation%252C%2520structure%252C%2520and%2520inhibition%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26spage%3D158%26epage%3D189%26doi%3D10.1002%2Fmed.21599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span> <span> </span><span class="NLM_article-title">High throughput artificial membrane permeability assay for blood-brain barrier</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/s0223-5234(03)00012-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2FS0223-5234%2803%2900012-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=12667689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=223-232&author=L.+Diauthor=E.+H.+Kernsauthor=K.+Fanauthor=O.+J.+McConnellauthor=G.+T.+Carter&title=High+throughput+artificial+membrane+permeability+assay+for+blood-brain+barrier&doi=10.1016%2Fs0223-5234%2803%2900012-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput artificial membrane permeability assay for blood-brain barrier</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Fan, Kristi; McConnell, Oliver J.; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">The recent advances in high throughput screening for biol. activities and combinatorial chem. have greatly expanded the no. of drug candidates.  Rapid screening for BBB penetration potential early in drug discovery programs provides important information for compd. selection and guidance of synthesis for desirable CNS properties.  In this paper, we discuss a modification of the parallel artificial membrane permeation assay (PAMPA) for the prediction of blood-brain barrier penetration (PAMPA-BBB).  The assay was developed with 30 structurally diverse com. drugs and validated with 14 Wyeth Research compds.  The PAMPA-BBB assay has the advantages of: predicting passive blood-brain barrier penetration with high success, high throughput, low cost, and reproducibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCg9Ka4mziLVg90H21EOLACvtfcHk0lgFFDosXsULJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D&md5=d228d5808ba8df23deed92c5e2bf3863</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900012-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900012-6%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DFan%26aufirst%3DK.%26aulast%3DMcConnell%26aufirst%3DO.%2BJ.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DHigh%2520throughput%2520artificial%2520membrane%2520permeability%2520assay%2520for%2520blood-brain%2520barrier%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D223%26epage%3D232%26doi%3D10.1016%2Fs0223-5234%2803%2900012-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmanic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagrovic, B.</span></span> <span> </span><span class="NLM_article-title">Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1016/j.bpj.2009.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.bpj.2009.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=20197040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1KktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2010&pages=861-871&author=A.+Kuzmanicauthor=B.+Zagrovic&title=Determination+of+ensemble-average+pairwise+root+mean-square+deviation+from+experimental+B-factors&doi=10.1016%2Fj.bpj.2009.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors</span></div><div class="casAuthors">Kuzmanic, Antonija; Zagrovic, Bojan</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">861-871</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Root mean-square deviation (RMSD) after roto-translational least-squares fitting is a commonly used measure of global structural similarity of macromols.  However, exptl. x-ray B-factors are used frequently to study local structural heterogeneity and dynamics in macromols. by providing direct information about root mean-square fluctuations (RMSF) that can also be calcd. from mol. dynamics simulations.  The authors provide a math. derivation showing that, given a set of conservative assumptions, a root mean-square ensemble-av. of an all-against-all distribution of pairwise RMSD for a single mol. species, 〈RMSD2〉1/2, is directly related to av. B-factors (〈B〉) and 〈RMSF2〉1/2.  The authors show this relation and explore its limits of validity on a heterogeneous ensemble of structures taken from mol. dynamics simulations of a villin headpiece generated using distributed-computing techniques and the <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="0741686b636e6960474f686a62">[email protected]</a> cluster.  The authors' results provide a basis for quantifying global structural diversity of macromols. in crystals directly from x-ray expts., and the authors show this on a large set of structures taken from the Protein Data Bank.  In particular, the ensemble-av. pairwise backbone RMSD for a microscopic ensemble underlying a typical protein x-ray structure is ∼1.1 Å, under the assumption that the principal contribution to exptl. B-factors is conformational variability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmaQXdWWHh7Vg90H21EOLACvtfcHk0lgFFDosXsULJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1KktL4%253D&md5=d4cff0514feab57795168526993f0d51</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2009.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2009.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DKuzmanic%26aufirst%3DA.%26aulast%3DZagrovic%26aufirst%3DB.%26atitle%3DDetermination%2520of%2520ensemble-average%2520pairwise%2520root%2520mean-square%2520deviation%2520from%2520experimental%2520B-factors%26jtitle%3DBiophys.%2520J.%26date%3D2010%26volume%3D98%26spage%3D861%26epage%3D871%26doi%3D10.1016%2Fj.bpj.2009.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almqvist, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axelsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatushchenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundbäck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D. M.</span></span> <span> </span><span class="NLM_article-title">The cellular thermal shift assay for evaluating drug target interactions in cells</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2100</span>– <span class="NLM_lpage">2122</span>, <span class="refDoi"> DOI: 10.1038/nprot.2014.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1038%2Fnprot.2014.138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=25101824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2100-2122&author=R.+Jafariauthor=H.+Almqvistauthor=H.+Axelssonauthor=M.+Ignatushchenkoauthor=T.+Lundb%C3%A4ckauthor=P.+Nordlundauthor=D.+M.+Molina&title=The+cellular+thermal+shift+assay+for+evaluating+drug+target+interactions+in+cells&doi=10.1038%2Fnprot.2014.138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The cellular thermal shift assay for evaluating drug target interactions in cells</span></div><div class="casAuthors">Jafari, Rozbeh; Almqvist, Helena; Axelsson, Hanna; Ignatushchenko, Marina; Lundbaeck, Thomas; Nordlund, Paer; Molina, Daniel Martinez</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2100-2122</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thermal shift assays are used to study thermal stabilization of proteins upon ligand binding.  Such assays have been used extensively on purified proteins in the drug discovery industry and in academia to detect interactions.  Recently, we published a proof-of-principle study describing the implementation of thermal shift assays in a cellular format, which we call the cellular thermal shift assay (CETSA).  The method allows studies of target engagement of drug candidates in a cellular context, herein exemplified with exptl. data on the human kinases p38α and ERK1/2.  The assay involves treatment of cells with a compd. of interest, heating to denature and ppt. proteins, cell lysis, and the sepn. of cell debris and aggregates from the sol. protein fraction.  Whereas unbound proteins denature and ppt. at elevated temps., ligand-bound proteins remain in soln.  We describe two procedures for detecting the stabilized protein in the sol. fraction of the samples.  One approach involves sample workup and detection using quant. western blotting, whereas the second is performed directly in soln. and relies on the induced proximity of two target-directed antibodies upon binding to sol. protein.  The latter protocol has been optimized to allow an increased throughput, as potential applications require large nos. of samples.  Both approaches can be completed in a day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzarqomAK6eLVg90H21EOLACvtfcHk0lg1SyWVIZgb-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ&md5=e7852e1a306bca1698a8e8463ae566b1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2014.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2014.138%26sid%3Dliteratum%253Aachs%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DAlmqvist%26aufirst%3DH.%26aulast%3DAxelsson%26aufirst%3DH.%26aulast%3DIgnatushchenko%26aufirst%3DM.%26aulast%3DLundb%25C3%25A4ck%26aufirst%3DT.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DMolina%26aufirst%3DD.%2BM.%26atitle%3DThe%2520cellular%2520thermal%2520shift%2520assay%2520for%2520evaluating%2520drug%2520target%2520interactions%2520in%2520cells%26jtitle%3DNat.%2520Protoc.%26date%3D2014%26volume%3D9%26spage%3D2100%26epage%3D2122%26doi%3D10.1038%2Fnprot.2014.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundbäck, T.</span></span> <span> </span><span class="NLM_article-title">CETSA: a target engagement assay with potential to transform drug discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">975</span>– <span class="NLM_lpage">978</span>, <span class="refDoi"> DOI: 10.4155/fmc.15.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.4155%2Ffmc.15.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=26062395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpslGgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=975-978&author=A.+J.+Jensenauthor=D.+M.+Molinaauthor=T.+Lundb%C3%A4ck&title=CETSA%3A+a+target+engagement+assay+with+potential+to+transform+drug+discovery&doi=10.4155%2Ffmc.15.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CETSA: a target engagement assay with potential to transform drug discovery</span></div><div class="casAuthors">Jensen, Annika Jenmalm; Molina, Daniel Martinez; Lundbaeck, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">975-978</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLq9NuYjGuYrVg90H21EOLACvtfcHk0lg1SyWVIZgb-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpslGgtLg%253D&md5=308cef6a198e47a4a45e28cf0d66d46f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.50%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DA.%2BJ.%26aulast%3DMolina%26aufirst%3DD.%2BM.%26aulast%3DLundb%25C3%25A4ck%26aufirst%3DT.%26atitle%3DCETSA%253A%2520a%2520target%2520engagement%2520assay%2520with%2520potential%2520to%2520transform%2520drug%2520discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D975%26epage%3D978%26doi%3D10.4155%2Ffmc.15.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olaru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffrezic-Renault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboul-Enein, H. Y.</span></span> <span> </span><span class="NLM_article-title">Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis</span>. <i>Crit. Rev. Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1080/10408347.2014.881250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1080%2F10408347.2014.881250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=25558771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvF2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=97-105&author=A.+Olaruauthor=C.+Balaauthor=N.+Jaffrezic-Renaultauthor=H.+Y.+Aboul-Enein&title=Surface+plasmon+resonance+%28SPR%29+biosensors+in+pharmaceutical+analysis&doi=10.1080%2F10408347.2014.881250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Surface Plasmon Resonance (SPR) Biosensors in Pharmaceutical Analysis</span></div><div class="casAuthors">Olaru, Andreea; Bala, Camelia; Jaffrezic-Renault, Nicole; Aboul-Enein, Hassan Y.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Analytical Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-105</span>CODEN:
                <span class="NLM_cas:coden">CCACBB</span>;
        ISSN:<span class="NLM_cas:issn">1040-8347</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  This review aims to highlight the applications of one of the most prominent optical biosensor technologies, surface plasmon resonance (SPR), in the drug discovery process and quality anal. of pharmaceutical compds. and their particularities.  SPR assay formats and exptl. issues are used for pharmacokinetic drug profiling, ADMET studies, high-throughput screening, and fragment-based drug screening, the last with an emphasis on the detection of small (drug) mols.  The classical method strengths and some applications of localized SPR and SPR imaging that are of high interest in the drug discovery process are presented, as well as possible challenges.  While similar works treat sep. the steps of drug discovery or focus only on the detection of drug residues in food or health safety, this review presents in a compact format the results and the progress obtained in both areas (drug discovery and quality anal.) based on the application of SPR biosensors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFltuwoLaZrrVg90H21EOLACvtfcHk0lg1SyWVIZgb-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvF2jsg%253D%253D&md5=e80f2bc3b0be491c441a45a67ca7fdab</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F10408347.2014.881250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10408347.2014.881250%26sid%3Dliteratum%253Aachs%26aulast%3DOlaru%26aufirst%3DA.%26aulast%3DBala%26aufirst%3DC.%26aulast%3DJaffrezic-Renault%26aufirst%3DN.%26aulast%3DAboul-Enein%26aufirst%3DH.%2BY.%26atitle%3DSurface%2520plasmon%2520resonance%2520%2528SPR%2529%2520biosensors%2520in%2520pharmaceutical%2520analysis%26jtitle%3DCrit.%2520Rev.%2520Anal.%2520Chem.%26date%3D2015%26volume%3D45%26spage%3D97%26epage%3D105%26doi%3D10.1080%2F10408347.2014.881250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span> <span> </span><span class="NLM_article-title">Development of a SPR aptasensor containing oriented aptamer for direct capture and detection of tetracycline in multiple honey samples</span>. <i>Biosens. Bioelectron.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/j.bios.2018.02.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.bios.2018.02.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=29522968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFyntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=1-7&author=S.+Wangauthor=Y.+Dongauthor=X.+Liang&title=Development+of+a+SPR+aptasensor+containing+oriented+aptamer+for+direct+capture+and+detection+of+tetracycline+in+multiple+honey+samples&doi=10.1016%2Fj.bios.2018.02.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a SPR aptasensor containing oriented aptamer for direct capture and detection of tetracycline in multiple honey samples</span></div><div class="casAuthors">Wang, Sai; Dong, Yiyang; Liang, Xingguo</div><div class="citationInfo"><span class="NLM_cas:title">Biosensors & Bioelectronics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">BBIOE4</span>;
        ISSN:<span class="NLM_cas:issn">0956-5663</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Although surface plasmon resonance (SPR) technique and aptamer technol. shows great potential in anal. and biol. chem., direct capture and anal. of small mols. using SPR remains tough.  Detection sensitivity of aptasensor and recognition ability of aptamer is limited, because direct immobilization of aptamer causes large steric hindrance and strand entanglement.  Herein, we chose a typical small mol.-tetracycline (Mw. 444.4 g/mol) as a model, and combined aptamer technol., DNA nanostructure, and com. Biacore T200 SPR instrument to develop a straightforward format SPR aptasensor.  Anti-tetracycline aptamer (Apt76) was fabricated on the top of a tetrahedron nanostructure to provide a better accessibility to tetracycline than the single-stranded Apt76 (ss-Apt76), and thus to improve sensitivity of the SPR aptasensor.  The aptasensor was then validated in real world application for tetracycline screening in multiple honey samples, achieving good recovery rates of 80.20-114.3%, intuitive sensorgrams indicating the binding kinetic properties, and high specificity towards tetracycline.  LOD of the tetrahedron-based SPR aptasensor was obtained using the real honey sample and calcd. to be 0.0069 μg/kg, which was 10-fold range lower than that of the ss-Apt76-based aptasensor.  The proof-of-concept demonstrated that aptamers of small mols. can be oriented immobilized on the SPR surface in a uniform nanoscale distance in both lateral and vertical direction, so as to achieve better conformational folding and better accessibility to small mols.  The concept is promising to be a universal and powerful tool for other ligand immobilization and SPR studies for both real world detection and mol. interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1sSUvXwxrhrVg90H21EOLACvtfcHk0ljTZXFu3A9TTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFyntbg%253D&md5=c64a636192a614f470f573992ef241a6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bios.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bios.2018.02.051%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DX.%26atitle%3DDevelopment%2520of%2520a%2520SPR%2520aptasensor%2520containing%2520oriented%2520aptamer%2520for%2520direct%2520capture%2520and%2520detection%2520of%2520tetracycline%2520in%2520multiple%2520honey%2520samples%26jtitle%3DBiosens.%2520Bioelectron.%26date%3D2018%26volume%3D109%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.bios.2018.02.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.-S.</span></span> <span> </span><span class="NLM_article-title">NADPH oxidase-derived H<sub>2</sub>O<sub>2</sub> mediates the regulatory effects of microglia on astrogliosis in experimental models of Parkinson’s disease</span>. <i>Redox Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.redox.2017.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.redox.2017.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=28237879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtl2jurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=162-170&author=L.+Houauthor=X.+Zhouauthor=C.+Zhangauthor=K.+Wangauthor=X.+Liuauthor=Y.+Cheauthor=F.+Sunauthor=H.+Liauthor=Q.+Wangauthor=D.+Zhangauthor=J.-S.+Hong&title=NADPH+oxidase-derived+H2O2+mediates+the+regulatory+effects+of+microglia+on+astrogliosis+in+experimental+models+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.redox.2017.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH oxidase-derived H2O2 mediates the regulatory effects of microglia on astrogliosis in experimental models of Parkinson's disease</span></div><div class="casAuthors">Hou, Liyan; Zhou, Xueying; Zhang, Cong; Wang, Ke; Liu, Xiaofang; Che, Yuning; Sun, Fuqiang; Li, Huihua; Wang, Qingshan; Zhang, Dan; Hong, Jau-Shyong</div><div class="citationInfo"><span class="NLM_cas:title">Redox Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">162-170</span>CODEN:
                <span class="NLM_cas:coden">RBEIB3</span>;
        ISSN:<span class="NLM_cas:issn">2213-2317</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Astrogliosis has long been recognized in Parkinson's disease (PD), the most common neurodegenerative movement disorder.  However, the mechanisms of how astroglia become activated remain unclear.  Reciprocal interactions between microglia and astroglia play a pivotal role in regulating the activities of astroglia.  The purpose of this study is to investigate the mechanism by which microglia regulate astrogliosis by using lipopolysaccharide (LPS) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse PD models.  We found that the activation of microglia preceded astroglia in the substantia nigra of mice treated with either LPS or MPTP.  Furthermore, suppression of microglial activation by pharmacol. inhibition or genetic deletion of NADPH oxidase (NOX2) in mice attenuated astrogliosis.  The important role of NOX2 in microglial regulation of astrogliosis was further mirrored in a mixed-glia culture system.  Mechanistically, H2O2, a product of microglial NOX2 activation, serves as a direct signal to regulate astrogliosis.  Astrogliosis was induced by H2O2 through a process in which extracellularly generated H2O2 diffused into the cytoplasm and subsequently stimulated activation of transcription factors, STAT1 and STAT3.  STAT1/3 activation regulated the immunol. functions of H2O2-induced astrogliosis since AG490, an inhibitor of STAT1/3, attenuated the gene expressions of both proinflammatory and neurotrophic factors in H2O2-treated astrocyte.  Our findings indicate that microglial NOX2-generated H2O2 is able to regulate the immunol. functions of astroglia via a STAT1/3-dependent manner, providing addnl. evidence for the immune pathogenesis and therapeutic studies of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3PyL18oUz6rVg90H21EOLACvtfcHk0ljTZXFu3A9TTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtl2jurk%253D&md5=c4de529006f34a9597ce51654701613b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.redox.2017.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.redox.2017.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHong%26aufirst%3DJ.-S.%26atitle%3DNADPH%2520oxidase-derived%2520H2O2%2520mediates%2520the%2520regulatory%2520effects%2520of%2520microglia%2520on%2520astrogliosis%2520in%2520experimental%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DRedox%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D162%26epage%3D170%26doi%3D10.1016%2Fj.redox.2017.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, H.</span></span> <span> </span><span class="NLM_article-title">Neurogenesis in Neurotoxin-induced Animal Models for Parkinson’s Disease-A Review of the Current Status</span>. <i>J. Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1293/tox.22.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1293%2Ftox.22.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=22271983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=101-108&author=X.+J.+Heauthor=H.+Nakayama&title=Neurogenesis+in+Neurotoxin-induced+Animal+Models+for+Parkinson%E2%80%99s+Disease-A+Review+of+the+Current+Status&doi=10.1293%2Ftox.22.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Neurogenesis in neurotoxin-induced animal models for Parkinson's disease - a review of the current status</span></div><div class="casAuthors">He, Xi Jun; Nakayama, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-108</span>CODEN:
                <span class="NLM_cas:coden">JTPAE7</span>;
        ISSN:<span class="NLM_cas:issn">0914-9198</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Toxicologic Pathology</span>)
        </div><div class="casAbstract">A review.  Animal models for Parkinson's disease (PD) are essential for understanding its pathogenesis and for development and testing of new therapies.  Discoveries of endogenous neurogenesis in the adult mammalian brain give new insight into the cell-based approach for treatment of neurodegenerative disorders, such as PD.  Although a great deal of interest has been focused on endogenous neurogenesis in neurotoxin-induced animal models for PD, it still remains controversial whether neural stem cells migrate into the injured area and contribute to repopulation of depleted dopaminergic neurons in neurotoxin-injured adult brains.  The purpose of this review is to examine the data available regarding neurogenesis in neurotoxin-induced animal models of PD.  It is hoped that data from the animal investigations available in the literature will promote understanding of the neurotoxin-induced animal models for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5LuHRl93aPbVg90H21EOLACvtfcHk0ljTZXFu3A9TTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKmt7Y%253D&md5=9d70c565c1c2cc0e28d87c7fe498d9df</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1293%2Ftox.22.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1293%252Ftox.22.101%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%2BJ.%26aulast%3DNakayama%26aufirst%3DH.%26atitle%3DNeurogenesis%2520in%2520Neurotoxin-induced%2520Animal%2520Models%2520for%2520Parkinson%25E2%2580%2599s%2520Disease-A%2520Review%2520of%2520the%2520Current%2520Status%26jtitle%3DJ.%2520Toxicol.%2520Pathol.%26date%3D2009%26volume%3D22%26spage%3D101%26epage%3D108%26doi%3D10.1293%2Ftox.22.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, L. M.</span></span> <span> </span><span class="NLM_article-title">MiR-302b-5p enhances the neuroprotective effect of IGF-1 in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease by regulating inducible nitric-oxide synthase</span>. <i>Cell Biochem. Funct.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.1002/cbf.3534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1002%2Fcbf.3534" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=1023-1035&author=X.+Cuiauthor=M.+P.+Liauthor=Z.+C.+Heauthor=L.+Huauthor=J.+P.+Liuauthor=J.+H.+Yanauthor=L.+M.+Hua&title=MiR-302b-5p+enhances+the+neuroprotective+effect+of+IGF-1+in+methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine-induced+Parkinson%E2%80%99s+disease+by+regulating+inducible+nitric-oxide+synthase&doi=10.1002%2Fcbf.3534"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcbf.3534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbf.3534%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DM.%2BP.%26aulast%3DHe%26aufirst%3DZ.%2BC.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%2BP.%26aulast%3DYan%26aufirst%3DJ.%2BH.%26aulast%3DHua%26aufirst%3DL.%2BM.%26atitle%3DMiR-302b-5p%2520enhances%2520the%2520neuroprotective%2520effect%2520of%2520IGF-1%2520in%2520methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine-induced%2520Parkinson%25E2%2580%2599s%2520disease%2520by%2520regulating%2520inducible%2520nitric-oxide%2520synthase%26jtitle%3DCell%2520Biochem.%2520Funct.%26date%3D2020%26volume%3D38%26spage%3D1023%26epage%3D1035%26doi%3D10.1002%2Fcbf.3534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Fischer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noelker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünewald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulinović, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerreiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombès, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oertel, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, A.</span></span> <span> </span><span class="NLM_article-title">Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1111/jnc.12343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1111%2Fjnc.12343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=23802648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKhu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2013&pages=782-792&author=D.+Alvarez-Fischerauthor=C.+Noelkerauthor=A.+Gr%C3%BCnewaldauthor=F.+Vulinovi%C4%87author=S.+Guerreiroauthor=J.+Fuchsauthor=L.+Luauthor=A.+Lomb%C3%A8sauthor=E.+C.+Hirschauthor=W.+H.+Oertelauthor=P.+P.+Michelauthor=A.+Hartmann&title=Probenecid+potentiates+MPTP%2FMPP%2B+toxicity+by+interference+with+cellular+energy+metabolism&doi=10.1111%2Fjnc.12343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism</span></div><div class="casAuthors">Alvarez-Fischer, Daniel; Noelker, Carmen; Gruenewald, Anne; Vulinovic, Franca; Guerreiro, Serge; Fuchs, Julia; Lu, Lixia; Lombes, Anne; Hirsch, Etienne C.; Oertel, Wolfgang H.; Michel, Patrick P.; Hartmann, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5&6</span>),
    <span class="NLM_cas:pages">782-792</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The uricosuric agent probenecid is co-administered with the dopaminergic neurotoxin MPTP to produce a chronic mouse model of Parkinson's disease.  It has been proposed that probenecid serves to elevate concns. of MPTP in the brain by reducing renal elimination of the toxin.  However, this mechanism has never been formally demonstrated to date and is questioned by the authors' previous data showing that intracerebral concns. of MPP+, the active metabolite of MPTP, are not modified by co-injection of probenecid.  In this study, the authors investigated the potentiating effects of probenecid in vivo and in vitro arguing against the possibility of altered metab. or impaired renal elimination of MPTP.  The authors find that probenecid (i) is toxic in itself to several neuronal populations apart from dopaminergic neurons, and (ii) that it also potentiates the effects of other mitochondrial complex I inhibitors such as rotenone.  On a mechanistic level, the authors show that probenecid is able to lower intracellular ATP concns. and that its toxic action on neuronal cells can be reversed by extracellular ATP.  Probenecid can potentiate the effect of mitochondrial toxins due to its impact on ATP metab. and could therefore be useful to model atypical parkinsonian syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop9u1iglGhO7Vg90H21EOLACvtfcHk0liNTKipZH6vWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKhu7jL&md5=bc619411839250d4fb387ebc18b1586b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fjnc.12343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.12343%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Fischer%26aufirst%3DD.%26aulast%3DNoelker%26aufirst%3DC.%26aulast%3DGr%25C3%25BCnewald%26aufirst%3DA.%26aulast%3DVulinovi%25C4%2587%26aufirst%3DF.%26aulast%3DGuerreiro%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DLomb%25C3%25A8s%26aufirst%3DA.%26aulast%3DHirsch%26aufirst%3DE.%2BC.%26aulast%3DOertel%26aufirst%3DW.%2BH.%26aulast%3DMichel%26aufirst%3DP.%2BP.%26aulast%3DHartmann%26aufirst%3DA.%26atitle%3DProbenecid%2520potentiates%2520MPTP%252FMPP%252B%2520toxicity%2520by%2520interference%2520with%2520cellular%2520energy%2520metabolism%26jtitle%3DJ.%2520Neurochem.%26date%3D2013%26volume%3D127%26spage%3D782%26epage%3D792%26doi%3D10.1111%2Fjnc.12343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meka, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Rischart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nidadavolu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motori, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponna, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboutalebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annamneedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finckh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miesbauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotermund, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatzelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winklhofer, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, E. R.</span></span> <span> </span><span class="NLM_article-title">Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1873</span>– <span class="NLM_lpage">1885</span>, <span class="refDoi"> DOI: 10.1172/jci79300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1172%2FJCI79300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=25822020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A280%3ADC%252BC2MnovFCntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=1873-1885&author=D.+P.+Mekaauthor=A.+K.+M%C3%BCller-Rischartauthor=P.+Nidadavoluauthor=B.+Mohammadiauthor=E.+Motoriauthor=S.+K.+Ponnaauthor=H.+Aboutalebiauthor=M.+Bassalauthor=A.+Annamneediauthor=B.+Finckhauthor=M.+Miesbauerauthor=N.+Rotermundauthor=C.+Lohrauthor=J.+Tatzeltauthor=K.+F.+Winklhoferauthor=E.+R.+Kramer&title=Parkin+cooperates+with+GDNF%2FRET+signaling+to+prevent+dopaminergic+neuron+degeneration&doi=10.1172%2Fjci79300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration</span></div><div class="casAuthors">Meka Durga Praveen; Muller-Rischart Anne Kathrin; Nidadavolu Prakash; Mohammadi Behnam; Motori Elisa; Ponna Srinivas Kumar; Aboutalebi Helia; Bassal Mahmoud; Annamneedi Anil; Finckh Barbara; Miesbauer Margit; Rotermund Natalie; Lohr Christian; Tatzelt Jorg; Winklhofer Konstanze F; Kramer Edgar R</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1873-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkin and the glial cell line-derived neurotrophic factor (GDNF) receptor RET have both been independently linked to the dopaminergic neuron degeneration that underlies Parkinson's disease (PD).  In the present study, we demonstrate that there is genetic crosstalk between parkin and the receptor tyrosine kinase RET in two different mouse models of PD.  Mice lacking both parkin and RET exhibited accelerated dopaminergic cell and axonal loss compared with parkin-deficient animals, which showed none, and RET-deficient mice, in which we found moderate degeneration.  Transgenic expression of parkin protected the dopaminergic systems of aged RET-deficient mice.  Downregulation of either parkin or RET in neuronal cells impaired mitochondrial function and morphology.  Parkin expression restored mitochondrial function in GDNF/RET-deficient cells, while GDNF stimulation rescued mitochondrial defects in parkin-deficient cells.  In both cases, improved mitochondrial function was the result of activation of the prosurvival NF-κB pathway, which was mediated by RET through the phosphoinositide-3-kinase (PI3K) pathway.  Taken together, these observations indicate that parkin and the RET signaling cascade converge to control mitochondrial integrity and thereby properly maintain substantia nigra pars compacta dopaminergic neurons and their innervation in the striatum.  The demonstration of crosstalk between parkin and RET highlights the interplay in the protein network that is altered in PD and suggests potential therapeutic targets and strategies to treat PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJ1yUqFoXEC7GbPKh4T9eAfW6udTcc2eZXuMqcrDuWh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnovFCntg%253D%253D&md5=d0c32187ee99f21afafd51d60fede891</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1172%2FJCI79300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI79300%26sid%3Dliteratum%253Aachs%26aulast%3DMeka%26aufirst%3DD.%2BP.%26aulast%3DM%25C3%25BCller-Rischart%26aufirst%3DA.%2BK.%26aulast%3DNidadavolu%26aufirst%3DP.%26aulast%3DMohammadi%26aufirst%3DB.%26aulast%3DMotori%26aufirst%3DE.%26aulast%3DPonna%26aufirst%3DS.%2BK.%26aulast%3DAboutalebi%26aufirst%3DH.%26aulast%3DBassal%26aufirst%3DM.%26aulast%3DAnnamneedi%26aufirst%3DA.%26aulast%3DFinckh%26aufirst%3DB.%26aulast%3DMiesbauer%26aufirst%3DM.%26aulast%3DRotermund%26aufirst%3DN.%26aulast%3DLohr%26aufirst%3DC.%26aulast%3DTatzelt%26aufirst%3DJ.%26aulast%3DWinklhofer%26aufirst%3DK.%2BF.%26aulast%3DKramer%26aufirst%3DE.%2BR.%26atitle%3DParkin%2520cooperates%2520with%2520GDNF%252FRET%2520signaling%2520to%2520prevent%2520dopaminergic%2520neuron%2520degeneration%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D1873%26epage%3D1885%26doi%3D10.1172%2Fjci79300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, D.-s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishizawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichinose, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtzman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, K.</span></span> <span> </span><span class="NLM_article-title">Prevention of dopaminergic neuron death by adeno-associated virus vector-mediated GDNF gene transfer in rat mesencephalic cells in vitro</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1016/s0304-3940(98)00313-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2FS0304-3940%2898%2900313-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=9665664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADyaK1cXivVGhtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1998&pages=61-64&author=D.-s.+Fanauthor=M.+Ogawaauthor=K.+Ikeguchiauthor=K.-i.+Fujimotoauthor=M.+Urabeauthor=A.+Kumeauthor=M.+Nishizawaauthor=N.+Matsushitaauthor=K.+Kiuchiauthor=H.+Ichinoseauthor=T.+Nagatsuauthor=G.+J.+Kurtzmanauthor=I.+Nakanoauthor=K.+Ozawa&title=Prevention+of+dopaminergic+neuron+death+by+adeno-associated+virus+vector-mediated+GDNF+gene+transfer+in+rat+mesencephalic+cells+in+vitro&doi=10.1016%2Fs0304-3940%2898%2900313-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of dopaminergic neuron death by adeno-associated virus vector-mediated GDNF gene transfer in rat mesencephalic cells in vitro</span></div><div class="casAuthors">Fan, Dong-sheng; Ogawa, Matsuo; Ikeguchi, Kunihiko; Fujimoto, Ken-ichi; Urabe, Masashi; Kume, Akihiro; Nishizawa, Masatoyo; Matsushita, Natsuki; Kiuchi, Kazutoshi; Ichinose, Hiroshi; Nagatsu, Toshiharu; Kurtzman, Gary J.; Nakano, Imaharu; Ozawa, Keiya</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-64</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Glial cell line-derived neurotrophic factor (GDNF) is known as a potent neurotrophic factor for dopaminergic neurons.  Since adeno-assocd. virus (AAV) vector is a suitable vehicle for gene transfer into neurons, rat E14 mesencephalic cells were transduced with an AAV vector expressing GDNF.  When compared with mock transduction, a larger no. of dopaminergic neurons survived in AAV-GDNF-transduced cultures (234% and 325% of controls at 1 and 2 wk, resp.; P<0.01).  Furthermore, the dopaminergic neurons in the latter cultures grew more prominent neurites than those in the former.  These findings suggest that AAV vector-mediated GDNF gene transfer may prevent dopaminergic neuron death, and is therefore a logical approach for the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTyKTiVh7u9rVg90H21EOLACvtfcHk0liNTKipZH6vWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivVGhtLk%253D&md5=4060ee638e4e7400c1b24b5afd010e72</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0304-3940%2898%2900313-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3940%252898%252900313-9%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DD.-s.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DIkeguchi%26aufirst%3DK.%26aulast%3DFujimoto%26aufirst%3DK.-i.%26aulast%3DUrabe%26aufirst%3DM.%26aulast%3DKume%26aufirst%3DA.%26aulast%3DNishizawa%26aufirst%3DM.%26aulast%3DMatsushita%26aufirst%3DN.%26aulast%3DKiuchi%26aufirst%3DK.%26aulast%3DIchinose%26aufirst%3DH.%26aulast%3DNagatsu%26aufirst%3DT.%26aulast%3DKurtzman%26aufirst%3DG.%2BJ.%26aulast%3DNakano%26aufirst%3DI.%26aulast%3DOzawa%26aufirst%3DK.%26atitle%3DPrevention%2520of%2520dopaminergic%2520neuron%2520death%2520by%2520adeno-associated%2520virus%2520vector-mediated%2520GDNF%2520gene%2520transfer%2520in%2520rat%2520mesencephalic%2520cells%2520in%2520vitro%26jtitle%3DNeurosci.%2520Lett.%26date%3D1998%26volume%3D248%26spage%3D61%26epage%3D64%26doi%3D10.1016%2Fs0304-3940%2898%2900313-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hevel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marletta, M. A.</span></span> <span> </span><span class="NLM_article-title">Nitric-Oxide Synthase Assays</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>233</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1016/s0076-6879(94)33028-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2FS0076-6879%2894%2933028-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=7516999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADyaK2MXitlSksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=1994&pages=250-258&author=J.+M.+Hevelauthor=M.+A.+Marletta&title=Nitric-Oxide+Synthase+Assays&doi=10.1016%2Fs0076-6879%2894%2933028-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide synthase assays</span></div><div class="casAuthors">Hevel, Joan M.; Marletta, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">233</span>
        (<span class="NLM_cas:issue">OXYGEN RADICALS IN BIOLOGICAL SYSTEMS, PT. C</span>),
    <span class="NLM_cas:pages">250-8</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    </div><div class="casAbstract">Several procedures are described for the anal. of nitric oxide synthase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmUa1x0Pt2JrVg90H21EOLACvtfcHk0li_Xe-RAmfPGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitlSksw%253D%253D&md5=29ca8a48095d9da8ec8d9421f43de0ea</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2894%2933028-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252894%252933028-X%26sid%3Dliteratum%253Aachs%26aulast%3DHevel%26aufirst%3DJ.%2BM.%26aulast%3DMarletta%26aufirst%3DM.%2BA.%26atitle%3DNitric-Oxide%2520Synthase%2520Assays%26jtitle%3DMethods%2520Enzymol.%26date%3D1994%26volume%3D233%26spage%3D250%26epage%3D258%26doi%3D10.1016%2Fs0076-6879%2894%2933028-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bourdonnec, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seida, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuthill, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeHaven, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolle, R. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of a series of aminopiperidines as novel iNOS inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.10.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.bmcl.2007.10.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=18024030" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=336-343&author=B.+L.+Bourdonnecauthor=L.+K.+Leisterauthor=C.+A.+Ajelloauthor=J.+A.+Casselauthor=P.+R.+Seidaauthor=H.+O%E2%80%99Hareauthor=M.+Guauthor=G.-H.+Chuauthor=P.+A.+Tuthillauthor=R.+N.+DeHavenauthor=R.+E.+Dolle&title=Discovery+of+a+series+of+aminopiperidines+as+novel+iNOS+inhibitors&doi=10.1016%2Fj.bmcl.2007.10.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.10.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.10.073%26sid%3Dliteratum%253Aachs%26aulast%3DBourdonnec%26aufirst%3DB.%2BL.%26aulast%3DLeister%26aufirst%3DL.%2BK.%26aulast%3DAjello%26aufirst%3DC.%2BA.%26aulast%3DCassel%26aufirst%3DJ.%2BA.%26aulast%3DSeida%26aufirst%3DP.%2BR.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DM.%26aulast%3DChu%26aufirst%3DG.-H.%26aulast%3DTuthill%26aufirst%3DP.%2BA.%26aulast%3DDeHaven%26aufirst%3DR.%2BN.%26aulast%3DDolle%26aufirst%3DR.%2BE.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%2520aminopiperidines%2520as%2520novel%2520iNOS%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D336%26epage%3D343%26doi%3D10.1016%2Fj.bmcl.2007.10.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chreifi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R. B.</span></span> <span> </span><span class="NLM_article-title">Optimization of blood-brain barrier permeability with potent and selective human neuronal nitric oxide synthase inhibitors having a 2-Aminopyridine scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2690</span>– <span class="NLM_lpage">2707</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b02032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b02032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFeruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2690-2707&author=H.+T.+Doauthor=H.+Liauthor=G.+Chreifiauthor=T.+L.+Poulosauthor=R.+B.+Silverman&title=Optimization+of+blood-brain+barrier+permeability+with+potent+and+selective+human+neuronal+nitric+oxide+synthase+inhibitors+having+a+2-Aminopyridine+scaffold&doi=10.1021%2Facs.jmedchem.8b02032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold</span></div><div class="casAuthors">Do, Ha T.; Li, Huiying; Chreifi, Georges; Poulos, Thomas L.; Silverman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2690-2707</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Effective delivery of therapeutic drugs into the human brain is one of the most challenging tasks in central nervous system drug development because of the blood-brain barrier (BBB).  To overcome the BBB, both passive permeability and efflux transporter liability of a compd. must be addressed.  Herein, we report our optimization related to BBB penetration of neuronal nitric oxide synthase (nNOS) inhibitors toward the development of new drugs for neurodegenerative diseases.  Various approaches, including enhancing lipophilicity and rigidity of new inhibitors and modulating the pKa of amino groups, have been employed.  In addn. to detg. inhibitor potency and selectivity, crystal structures of most newly designed compds. complexed to various nitric oxide synthase isoforms have been detd.  We have discovered a new analog (21), which exhibits not only excellent potency (Ki < 30 nM) in nNOS inhibition but also a significantly low P-glycoprotein and breast-cancer-resistant protein substrate liability as indicated by an efflux ratio of 0.8 in the Caco-2 bidirectional assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8cFYB2VOYWLVg90H21EOLACvtfcHk0li_Xe-RAmfPGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFeruro%253D&md5=1c357353833e5786f82ec591f51fd0f3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b02032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b02032%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DH.%2BT.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DChreifi%26aufirst%3DG.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26aulast%3DSilverman%26aufirst%3DR.%2BB.%26atitle%3DOptimization%2520of%2520blood-brain%2520barrier%2520permeability%2520with%2520potent%2520and%2520selective%2520human%2520neuronal%2520nitric%2520oxide%2520synthase%2520inhibitors%2520having%2520a%25202-Aminopyridine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2690%26epage%3D2707%26doi%3D10.1021%2Facs.jmedchem.8b02032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of Kukoamine A on neurotoxin-induced Parkinson’s model through apoptosis inhibition and autophagy enhancement</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.02.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.neuropharm.2017.02.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=28238714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Wht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=352-363&author=X.+Huauthor=Q.+Songauthor=X.+Liauthor=D.+Liauthor=Q.+Zhangauthor=W.+Mengauthor=Q.+Zhao&title=Neuroprotective+effects+of+Kukoamine+A+on+neurotoxin-induced+Parkinson%E2%80%99s+model+through+apoptosis+inhibition+and+autophagy+enhancement&doi=10.1016%2Fj.neuropharm.2017.02.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of Kukoamine A on neurotoxin-induced Parkinson's model through apoptosis inhibition and autophagy enhancement</span></div><div class="casAuthors">Hu, Xiao Long; Song, Qi; Li, Xin; Li, Dan Dan; Zhang, Qiao; Meng, Wei Hong; Zhao, Qing Chun</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">352-363</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in substantia nigra (SN).  Our previous study demonstrated Kukoamine A to exhibit strong neuroprotective effects through anti-oxidative stress, anti-inflammation, anti-excitoxicity.  In the present study, MPP+ and MPTP-induced PD models of cell and animal were used to investigate the effects of KuA on PD.  Our results demonstrated that KuA ameliorated cell loss and mitochondrial membrane potential (MMP) loss, and inhibited Bax/Bcl-2 ratio and MAPKs family that were induced by MPP+.  In addn., animal expts. showed that KuA improved the motor function and neuronal activity, and increased the pos. cells of tyrosine hydroxylase (TH) both in substantia nigra (SN) and striatum (Str).  Moreover, KuA could decrease the expression of α-synuclein in brain.  Finally, KuA exerted apparent autophagy enhancement both in vitro and in vivo.  In conclusion, KuA protected against neurotoxin-induced PD due to the apoptosis inhibition and autophagy enhancement, suggesting that KuA treatment might represent a neuroprotective treatment for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZhR9WcUXI0bVg90H21EOLACvtfcHk0lgT3FRLxAAmnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Wht7g%253D&md5=95f453a39449d7bb633acd19c387bf62</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.02.022%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMeng%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DNeuroprotective%2520effects%2520of%2520Kukoamine%2520A%2520on%2520neurotoxin-induced%2520Parkinson%25E2%2580%2599s%2520model%2520through%2520apoptosis%2520inhibition%2520and%2520autophagy%2520enhancement%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D117%26spage%3D352%26epage%3D363%26doi%3D10.1016%2Fj.neuropharm.2017.02.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capitelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sereniki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, M. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reksidler, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tufik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vital, M. A. B. F.</span></span> <span> </span><span class="NLM_article-title">Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>594</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2008.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=10.1016%2Fj.ejphar.2008.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=18674531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVynurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=594&publication_year=2008&pages=101-108&author=C.+Capitelliauthor=A.+Serenikiauthor=M.+M.+S.+Limaauthor=A.+B.+Reksidlerauthor=S.+Tufikauthor=M.+A.+B.+F.+Vital&title=Melatonin+attenuates+tyrosine+hydroxylase+loss+and+hypolocomotion+in+MPTP-lesioned+rats&doi=10.1016%2Fj.ejphar.2008.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats</span></div><div class="casAuthors">Capitelli, Caroline; Sereniki, Adriana; Lima, Marcelo Meira Santos; Reksidler, Angela Braga; Tufik, Sergio; Vital, Maria Aparecida Barbato Frazao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">594</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">101-108</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Parkinson's disease is a chronic neurol. disease characterized by dopaminergic neuron degeneration in the substantia nigra pars compacta.  Melatonin is a powerful antioxidant agent secreted by the pineal gland which has numerous physiol. functions and seems to exert an important neuroprotective effect.  The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model has been used to understand the pathophysiol. of the disease because of its capacity to mimic biochem. and histol. features obsd. in Parkinson's disease.  This study investigated the effect of pretreatment with melatonin (50 mg/kg) on MPTP-lesioned animals 24 h and 7 days after neurotoxin infusion using the open-field test, two-way avoidance task and immunohistochem.  Twenty-four hours after lesioning, the MPTP + vehicle group exhibited hypolocomotion and significant loss of tyrosine hydroxylase-immunoreactive cells, whereas no differences in these parameters were obsd. in lesioned animals receiving melatonin.  Seven days after surgery, the MPTP-lesioned rats did not show hypolocomotion compared to control animals, while there was a significant dopaminergic neuronal loss.  In the two-way avoidance task, MPTP-treated animals presented a cognitive deficit compared to the control groups and melatonin administration did not repair this defect.  The present results suggest that melatonin reduces neuronal loss in the MPTP animal model of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWUUDQthb4SLVg90H21EOLACvtfcHk0lgT3FRLxAAmnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVynurzK&md5=fc576dee7ba2fffcb4509ea54910a4e5</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2008.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2008.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DCapitelli%26aufirst%3DC.%26aulast%3DSereniki%26aufirst%3DA.%26aulast%3DLima%26aufirst%3DM.%2BM.%2BS.%26aulast%3DReksidler%26aufirst%3DA.%2BB.%26aulast%3DTufik%26aufirst%3DS.%26aulast%3DVital%26aufirst%3DM.%2BA.%2BB.%2BF.%26atitle%3DMelatonin%2520attenuates%2520tyrosine%2520hydroxylase%2520loss%2520and%2520hypolocomotion%2520in%2520MPTP-lesioned%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D594%26spage%3D101%26epage%3D108%26doi%3D10.1016%2Fj.ejphar.2008.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R35" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R35','PDB','1R35'); return false;">PDB: 1R35</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i77"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00578">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_07817"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00578?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00578</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Structure characterization of compounds <b>1</b>–<b>20</b> by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and ESI/HRMS spectroscopy; HPLC analysis of compounds <b>1</b>–<b>20</b>; chemical structures of 209 designed compounds; docking scores (-kcal/mol) and BBB level prediction of 209 compounds; organ coefficients and blood biochemistry analysis; correlation coefficient R2; H–E staining of main viscera; and effects of <b>18</b> on the body weight and hemocyte number (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular string files for compounds <b>1</b>–<b>20</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_002.csv">CSV</a>)</p></li><li><p class="inline">Compound <b>18</b> with 1R35 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf">jm1c00578_si_001.pdf (2.55 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_002.csv">jm1c00578_si_002.csv (1.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_003.pdb">jm1c00578_si_003.pdb (534.68 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00578&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-11%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00578%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00578" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                13MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995e920b66d1ef","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
